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RESUMO 
Dende os anos 60, a prevalencia de asma incrementouse 
aproximadamente un 50% por década globalmente, xunto coa súa morbilidade, 
mortalidade e carga económica. Soamente na Unión Europea, a prevalencia de 
asma dobrouse durante os anos 90, alcanzándose 30 millóns de asmáticos no 
ano 2000, cun custo anual de 17,7 billóns de euros para os sistemas de saúde. 
A investigación na fisiopatoloxía da asma e os subseguintes avances 
terapéuticos tiveron un significativo impacto no manexo e control da 
enfermidade, aínda que unha proporción de aproximadamente o 10% dos 
asmáticos aínda padece enfermidade grave de difícil manexo, refractaria á 
terapia máxima dispoñible. Como resultado, a asma converteuse nunha 
prioridade de investigación para os sistemas de saúde dos países 
industrializados e lévanse a cabo extensos traballos en busca dun mellor 
entendemento dos mecanismos implicados na enfermidade, e do 
desenvolvemento de terapias innovadoras. 
Dende o punto de vista fisiopatolóxico, a inflamación crónica e a 
remodelación das vías respiratorias están baixo as manifestacións clínicas da 
asma. A remodelación de vías respiratorias consiste nunha serie de 
anormalidades estruturais que se desenvolven en asociación á inflamación 
crónica, as cales principalmente inclúen hiperplasia e hipertrofia de células 
produtoras de moco e glándulas mucosas, fibrose subepitelial, 
neovascularización e un incremento da masa de músculo liso. Os datos 
contribuídos por estudos clínicos, modelos de asma experimental e modelado 
matemático da mecánica de vías respiratorias converxeron en sinalar o 
crecemento da masa de músculo liso como o compoñente da remodelación de 
vías respiratorias principalmente implicado no mecanismo da hiperreactividad 
bronquial, a obstrución ao fluxo aéreo e a gravidade da asma. O crecemento 
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do músculo liso das vías respiratorias na asma parece resultar dunha 
combinación de diferentes mecanismos que inclúen hiperplasia debida a 
proliferación de miocitos residentes, hipertrofia celular e o recrutamento e 
diferenciación de células proxenitoras circulantes derivadas de medula ósea, 
denominadas fibrocitos. A maior parte do coñecemento sobre os mecanismos 
da remodelación do músculo liso foi inferido a partir de modelos de asma 
experimental e estudos de bioloxía celular e molecular in vitro, e estes datos 
necesitan ser trasladados ao campo clínico para o avance do coñecemento 
dos mecanismos da asma humana real, así como para o desenvolvemento de 
novos tratamentos. Nesta fronte, as biopsias bronquiais obtidas mediante 
broncoscopia son a referencia clínica en tanto que constitúen unha mostraxe 
da parede da vía aérea viva que nos permite analizar a súa estrutura e os 
mecanismos inmunobiolóxicos implicados na remodelación, tanto nos niveis 
histopatolóxico como ultraestrutural, así como mediante técnicas de bioloxía 
celular e molecular in situ. 
A recolección e procesamento de biopsias bronquiais de alta calidade, que 
mostren apropiadamente músculo liso analizable para estudos de morfoloxía 
cuantitativa, leva consigo unha serie de complexidades metodolóxicas e 
require unha especial loxística e cooperación. Por iso, o obxectivo primario do 
traballo de investigación presentado nesta tese foi en si mesmo o 
desenvolvemento dun Biobanco de Biopsias Bronquiais, mediante a 
implementación da loxística e procedementos operativos estandarizados 
necesarios que nos permitisen establecer unha rede para a recolección 
multicéntrica de biopsias bronquiais, obtidas mediante broncoscopias 
realizadas baixo indicación segundo a práctica clínica, e que fosen válidas para 
finalidades de investigación. Dúas premisas principais foron tidas en 
consideración: (i) maximizar a simplicidade dos procedementos no punto de 
obtención das biopsias; e (ii) establecer un método de procesamento e 
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conservación de mostras que permitise o espectro máis amplo posible de 
procedementos subseguintes de investigación, de modo que o Biobanco de 
Biopsias Bronquiais se establecese como unha estrutura especializada, estable 
e sostible, capaz de servir aos obxectivos de proxectos específicos de 
investigadores cualificados, como parte do Programa Integrado de 
Investigación en Asma (PII Asma) da Sociedad Española de Neumología y 
Cirugía Torácica (SEPAR). A modo conciso: aos investigadores colaboradores 
dos centros participantes proporciónanselles kits que conteñen un fórceps de 
biopsia Olympus 35C, un xogo de crioviales de tapa roscada pre-cargados con 
formalina (formaldehido ao 4% en phosphate-buffered saline, PBS) como 
fixador, materiais de embalaxe, formularios de consentimento informado, e 
formularios de case report form (CRF) que inclúe un rexistro de anonimización 
con códigos pre-numerados. As biopsias bronquiais obtéñense de acordo ás 
recomendacións do Workshop Statement de 1990 sobre o uso da 
broncoscopia e instrumentación broncoscópica para finalidades de 
investigación en asma e outras enfermidades de vías respiratorias, e 
subseguintes recomendacións. Obtéñense biopsias bronquiais de pacientes 
asmáticos, suxeitos non asmáticos baixo investigación diagnóstica dunha 
patoloxía pulmonar focal (estes constitúen un grupo de vía respiratoria de 
control), e suxeitos cunha patoloxía inflamatoria de vía respiratoria distinta de 
asma, como sarcoidose, bronquite eosinófila idiopática ou enfermidade 
pulmonar obstrutiva crónica (EPOC). Os suxeitos con sarcoidose nos que non 
se demostra afectación inflamatoria granulomatosa das vías respiratorias 
reclasifícanse como parte do grupo de vía respiratoria de control. Durante a 
broncoscopia, as biopsias libéranse nos tubos pre-cargados con fixador. Unha 
vez empaquetados cos materiais proporcionados, realízase unha chamada á 
compañía DHL para a recollida e transporte das mostras, baixo un número de 
conta de cliente establecido. As biopsias fíxanse en formalina durante o 
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transporte nocturno por DHL, durante un período controlado de 24 horas. Á súa 
recepción no Biobanco de Biopsias Bronquiais, as biopsias son transferidas a 
etanol ao 70% e procesadas durante a noite seguinte nun procesador de 
tecidos convencional de histopatoloxía, para inclusión en parafina. Dos bloques 
de parafina realízanse seccións en microtomo, das cales unha se tingue con 
hematoxilina-eosina para avaliación histopatológica xeral e de control de 
calidade, e o resto das seccións xunto coa porción remanente dos bloques de 
parafina se almacenan para estudos subseguintes correspondentes a 
proxectos de investigación específicos. 
Outros obxectivos do traballo presentado nesta tese foron explotar as 
mostras do Biobanco de Biopsias Bronquiais para obxectivos científicos 
pertinentes á liña de investigación principal da Unidade de Pneumoloxía 
Experimental que desenvolve o biobanco. A utilización das biopsias bronquiais 
para tales obxectivos científicos permitíronnos vincular resultados xerados por 
modelos animais de asma experimental e estudos in vitro de bioloxía celular e 
molecular, coa xeración de evidencia clínica, o cal é a finalidade fundamental 
da investigación translacional. Os devanditos obxectivos, que se detallan nos 
parágrafos seguintes, incluíron investigacións sobre: (i) unha teoría de 
"sinapse" ente células T e células musculares lisas implicada no mecanismo da 
remodelación do músculo liso das vías respiratorias; (ii) o papel da apoptose 
de miocitos na remodelación do músculo liso de vías respiratorias; (iii) o papel 
das células T reguladoras na asma; e (iv) a presenza de células nai 
mesenquimais na parede da vía respiratoria de suxeitos con asma. 
Análise translacional dunha "sinapse" entre células T e células musculares 
lisas na remodelación de vías respiratorias. O coñecido papel das células T en 
dirixir a inflamación crónica das vías respiratorias, e a asociación entre 
inflamación e remodelación, previamente conduciu á hipótese de que as 
células T inducen remodelación do músculo liso. Mediante un modelo de asma 
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experimental, demostrárase que as células T inducen in vivo proliferación de 
células musculares lisas e un incremento na masa de músculo liso das vías 
respiratorias. A análise de seccións pulmonares mediante microscopía confocal 
suxeriu a existencia de contacto directo entre células T e células musculares 
lisas e, en experimentos de cocultivo in vitro, demostrouse que o crecemento 
do músculo liso da vía respiratoria dependía de contacto directo entre as 
células T e os miocitos. Este conxunto de datos proporcionou soporte á 
hipótese sobre a implicación dunha interacción directa entre células T e 
miocitos no mecanismo da remodelación do músculo liso das vías 
respiratorias. No traballo presentado nesta tese, estudamos a relevancia desta 
hipótese na asma humana, analizando biopsias bronquiais en busca de 
evidencia do devandito contacto entre células T e miocitos ou as súas 
potenciais células precursoras, e a relación deste contacto coa proliferación 
das células diana e o incremento da masa de músculo liso. Utilizouse α-actina 
de músculo liso (alpha smooth muscle actin, α-SMA) como marcador de 
células musculares lisas e fenotipos celulares menos diferenciados que poden 
potencialmente ser precursores de miocitos, dado que a α-SMA é expresada 
por células musculares lisas, miofibroblastos, e fibrocitos. Adicionalmente, 
analizouse a expresión e distribución do receptor de adhesión leucocitaria 
vascular cell adhesion molecule-1 (VCAM-1), o cal é un ligando de células T 
implicado na interacción directa entre células T e células musculares lisas. 
Analizáronse seccións de tecido de biopsias bronquiais de 16 pacientes con 
asma moderado, 14 con asma grave e 17 suxeitos control. As mostras dos 
doentes asmáticos mostraron un incremento da masa de músculo liso de vías 
respiratorias proporcional á gravidade da asma. Tamén nos asmáticos, 
observouse a existencia dun espectro de fenotipos de células α-SMA+ 
localizado en lamina propria, abranguendo dende células pouco diferenciadas 
ata formacións con aparencia de células musculares lisas maduras, estas 
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últimas en aposición ao límite externo dos feixes do músculo liso bronquial. 
Este espectro de fenotipos celulares α-SMA+, que denominamos non-organized 
airway contractile elements (NOACE), suxire ser a expresión histopatolóxica 
dun rango dinámico de células α-SMA+, onde células circulantes precursoras 
son recrutadas da microvasculatura da circulación bronquial situada en lamina 
propria e, seguidamente, migran e diferéncianse ata finalmente integrarse no 
músculo liso hiperplásico da vía respiratoria en forma de miocitos 
terminalmente diferenciados. Mediante tripla inmunohistoquímica simultánea 
de células T, proliferating cell nuclear antigen (PCNA) e α-SMA, mostramos 
que existen células en proliferación (PCNA+) tanto nos feixes de músculo liso 
das vías respiratorias coma no NOACE, suxerindo polo tanto que o crecemento 
hiperplásico do músculo liso na asma é en parte debido á proliferación de 
miocitos residentes, máis a adición de células diferenciadas a partir dun 
conxunto de precursores que se expande no NOACE. Nas mesmas seccións 
de tecido, observouse que as células T infiltraban o músculo liso das vías 
respiratorias en proporción á gravidade da asma, e que algunhas delas 
estaban en microlocalización (en xustaposición) con células PCNA+α-SMA+, 
tanto nos feixes de músculo liso coma no NOACE, suxerindo contacto directo 
entre as células T e células α-SMA+ en proliferación activa. A frecuencia de 
tales eventos de xustaposición celular correlacionouse así mesmo coa 
gravidade da asma. Finalmente, achouse que a expresión de VCAM-1 estaba 
regulada á alza nos suxeitos con asma, no endotelio, músculo liso das vías 
respiratorias e NOACE. Nos miocitos do músculo bronquial e o NOACE, a 
VCAM-1 expresábase en forma de parches discoides definidos suxestivos de 
focalización e agrupamento de receptores para a adhesión intercelular. Na 
análise de regresión multivariante realizada, a infiltración por células T do 
músculo liso bronquial foi o maior preditor do incremento da masa de músculo 
liso, seguido da frecuencia de células α-SMA+PCNA+ no músculo liso e 
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NOACE. En resumo, en consistencia coa previa evidencia experimental da 
implicación dun contacto intercelular directo mediado por células T na 
remodelación do músculo de vías respiratorias, o presente estudo en biopsias 
bronquiais mostrou que as células T infiltran o músculo liso bronquial e 
xustapoñense a células α-SMA+ en proliferación, nas vías respiratorias de 
suxeitos con asma. O receptor VCAM-1 pode estar implicado en mediar esta 
interacción entre células T e células α-SMA+. É plausible que as células T 
transmitan sinais morfoxénicas a células estruturais α-SMA+ ou os seus 
precursores a través dunha "sinapse" mediada por receptores, no contexto da 
inflamación crónica e as respostas disreguladas de reparación asociadas. 
Papel da apoptose na remodelación do músculo liso das vías respiratorias. 
Os estudos previamente realizados sobre remodelación do músculo liso das 
vías respiratorias maiormente enfocáranse nos seus mecanismos de 
crecemento en termos de hiperplasia/hipertrofia, máis migración e 
diferenciación de células precursoras. Os experimentos previamente referidos 
demostrativos da indución por células T de remodelación do músculo liso de 
vías respiratorias nun modelo de asma experimental a curto prazo en rata, 
tamén suxeriron que o crecemento do músculo liso pode acontecer mediante 
unha combinación de hiperplasia e inhibición de apoptose de miocitos. 
Contrariamente aos devanditos resultados, un posterior estudo en cabalos con 
heaves, unha enfermidade obstrutiva de vías respiratorias de ocorrencia 
natural debida a sensibilización ao feo, mostrou que a apoptose de células 
musculares lisas da vía respiratoria estaba incrementada. Tales resultados 
discordantes conducíronnos á hipótese de que a apoptose está implicada na 
homeostase do músculo liso das vías respiratorias, e pode estar suxeita a 
regulación a través da historia natural da asma, a medida que a remodelación 
de vías respiratorias se desenvolve. 
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Para estudar esta hipótese, realizamos primeiro un estudo en asma 
experimental murina (datos non publicados, non parte da presente tese), 
baseado en sensibilización alérxica seguida de broncoprovocación alérxica 
repetida, con dous puntos de corte de obtención de datos: (i) un corte 
temperán reflectindo enfermidade incipiente, e (ii) un corte tardío reflectindo 
cronicidade prolongada. No corte temperán, os ratos con asma experimental 
mostraron ausencia de cambios na liña de base de frecuencia de apoptose de 
células musculares lisas en comparación cos animais control, e 
hiperreactividad de vías respiratorias asociada con remodelación do músculo 
liso, cuxa masa estaba xa incrementada neste punto. No corte tardío, a 
apoptose de células de músculo liso resultou regulada á alza nos animais con 
asma experimental. En conxunto os datos suxeriron que existe unha liña de 
base de frecuencia de apoptose no músculo liso das vías respiratorias, 
probablemente implicada na homeostase desta estrutura e que, en resposta á 
remodelación do músculo liso durante a progresión da asma, a frecuencia de 
apoptose se incrementa. Para proporcionar unha demostración máis 
mecanicista deste concepto, desenvolvemos outro modelo murino no cal a 
apoptose foi suxeita a inhibición farmacolóxica durante o desenvolvemento da 
asma experimental, por medio dun fármaco bloqueador de caspasas de amplo 
espectro. Nos animais con asma experimental, a inhibición in vivo da apoptose 
conduciu a: (i) mecánica pulmonar caótica, reflectida en forma dunha resposta 
inusual á broncoprovocación con metacolina, onde o trazado de resistencia 
pulmonar (RL) era atípico, suxerindo unha especie de "fibrilación" muscular; e 
(ii) un crecemento inusitado e desestruturado do tecido contráctil das vías 
respiratorias, mostrado en forma dun patrón inusual de remodelación de 
músculo liso con engrosamento esaxerado desta capa, xunto con trazos 
morfolóxicos suxestivos dun crecemento desorganizado desta estrutura. En 
conxunto, os datos destes modelos de asma experimental mostraron que a 
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apoptose de células do músculo liso das vías respiratorias está implicada na 
homeostase desta estrutura, e que a frecuencia de apoptose se incrementa en 
resposta á remodelación do músculo liso ao longo do desenvolvemento da 
enfermidade. Tales achados conducíronnos a levar a cabo o estudo en 
biopsias bronquiais humanas mostrado nesta tese, en busca de evidencia 
adicional de que a apoptose de células musculares lisas desempeña un papel 
na fisiopatoloxía da asma. Neste estudo, analizamos seccións de tecido de 
biopsias bronquiais de 59 pacientes con asma, incluíndo 7 con asma 
intermitente, 33 con asma moderado e 19 con asma grave, máis 13 suxeitos 
control. En primeiro lugar, levamos a cabo in situ a técnica de terminal 
deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) e 
efectuamos colocalización deste sinal con α-SMA. Nunha subsecuente análise 
exploratoria, parcialmente limitada pola dispoñibilidade de mostras, realizamos 
colocalización con α-SMA de cleaved poly ADP ribose polymerase (c-PARP), 
unha proteína fragmentada, que é produto colateral da actividade das 
caspasas e o proceso de apoptose. Esta última análise levouse a cabo en 
seccións de tecido de biopsias de 5 asmáticos moderados e 8 graves, e os 13 
suxeitos control. En consistencia con datos previos, a masa de músculo liso de 
vías respiratorias resultou incrementada nos suxeitos con asma, mostrando un 
gradiente significativo dende os suxeitos control ata os asmáticos graves. 
Resultou rechamante que nos suxeitos con asma intermitente existía xa un 
incremento, ao bordo da significación estatística, do músculo liso. Nas biopsias 
dos suxeitos asmáticos observouse unha maior frecuencia de células 
TUNEL+α-SMA+, que non alcanzou significación estatística, pero os asmáticos 
graves mostraron non obstante un incremento significativo na frecuencia de 
células c-PARP+α-SMA+, sobre os asmáticos moderados e os suxeitos control. 
En conxunto os datos suxiren, en consistencia cos modelos animais, que existe 
un incremento da apoptose de miocitos implicada nos mecanismos da 
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remodelación do músculo das vías respiratorias, probablemente 
desempeñando unha función reguladora en resposta ao crecemento do 
músculo liso. 
Células T reguladoras (Tregs) e células nai mesenquimais (mesenchymal 
stem cells, MSCs) en biopsias bronquiais. A investigación sobre o papel das 
respostas inmunitarias adaptativas na asma enfocárase extensamente sobre 
as células T CD4+ efectoras, como condutoras centrais de tales respostas. Non 
obstante, tras o achado da existencia de células T CD4+CD25+ 
inmunoreguladoras nos anos 90, e tras o descubrimento así mesmo do factor 
de transcrición FOXP3 como marcador e efector molecular clave na función 
das células T CD4+ reguladoras, produciuse un importante xiro conceptual, xa 
que as células T CD4+ deixaban de ser exclusivamente células T efectoras. 
Estes achados incitaron o extenso e rápido desenvolvemento de traballos de 
investigación sobre as Tregs, aínda que no campo da asma se xeraron datos 
moi escasos e inconsistentes. A hipótese que inicialmente xurdiu e se 
xeneralizou foi que as células Treg estarían diminuídas na asma, e polo tanto a 
inflamación crónica das vías respiratorias desenvolveríase como resultado dun 
fallo desta rama reguladora. Non obstante, a maioría dos escasos estudos 
realizados limitáronse a análise de sangue periférico que mostraron células 
Treg diminuídas en cantidade ou na súa capacidade de resposta a estímulos 
quimiotácticos, máis dous estudos feitos en lavado broncoalveolar, os cales 
mostraron células Treg diminuídas ou incrementadas, respectivamente. En 
ausencia de datos directos sobre células Treg nas vías respiratorias, 
formulamos a hipótese de que a inflamación crónica na asma non xorde dun 
fallo primario das células Treg senón que, ao contrario, as células Treg poden 
estar de forma reactiva incrementadas en resposta á inflamación sostida e 
poden participar activamente en inducir remodelación a través da súa citoquina 
principalmente producida, TGF-β, a cal é un potente factor fibroxénico. Baixo 
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esta hipótese, desenvolvemos un modelo de asma experimental (datos non 
publicados, non parte desta tese), con tres puntos de corte de colección de 
datos, representando respectivamente enfermidade moi temperá, un punto 
intermedio de desenvolvemento da enfermidade, e cronicidade a longo prazo. 
A hiperreactividade de vías respiratorias alcanzou o seu máximo no punto 
intermedio, cun subseguinte declive. De forma concomitante, observáronse 
células Treg produtoras de IL-10 e TGF-β, identificadas mediante 
colocalización por inmunofluorescencia de FOXP3 e hibridación in situ para IL-
10 e TGF-β, que resultaron nun incremento gradual e significativo dende a 
enfermidade temperá ata a enfermidade crónica a longo prazo, e este achado 
se asociou cun incremento de células caliciformes, masa mucosa epitelial, e 
fibrose subepitelial nas vías respiratorias. Nas biopsias bronquiais, levamos a 
cabo unha análise exploratoria sobre mostras de 29 pacientes con asma grave 
e 5 suxeitos control, no que se realizou detección inmunohistoquímica de 
FOXP3 seguida de tinguidura de contraste con hematoxilina. O factor FOXP3 
resultou expresarse exclusivamente en células linfoides principalmente 
localizadas en lamina propria, as cales estaban virtualmente ausentes nos 
suxeitos control e incrementadas de forma importante e significativa nos 
doentes con asma grave. Este resultado é consistente coa hipótese de que as 
células Treg infiltran de forma reactiva a parede da vía respiratoria dos suxeitos 
con asma, e poden participar activamente nos mecanismos da remodelación. 
En canto ás MSCs, estas comparten coas Tregs as propiedades de ser 
inmunoreguladoras e simultáneamente ter a capacidade de participar en 
procesos de reparación tisular e, polo tanto, na remodelación de vías 
respiratorias como resposta reparadora disregulada. 
A efectividade do transplante de MSCs para o tratamento da enfermidade 
enxerto-contra-hóspede conduciu a un despregamento de investigación sobre 
o potencial uso de MSCs para tratar diversas enfermidades inflamatorias 
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crónicas. No caso da asma, esta tendencia orixinou investigacións rápidas que 
se enfocaron nas propiedades inmunoreguladoras das MSCs, ignorando non 
obstante o feito de que as MSCs teñen o potencial de diferenciarse cara a 
células estruturais de tecidos mesenquimais, incluíndo células musculares 
lisas, e poderían polo tanto favorecer a remodelación de vías respiratorias en 
vez de resultar nun efecto terapéutico se se administran como axentes 
antiinflamatorios. De feito, existe evidencia acumulada de que os fibrocitos, un 
tipo de célula proxenitora circulante derivada da medula ósea, son recrutados á 
parede das vías respiratorias dos asmáticos e contribúen á remodelación do 
músculo liso. Nun estudo recentemente publicado levado a cabo na nosa 
Unidade de Pneumoloxía Experimental, transplantáronse MSCs derivadas de 
tecido adiposo de ratos doadores de cepa consanguínea, xeneticamente 
modificadas para a expresión permanente de green fluorescent protein (GFP) e 
o seu seguimento in vivo, a ratos receptores con asma experimental 
establecida. 
As MSCs diminuíron rapidamente a inflamación das vías respiratorias tras a 
súa administración, aínda que este efecto terapéutico se seguiu dun rebote con 
pleno restablecemento da inflamación tras dúas semanas de exposición 
alerxénica continuada. Pola contra, a hiperreactividade de vías respiratorias 
atenuouse significativamente neste punto tardío tras o tratamento, e este 
efecto acompañouse dunha significativa regresión da masa de músculo liso 
das vías respiratorias, o cal foi un resultado inesperado contrario á hipótese 
orixinal. Ademais, as MSCs transferidas sinalizadas mediante GFP non se 
integraron nin diferenciaron en ningún tipo de estrutura da parede da vía 
respiratoria, incluíndo o músculo liso. Estes resultados prometedores 
conducíronnos a levar a cabo un estudo piloto para analizar a presenza de 
MSCs en biopsias bronquiais, baseado na detección inmunohistoquímica de 
STRO-1, que é un marcador de MSCs derivadas do estroma da medula ósea. 
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Analizáronse seccións de tecido de biopsias de 8 pacientes con asma grave e 
4 suxeitos control. Nos suxeitos control, non se detectou practicamente a 
expresión de STRO-1. Pola contra, nas mostras dos suxeitos con asma grave 
encontráronse células STRO-1+ en significativas cantidades, localizadas en 
lamina propria. Nestes suxeitos, acháronse así mesmo agrupamentos do 
antíxeno STRO-1 no músculo liso bronquial, suxestivos dunha expresión 
residual de STRO-1 por previas MSCs que terían recentemente migrado e se 
terían integrado e diferenciado como miocitos no músculo liso das vías 
respiratorias. Este resultado, en desacordo cos datos do previo estudo sobre 
tratamento con MSCs en asma experimental murina, suxire que poden existir 
diferentes poboacións celulares proxenitoras, incluíndo MSCs de orixe en 
estroma medular, que pódense recrutar durante a remodelación do músculo 
liso das vías respiratorias na asma. En vista de tal predicible complexidade, 
serán necesarios estudos subseguintes e un sólido desenvolvemento 
preclínico previos a calquera potencial terapia baseada en MSCs para a asma, 
e o futuro pode guiarnos cara a investigar sobre a produción e uso terapéutico 
de mediadores derivados das MSCs, máis que sobre o emprego directo das 
devanditas células. 
Á parte dos proxectos e resultados aquí resumidos, o Biobanco de Biopsias 
Bronquiais alcanzou así mesmo o seu compromiso de servir a proxectos 
dirixidos por outros investigadores, con tres de tales proxectos en 
desenvolvemento presente, en diferentes estadios. En resumo, o Biobanco de 
Biopsias Bronquiais foi exitosamente conducido dende a súa concepción como 
unha novidosa iniciativa ata a súa implementación na práctica, e ademais: 
promoveu a colaboración multicéntrica; xerou un fluxo sostido de biopsias de 
calidade que permiten xerar resultados válidos para obxectivos científicos; 
permitiunos enlazar resultados de modelos animais de asma experimental e 
estudos in vitro de bioloxía celular e molecular coa xeración de evidencia 
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clínica de soporte, o cal é a finalidade última da investigación translacional; 
evolucionou para adherirse a desenvolvementos normativos que aconteceron 
paralelamente; e proporcionou soporte loxístico, base de coñecemento 
metodolóxico, formación, e servizos de xestión e análise de mostras para 
proxectos iniciados por distintos investigadores cualificados. Adicionalmente, a 
súa loxística, procedementos operativos estandarizados e base de 
coñecemento proporcionan unha preparación previa á previsible necesidade 
futura de desenvolver e implementar ensaios clínicos enfocados no 
desenvolvemento de terapias innovadoras que fagan diana na remodelación de 
vías respiratorias. 
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RESUMEN 
Desde los años 60, la prevalencia de asma se ha incrementado 
aproximadamente un 50% por década globalmente, junto con su morbilidad, 
mortalidad y carga económica. Solamente en la Unión Europea, la prevalencia 
de asma se dobló durante los años 90, alcanzándose 30 millones de asmáticos 
en el año 2000, con un coste anual de 17,7 billones de euros para los sistemas 
de salud. La investigación en la fisiopatología del asma y los subsiguientes 
avances terapéuticos han tenido un significativo impacto en el manejo y control 
de la enfermedad, aunque una proporción de aproximadamente el 10% de los 
asmáticos aún padece enfermedad grave de difícil manejo, refractaria a la 
terapia máxima disponible. Como resultado, el asma se ha convertido en una 
prioridad de investigación para los sistemas de salud de los países 
industrializados y se llevan a cabo extensos trabajos en busca de un mejor 
entendimiento de los mecanismos implicados en la enfermedad, y del 
desarrollo de terapias innovadoras. 
Desde el punto de vista fisiopatológico, la inflamación crónica y la 
remodelación de las vías respiratorias subyace a las manifestaciones clínicas 
del asma. La remodelación de vías respiratorias consiste en una serie de 
anormalidades estructurales que se desarrollan en asociación a la inflamación 
crónica, las cuales principalmente incluyen hiperplasia e hipertrofia de células 
productoras de moco y glándulas mucosas, fibrosis subepitelial, 
neovascularización y un incremento de la masa de músculo liso. Los datos 
contribuidos por estudios clínicos, modelos de asma experimental y modelado 
matemático de la mecánica de vías respiratorias han convergido en señalar el 
crecimiento de la masa de músculo liso como el componente de la 
remodelación de vías respiratorias principalmente implicado en el mecanismo 
de la hiperreactividad bronquial, la obstrucción al flujo aéreo y la gravedad del 
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asma. El crecimiento del músculo liso de las vías respiratorias en el asma 
parece resultar de una combinación de diferentes mecanismos que incluyen 
hiperplasia debida a proliferación de miocitos residentes, hipertrofia celular y el 
reclutamiento y diferenciación de células progenitoras circulantes derivadas de 
médula ósea, denominadas fibrocitos. La mayor parte del conocimiento sobre 
los mecanismos de la remodelación del músculo liso ha sido inferido a partir de 
modelos de asma experimental y estudios de biología celular y molecular in 
vitro, y estos datos necesitan ser trasladados al campo clínico para el avance 
del conocimiento de los mecanismos del asma humana real, así como para el 
desarrollo de nuevos tratamientos. En este frente, las biopsias bronquiales 
obtenidas mediante broncoscopia son la referencia clínica en tanto que 
constituyen un muestreo de la pared de la vía aérea viva que nos permite 
analizar su estructura y los mecanismos inmunobiológicos implicados en la 
remodelación, tanto en los niveles histopatológico como ultraestructural, así 
como mediante técnicas de biología celular y molecular in situ. 
La recolección y procesamiento de biopsias bronquiales de alta calidad, 
que muestreen apropiadamente músculo liso analizable para estudios de 
morfología cuantitativa, conlleva una serie de complejidades metodológicas y 
requiere una especial logística y cooperación. Por ello, el objetivo primario del 
trabajo de investigación presentado en esta tesis ha sido en sí mismo el 
desarrollo de un Biobanco de Biopsias Bronquiales, mediante la 
implementación de la logística y procedimientos operativos estandarizados 
necesarios que nos permitiesen establecer una red para la recolección 
multicéntrica de biopsias bronquiales, obtenidas mediante broncoscopias 
realizadas bajo indicación según práctica clínica, y que fuesen válidas para 
finalidades de investigación. Dos premisas principales han sido tenidas en 
consideración: (i) maximizar la simplicidad de los procedimientos en el punto 
de obtención de las biopsias; y (ii) establecer un método de procesamiento y 
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conservación de muestras que permitiese el espectro más amplio posible de 
procedimientos subsiguientes de investigación, de modo que el Biobanco de 
Biopsias Bronquiales se estableciese como una estructura especializada, 
estable y sostenible, capaz de servir a los objetivos de proyectos específicos 
de investigadores cualificados, como parte del Programa Integrado de 
Investigación en Asma (PII Asma) de la Sociedad Española de Neumología y 
Cirugía Torácica (SEPAR). A modo conciso: a los investigadores 
colaboradores de los centros participantes se les proporcionan kits que 
contienen un fórceps de biopsia Olympus 35C, un juego de crioviales de tapa 
roscada pre-cargados con formalina (formaldehído al 4% en phosphate-
buffered saline, PBS) como fijador, materiales de embalaje, formularios de 
consentimiento informado, y formularios de case report form (CRF) que 
incluyen un registro de anonimización con códigos pre-numerados. Las 
biopsias bronquiales se obtienen de acuerdo a las recomendaciones del 
Workshop Statement de 1990 sobre el uso de la broncoscopia e 
instrumentación broncoscópica para finalidades de investigación en asma y 
otras enfermedades de vías respiratorias, y subsiguientes recomendaciones. 
Se obtienen biopsias bronquiales de pacientes asmáticos, sujetos no 
asmáticos bajo investigación diagnóstica de una patología pulmonar focal 
(éstos constituyen un grupo de vía respiratoria de control), y sujetos con una 
patología inflamatoria de vía respiratoria distinta de asma, como sarcoidosis, 
bronquitis eosinófila idiopática o enfermedad pulmonar obstructiva crónica 
(EPOC). Los sujetos con sarcoidosis en los que es no se demuestra afectación 
inflamatoria granulomatosa de las vías respiratorias se reclasifican como parte 
del grupo de vía respiratoria de control. Durante la broncoscopia, las biopsias 
se liberan en los tubos pre-cargados con fijador. Una vez empaquetados con 
los materiales proporcionados, se realiza una llamada a la compañía DHL para 
la recogida y transporte de las muestras, bajo un número de cuenta de cliente 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- XXII - 
preestablecido. Las biopsias se fijan en formalina durante el transporte 
nocturno por DHL, durante un periodo controlado de 24 horas. A su recepción 
en el Biobanco de Biopsias Bronquiales, las biopsias son transferidas a etanol 
al 70% y procesadas durante la noche siguiente en un procesador de tejidos 
convencional de histopatología, para inclusión en parafina. De los bloques de 
parafina se realizan secciones en microtomo, de las cuales una se tiñe con 
hematoxilina-eosina para evaluación histopatológica general y de control de 
calidad, y el resto de las secciones junto con la porción remanente de los 
bloques de parafina se almacenan para estudios subsiguientes 
correspondientes a proyectos de investigación específicos. 
Otros objetivos del trabajo presentado en esta tesis han sido explotar las 
muestras del Biobanco de Biopsias Bronquiales para objetivos científicos 
pertinentes a la línea de investigación principal de la Unidad de Neumología 
Experimental que desarrolla el biobanco. La utilización de las biopsias 
bronquiales para tales objetivos científicos nos han permitido vincular 
resultados generados por modelos animales de asma experimental y estudios 
in vitro de biología celular y molecular, con la generación de evidencia clínica, 
lo cual es la finalidad fundamental de la investigación traslacional. Dichos 
objetivos, que se detallan en los párrafos siguientes, han incluido 
investigaciones sobre: (i) una teoría de "sinapsis" ente células T y células 
musculares lisas implicada en el mecanismo de la remodelación del músculo 
liso de las vías respiratorias; (ii) el papel de la apoptosis de miocitos en la 
remodelación del músculo liso de vías respiratorias; (iii) el papel de las células 
T reguladoras en el asma; y (iv) la presencia de células madre mesenquimales 
en la pared de la vía respiratoria de sujetos con asma. 
Análisis traslacional de una "sinapsis" entre células T y células musculares 
lisas en la remodelación de vías respiratorias. El conocido papel de las células 
T en dirigir la inflamación crónica de las vías respiratorias, y la asociación entre 
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inflamación y remodelación, había previamente conducido a la hipótesis de que 
las células T inducen remodelación del músculo liso. Mediante un modelo de 
asma experimental, se había demostrado que las células T inducen in vivo 
proliferación de células musculares lisas y un incremento en la masa de 
músculo liso de las vías respiratorias. El análisis de secciones pulmonares 
mediante microscopía confocal había sugerido la existencia de contacto directo 
entre células T y células musculares lisas y, en experimentos de cocultivo in 
vitro, se demostró que el crecimiento del músculo liso de la vía respiratoria 
dependía de contacto directo entre las células T y los miocitos. Este conjunto 
de datos proporcionó soporte a la hipótesis sobre la implicación de una 
interacción directa entre células T y miocitos en el mecanismo de la 
remodelación del músculo liso de las vías respiratorias. En el trabajo 
presentado en esta tesis, hemos estudiado la relevancia de esta hipótesis en el 
asma humana, analizando biopsias bronquiales en busca de evidencia de 
dicho contacto entre células T y miocitos o sus potenciales células precursoras, 
y la relación de este contacto con la proliferación de las células diana y el 
incremento de la masa de músculo liso. Se utilizó α-actina de músculo liso 
(alpha smooth muscle actin, α-SMA) como marcador de células musculares 
lisas y fenotipos celulares menos diferenciados que pueden potencialmente ser 
precursores de miocitos, dado que la α-SMA es expresada por células 
musculares lisas, miofibroblastos, y fibrocitos. Adicionalmente, se analizó la 
expresión y distribución del receptor de adhesión leucocitaria vascular cell 
adhesion molecule-1 (VCAM-1), el cual es un ligando de células T implicado en 
la interacción directa entre células T y células musculares lisas. Se analizaron 
secciones de tejido de biopsias bronquiales de 16 pacientes con asma 
moderada, 14 con asma grave y 17 sujetos control. Las muestras de los 
pacientes con asma mostraron un incremento de la masa de músculo liso de 
vías respiratorias proporcional a la gravedad del asma. También en los 
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asmáticos, se observó la existencia de un espectro de fenotipos de células α-
SMA+ localizado en la lamina propria, abarcando desde células poco 
diferenciadas hasta formaciones con apariencia de células musculares lisas 
maduras, estas últimas en aposición al límite externo de los haces del músculo 
liso bronquial. Este espectro de fenotipos celulares α-SMA+, que hemos 
denominado non-organized airway contractile elements (NOACE), sugiere ser 
la expresión histopatológica de un rango dinámico de células α-SMA+, donde 
células circulantes precursoras son reclutadas de la microvasculatura de la 
circulación bronquial situada en la lamina propria y, seguidamente, migran y se 
diferencian hasta finalmente integrarse en el músculo liso hiperplásico de la vía 
respiratoria en forma de miocitos terminalmente diferenciados. Mediante triple 
inmunohistoquímica simultánea de células T, proliferating cell nuclear antigen 
(PCNA) y α-SMA, hemos mostrado que existen células en proliferación 
(PCNA+) tanto en los haces de músculo liso de las vías respiratorias como en 
el NOACE, sugiriendo por lo tanto que el crecimiento hiperplásico del músculo 
liso en el asma es en parte debido a la proliferación de miocitos residentes, 
más la adición de células diferenciadas a partir de un conjunto de precursores 
que se expande en el NOACE. En las mismas secciones de tejido, se observó 
que las células T infiltraban el músculo liso de las vías respiratorias en 
proporción a la gravedad del asma, y que algunas de ellas estaban en 
microlocalización (yuxtapuestas) con células PCNA+α-SMA+, tanto en los haces 
de músculo liso como en el NOACE, sugiriendo contacto directo entre las 
células T y células α-SMA+ en proliferación activa. La frecuencia de tales 
eventos de yuxtaposición celular se correlacionó asimismo con la gravedad del 
asma. Finalmente, se halló que la expresión de VCAM-1 estaba regulada al 
alza en los sujetos con asma, en el endotelio, músculo liso de las vías 
respiratorias y NOACE. En los miocitos del músculo bronquial y el NOACE, la 
VCAM-1 se expresaba en forma de parches discoides definidos sugerentes de 
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focalización y agrupamiento de receptores para la adhesión intercelular. En el 
análisis de regresión multivariante realizado, la infiltración por células T del 
músculo liso bronquial fue el mayor predictor del incremento de la masa de 
músculo liso, seguido de la frecuencia de células α-SMA+PCNA+ en el músculo 
liso y NOACE. En resumen, en consistencia con la previa evidencia 
experimental de la implicación de un contacto intercelular directo mediado por 
células T en la remodelación del músculo de vías respiratorias, el presente 
estudio en biopsias bronquiales ha mostrado que las células T infiltran el 
músculo liso bronquial y se yuxtaponen a células α-SMA+ en proliferación, en 
las vías respiratorias de sujetos con asma. El receptor VCAM-1 puede estar 
implicado en mediar esta interacción entre células T y células α-SMA+. Es 
plausible que las células T transmitan señales morfogénicas a células 
estructurales α-SMA+ o sus precursores a través de una "sinapsis" mediada por 
receptores, en el contexto de la inflamación crónica y las respuestas 
disreguladas de reparación asociadas.  
Papel de la apoptosis en la remodelación del músculo liso de las vías 
respiratorias. Los estudios previamente realizados sobre remodelación del 
músculo liso de las vías respiratorias se habían mayormente enfocado en sus 
mecanismos de crecimiento en términos de hiperplasia/hipertrofia, más 
migración y diferenciación de células precursoras. Los experimentos 
previamente referidos, demostrativos de la inducción por células T de 
remodelación del músculo liso de vías respiratorias en un modelo de asma 
experimental a corto plazo en rata, también sugirieron que el crecimiento del 
músculo liso puede ocurrir mediante una combinación de hiperplasia e 
inhibición de apoptosis de miocitos. Contrariamente a dichos resultados, un 
posterior estudio en caballos con heaves, una enfermedad obstructiva de vías 
respiratorias de ocurrencia natural debida a sensibilización al heno, mostró que 
la apoptosis de células musculares lisas de la vía respiratoria estaba 
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incrementada. Tales resultados discordantes nos condujeron a la hipótesis de 
que la apoptosis está implicada en la homeostasis del músculo liso de las vías 
respiratorias, y puede estar sujeta a regulación a través de la historia natural 
del asma, a medida que la remodelación de vías respiratorias se desarrolla. 
Para estudiar esta hipótesis, realizamos primero un estudio en asma 
experimental murina (datos no publicados, no parte de la presente tesis), 
basado en sensibilización alérgica seguida de broncoprovocación alérgica 
repetida, con dos puntos de corte de obtención de datos: (i) un corte temprano 
reflejando enfermedad incipiente, y (ii) un corte tardío reflejando cronicidad 
prolongada. En el corte temprano, los ratones con asma experimental 
mostraron ausencia de cambios en la línea de base de frecuencia de apoptosis 
de células musculares lisas en comparación con los animales control, e 
hiperreactividad de vías respiratorias asociada con remodelación del músculo 
liso, cuya masa estaba ya incrementada en este punto. En el corte tardío, la 
apoptosis de células de músculo liso resultó regulada al alza en los animales 
con asma experimental. En conjunto los datos sugirieron que existe una línea 
de base de frecuencia de apoptosis en el músculo liso de las vías respiratorias, 
probablemente implicada en la homeostasis de esta estructura y que, en 
respuesta a la remodelación del músculo liso durante la progresión del asma, 
la frecuencia de apoptosis se incrementa. Para proporcionar una demostración 
más mecanicista de este concepto, desarrollamos otro modelo murino en el 
cual la apoptosis fue sujeta a inhibición farmacológica durante el desarrollo del 
asma experimental, por medio de un fármaco bloqueador de caspasas de 
amplio espectro. En los animales con asma experimental, la inhibición in vivo 
de la apoptosis condujo a: (i) mecánica pulmonar caótica, reflejada en forma de 
una respuesta inusual a la broncoprovocación con metacolina, donde el 
trazado de resistencia pulmonar (RL) era atípico, sugiriendo una especie de 
"fibrilación" muscular; y (ii) un crecimiento inusitado y desestructurado del tejido 
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contráctil de las vías respiratorias, mostrado en forma de un patrón inusual de 
remodelación de músculo liso con engrosamiento exagerado de esta capa, 
junto con rasgos morfológicos sugerentes de un crecimiento desorganizado de 
esta estructura. En conjunto, los datos de estos modelos de asma experimental 
mostraron que la apoptosis de células del músculo liso de las vías respiratorias 
está implicada en la homeostasis de esta estructura, y que la frecuencia de 
apoptosis se incrementa en respuesta a la remodelación del músculo liso a lo 
largo del desarrollo de la enfermedad. Tales hallazgos nos condujeron a llevar 
a cabo el estudio en biopsias bronquiales humanas mostrado en esta tesis, en 
busca de evidencia adicional de que la apoptosis de células musculares lisas 
desempeña un papel en la fisiopatología del asma. En este estudio, 
analizamos secciones de tejido de biopsias bronquiales de 59 pacientes con 
asma, incluyendo 7 con asma intermitente, 33 con asma moderada y 19 con 
asma grave, más 13 sujetos control. En primer lugar, llevamos a cabo in situ la 
técnica de terminal deoxynucleotidyl transferase mediated dUTP nick end 
labeling (TUNEL) y efectuamos colocalización de esta señal con α-SMA. En un 
subsecuente análisis exploratorio, parcialmente limitado por la disponibilidad de 
muestras, realizamos colocalización con α-SMA de cleaved poly ADP ribose 
polymerase (c-PARP), una proteína fragmentada que es producto colateral de 
la actividad de las caspasas y el proceso de apoptosis. Este último análisis se 
llevó a cabo en secciones de tejido de biopsias de 5 asmáticos moderados y 8 
graves, y los 13 sujetos control. En consistencia con datos previos, la masa de 
músculo liso de vías respiratorias resultó incrementada en los sujetos con 
asma, mostrando un gradiente significativo desde los sujetos control hasta los 
asmáticos graves. Resultó llamativo que en los sujetos con asma intermitente 
existía ya un incremento, al borde de la significación estadística, del músculo 
liso. En las biopsias de los sujetos asmáticos se observó una mayor frecuencia 
de células TUNEL+α-SMA+, que no alcanzó significación estadística, pero los 
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asmáticos graves mostraron sin embargo un incremento significativo en la 
frecuencia de células c-PARP+α-SMA+, sobre los asmáticos moderados y los 
sujetos control. En conjunto los datos sugieren, en consistencia con los 
modelos animales, que existe un incremento de la apoptosis de miocitos 
implicada en los mecanismos de la remodelación del músculo de las vías 
respiratorias, probablemente desempeñando una función reguladora en 
respuesta al crecimiento del músculo liso. 
Células T reguladoras (Tregs) y células madre mesenquimales (MSCs) en 
biopsias bronquiales. La investigación sobre el papel de las respuestas 
inmunitarias adaptativas en el asma se había enfocado extensamente sobre 
las células T CD4+ efectoras, como conductoras centrales de tales respuestas. 
Sin embargo, tras el hallazgo de la existencia de células T CD4+CD25+ 
inmunoreguladoras en los años 90, y tras el descubrimiento asimismo del 
factor de transcripción FOXP3 como marcador y efector molecular clave en la 
función de las células T CD4+ reguladoras, se produjo un importante giro 
conceptual, ya que las células T CD4+ dejaban de ser exclusivamente células T 
efectoras. Estos hallazgos incitaron el extenso y rápido desarrollo de trabajos 
de investigación sobre las Tregs, aunque en el campo del asma se generaron 
datos muy escasos e inconsistentes. La hipótesis que inicialmente surgió y se 
generalizó fue que las células Treg estarían disminuidas en el asma, y por lo 
tanto la inflamación crónica de las vías respiratorias se desarrollaría como 
resultado de un fallo de esta rama reguladora. Sin embargo, la mayoría de los 
escasos estudios realizados se limitaron a análisis de sangre periférica que 
mostraron células Treg disminuidas en cantidad o en su capacidad de 
respuesta a estímulos quimiotácticos, más dos estudios hechos en lavado 
broncoalveolar, los cuales mostraron células Treg disminuidas o 
incrementadas, respectivamente. En ausencia de datos directos sobre células 
Treg en las vías respiratorias, formulamos la hipótesis de que la inflamación 
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crónica en el asma no surge de un fallo primario de las células Treg sino que, 
al contrario, las células Treg pueden estar de forma reactiva incrementadas en 
respuesta a la inflamación sostenida y pueden participar activamente en inducir 
remodelación a través de su citoquina principalmente producida, TGF-β, la cual 
es un potente factor fibrogénico. Bajo esta hipótesis, desarrollamos un modelo 
de asma experimental (datos no publicados, no parte de esta tesis), con tres 
puntos de corte de colección de datos, representando respectivamente 
enfermedad muy temprana, un punto intermedio de desarrollo de la 
enfermedad, y cronicidad a largo plazo. La hiperreactividad de vías 
respiratorias alcanzó su máximo en el punto intermedio, con un subsiguiente 
declive. De forma concomitante, se observaron células Treg productoras de IL-
10 y TGF-β, identificadas mediante colocalización por inmunofluorescencia de 
FOXP3 e hibridación in situ para IL-10 y TGF-β, que resultaron en un 
incremento gradual y significativo desde la enfermedad temprana hasta la 
enfermedad crónica a largo plazo, y este hallazgo se asoció con un incremento 
de células caliciformes, masa mucosa epitelial, y fibrosis subepitelial en las 
vías respiratorias. En las biopsias bronquiales, llevamos a cabo un análisis 
exploratorio sobre muestras de 29 pacientes con asma grave y 5 sujetos 
control, en el que se realizó detección inmunohistoquímica de FOXP3 seguida 
de tinción de contraste con hematoxilina. El factor FOXP3 resultó expresarse 
exclusivamente en células linfoides principalmente localizadas en la lamina 
propria, las cuales estaban virtualmente ausentes en los sujetos control e 
incrementadas de forma importante y significativa en los pacientes con asma 
grave. Este resultado es consistente con la hipótesis de que las células Treg 
infiltran de forma reactiva la pared de la vía respiratoria de los sujetos con 
asma, y pueden participar activamente en los mecanismos de la remodelación. 
En cuanto a las MSCs, éstas comparten con las Tregs las propiedades de ser 
inmunoreguladoras y simultáneamente tener la capacidad de participar en 
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procesos de reparación tisular y, por lo tanto, en la remodelación de vías 
respiratorias como respuesta reparadora disregulada. La efectividad del 
trasplante de MSCs para el tratamiento de la enfermedad injerto-contra-
huésped condujo a un despliegue de investigación sobre el potencial uso de 
MSCs para tratar diversas enfermedades inflamatorias crónicas. En el caso del 
asma, esta tendencia originó investigaciones rápidas que se enfocaron en las 
propiedades inmunoreguladoras de las MSCs, ignorando sin embargo el hecho 
de que las MSCs tienen el potencial de diferenciarse hacia células 
estructurales de tejidos mesenquimales, incluyendo células musculares lisas, y 
podrían por lo tanto favorecer la remodelación de vías respiratorias en vez de 
resultar en un efecto terapéutico si se administran como agentes 
antiinflamatorios. De hecho, existe evidencia acumulada de que los fibrocitos, 
un tipo de célula progenitora circulante derivada de la médula ósea, son 
reclutados a la pared de las vías respiratorias de los asmáticos y contribuyen a 
la remodelación del músculo liso. En un estudio recientemente publicado 
llevado a cabo en nuestra Unidad de Neumología Experimental, se 
trasplantaron MSCs derivadas de tejido adiposo de ratones donantes de cepa 
consanguínea, genéticamente modificadas para la expresión permanente de 
green fluorescent protein (GFP) y su seguimiento in vivo, a ratones receptores 
con asma experimental establecida. Las MSCs disminuyeron rápidamente la 
inflamación de las vías respiratorias tras su administración, aunque este efecto 
terapéutico se siguió de un rebote con pleno restablecimiento de la inflamación 
tras dos semanas de exposición alergénica continuada. Por el contrario, la 
hiperreactividad de vías respiratorias se atenuó significativamente en este 
punto tardío tras el tratamiento, y este efecto se acompañó de una significativa 
regresión de la masa de músculo liso de las vías respiratorias, lo cual fue un 
resultado inesperado contrario a la hipótesis original. Además, las MSCs 
transferidas señalizadas mediante GFP no se integraron ni diferenciaron en 
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ningún tipo de estructura de la pared de la vía respiratoria, incluyendo el 
músculo liso. Estos resultados prometedores nos condujeron a llevar a cabo un 
estudio piloto para analizar la presencia de MSCs en biopsias bronquiales, 
basado en la detección inmunohistoquímica de STRO-1, que es un marcador 
de MSCs derivadas del estroma de la médula ósea. Se analizaron secciones 
de tejido de biopsias de 8 pacientes con asma grave y 4 sujetos control. En los 
sujetos control, no se detectó prácticamente la expresión de STRO-1. Por el 
contrario, en las muestras de los sujetos con asma grave se encontraron 
células STRO-1+ en significativas cantidades, localizadas en la lamina propria. 
En estos sujetos, se hallaron asimismo agrupamientos del antígeno STRO-1 en 
el músculo liso bronquial, sugerentes de una expresión residual de STRO-1 por 
previas MSCs que habrían recientemente migrado y se habrían integrado 
diferenciado como miocitos en el músculo liso de las vías respiratorias. Este 
resultado, en desacuerdo con los datos del previo estudio sobre tratamiento 
con MSCs en asma experimental murina, sugiere que pueden existir diferentes 
poblaciones celulares progenitoras, incluyendo MSCs de origen en estroma 
medular, que pueden ser reclutadas durante la remodelación del músculo liso 
de las vías respiratorias en el asma. En vista de tal predecible complejidad, 
serán necesarios estudios subsiguientes y un sólido desarrollo preclínico 
previos a cualquier potencial terapia basada en MSCs para el asma, y el futuro 
puede guiarnos hacia investigar sobre la producción y uso terapéutico de 
mediadores derivados de las MSCs, más que sobre el empleo directo de 
dichas células. 
Aparte de los proyectos y resultados aquí resumidos, el Biobanco de 
Biopsias Bronquiales ha alcanzado asimismo su compromiso de servir a 
proyectos dirigidos por otros investigadores, con tres de tales proyectos en 
desarrollo presente, en diferentes estadios. En resumen, el Biobanco de 
Biopsias Bronquiales ha sido exitosamente conducido desde su concepción 
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como una novedosa iniciativa hasta su implementación en la práctica, y: ha 
promovido la colaboración multicéntrica; ha generado un flujo sostenido de 
biopsias de calidad que permiten generar resultados válidos para objetivos 
científicos; nos ha permitido enlazar resultados de modelos animales de asma 
experimental y estudios in vitro de biología celular y molecular con la 
generación de evidencia clínica de soporte, lo cual es la finalidad última de la 
investigación traslacional; ha evolucionado para adherirse a desarrollos 
normativos que han ocurrido paralelamente; y ha proporcionado soporte 
logístico, base de conocimiento metodológico, formación, y servicios de gestión 
y análisis de muestras para proyectos iniciados por distintos investigadores 
cualificados. Adicionalmente, su logística, procedimientos operativos 
estandarizados y base de conocimiento proporcionan una preparación previa a 
la previsible necesidad futura de desarrollar e implementar ensayos clínicos 
enfocados en el desarrollo de terapias innovadoras que hagan diana en la 
remodelación de vías respiratorias.  
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SUMMARY 
Since the 1960s, the prevalence of asthma has increased by 50% per 
decade worldwide, along with its morbidity, mortality and economic burden. 
Only in the European Union, the prevalence of asthma doubled during the 
1990s, to reach up to 30 million asthmatics by the year 2000, with an annual 
cost of €17.7 billion for the health systems. Research on asthma 
pathophysiology and the subsequent therapeutic advances have had a 
significant impact in the management and control of the disease, yet a portion 
of approximately 10% of asthmatics still suffer from severe, difficult-to-manage 
disease, which can be refractory to the maximum available therapy. As a result, 
asthma has become a research priority for the health systems of the 
industrialized countries and extensive investigations are being carried out in 
seek of a better understanding of the disease mechanisms involved, and the 
development of innovative therapies. 
From the pathophysiology standpoint, chronic airway inflammation and 
remodeling underlie the clinical manifestations of asthma. Airway remodeling 
consists of a series of structural abnormalities that develop in association with 
chronic inflammation, mostly comprising hyperplasia and hypertrophy of mucus 
producing cells and glands, subepithelial fibrosis, neovascularization and an 
increase of airway smooth muscle mass. Data contributed from clinical studies, 
experimental asthma models and mathematical modeling of airway mechanics 
have converged into highlighting the increased airway smooth muscle mass as 
the airway remodeling feature chiefly involved in the mechanism of airway 
hyperresponsiveness, airflow obstruction and asthma severity. Airway smooth 
muscle growth in asthma appears to result from a combination of different 
mechanisms including hyperplasia due to proliferation of resident myocytes, cell 
hypertrophy, and the recruitment and differentiation of circulating, bone marrow-
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derived progenitor cells termed fibrocytes. Most of the knowledge on the 
mechanisms of airway smooth muscle remodeling has been inferred from 
experimental asthma models and in vitro cell and molecular biology studies, yet 
such data need translation into the clinical grounds for the advancement of 
knowledge on the mechanisms of actual human asthma, and for the 
development of novel treatments. On this front, bronchial biopsy obtained by 
means of bronchoscopy is the clinical benchmark as a live airway wall sample 
that allows us to analyze its structure and the immunobiological mechanisms 
involved in remodeling, at histopathological and ultrastructural level, and by 
means of in situ cell and molecular biology technologies. 
The collection and processing of quality bronchial biopsies that properly 
sample assessable airway smooth muscle for studies involving quantitative 
morphology implies a series of methodological complexities, and requires 
special logistics and a networking setup. Thus, the primary objective of the 
research work presented in this thesis was in itself to develop a Bronchial 
Biopsy Biobank through the implementation of the necessary logistics and 
standard operating procedures, that would allow us to establish a network for 
multicentric collection of bronchial biopsies, obtained by means of 
bronchoscopies indicated as per clinical practice, yet valid for research 
purposes. Two major premises have been taken into consideration: (i) to 
maximize the simplicity of procedures at the bronchoscopy and biopsy 
collection site; and (ii) to set up specimen processing and preservation methods 
suitable for the widest possible spectrum of subsequent investigational 
procedures, so as to establish the Bronchial Biopsy Biobank as a specialized, 
stable, sustainable structure able to serve the objectives of specific research 
projects from qualified investigators, as part of the Asthma Integrated Research 
Program (PII Asma) of the Sociedad Española de Neumología y Cirugía 
Torácica (SEPAR). Briefly, collaborating investigators at the participating sites 
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are provided with kits containing an Olympus 35C biopsy forceps, a set of 
screw-cap cryotubes preloaded with formalin (4% formaldehyde in PBS) as a 
fixative, shipping materials, informed consent formularies, and CRF documents 
including an anonymized registry with prenumbered subject codes. Bronchial 
biopsies are collected as per the 1990 workshop statement on the use of 
bronchoscopy and bronchoscopic instrumentation for research purposes in 
asthma and other airway diseases, and subsequent recommendations. The 
bronchial biopsies are collected from asthmatics, non-asthmatic subjects 
undergoing diagnostic investigations for a focal pulmonary condition (these 
provide a control airway wall group), or subjects with an airway inflammatory 
condition other than asthma, such as sarcoidosis, idiopathic eosinophilic 
bronchitis or COPD (these are a control airway inflammatory pathology group). 
Subjects with sarcoidosis not involving the airways are classed as control 
airway wall group. During bronchoscopy, the biopsies are dropped into the 
tubes preloaded with fixative. Once packed with the materials provided, a call is 
made to the DHL courier company for pickup and transportation under a preset 
client account number. The biopsies get fixed in formalin during the overnight 
shipment by DHL, for a controlled period of 24 hours. Upon receipt at the 
Bronchial Biopsy Biobank site, the biopsies are transferred to 70% ethanol and 
run over the next night in a conventional histopathology tissue processor for 
paraffin embedding. Microtome tissue sections are made from the paraffin 
blocks, out of which one is hematoxylin-eosin stained for general 
histopathological and quality assessment, and the rest of the sections along 
with the remaining part of the paraffin blocks are stored for subsequent studies 
pertaining to specific research projects. 
Other objectives for the work presented in this thesis have been to exploit 
the Bronchial Biopsy Biobank specimens for specific scientific aims pertaining 
to the core research line of the institutional Experimental Pneumology Unit that 
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fosters the development of the Biobank. The application of the Bronchial Biopsy 
Biobank specimens to such scientific aims has allowed us to bridge outcomes 
from experimental asthma animal models and in vitro cell and molecular biology 
studies with the generation of clinical supportive evidence, which is the ultimate 
goal of translational research. Such objectives, detailed in the paragraphs 
following below, have included investigations on: (i) a T cell/myocyte "synapse" 
involved in airway smooth muscle remodeling; (ii) the role of myocyte apoptosis 
in airway smooth muscle remodeling; (iii) the role of regulatory T cells in 
asthma; and (iv) the presence of mesenchymal stem cells in the airway wall of 
subjects with asthma. 
Translational analysis of a T-cell/airway smooth muscle cell "synapse" in 
airway remodeling. The role of T cells in driving chronic airway inflammation, 
and the association of inflammation with airway remodeling, led to the prior 
hypothesis that T cells drive airway smooth muscle remodeling. By means of an 
experimental asthma model, it had been demonstrated that T cells induce 
airway smooth muscle cell proliferation and an increase in airway smooth 
muscle mass. Confocal microscopy had  suggested direct contact between T 
cells and airway smooth muscle cells in vivo and, in an in vitro coculture 
system, the growth of airway smooth muscle depended on direct contact 
between the T cells and the myocytes. These data supported the hypothesis 
that a direct interaction between T cells and myocytes is involved in the 
mechanism of airway smooth muscle remodeling. In the work presented in this 
thesis, we studied the relevance of this hypothesis to human asthma by 
analyzing bronchial biopsies for evidence suggesting contact between T cells 
and airway smooth muscle cells or their potential precursors, and its 
relationship with target cell proliferation and airway smooth muscle mass. We 
employed α-SMA as a marker of both smooth muscle cells and less 
differentiated cell phenotypes that may potentially act as smooth muscle 
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precursors, since α-SMA is expressed by smooth muscle cells, myofibroblasts, 
and poorly differentiated cells suggested to derive from circulating fibrocytes. 
Furthermore, we analyzed the expression and distribution of vascular cell 
adhesion molecule-1 (VCAM-1), a T cell ligand suggested to play a role in a 
direct interaction between T cells and airway smooth muscle cells. We analyzed 
bronchial biopsy tissue sections from 16 moderate and 14 severe asthmatics, 
and 7 control subjects. The subjects with asthma showed increased airway 
smooth muscle mass in proportion to asthma severity. Also in the subjects with 
asthma, we observed the existence of a spectrum of α-SMA+ cell phenotypes 
located in the lamina propria, ranging from poorly differentiated cells to mature, 
smooth muscle-like cells apposing the outer edge of the airway smooth muscle 
bundles. This α-SMA+ cell phenotype spectrum, which we termed non-
organized airway contractile elements (NOACE), suggested to us that it may be 
the histopathological expression of a dynamic α-SMA+ transfer whereby 
circulating precursor cells are recruited out of the bronchial circulation 
microvasculature in the lamina propria, and they progressively migrate and 
differentiate so as to finally integrate into the hyperplastic airway smooth 
muscle layer as fully differentiated myocytes. Triple coimmunostaining of T 
cells, proliferating cell nuclear antigen (PCNA) and α-SMA, showed that 
proliferating (PCNA+) cells exist both in the airway smooth muscle bundles and 
NOACE, therefore suggesting that the hyperplastic growth of airway smooth 
muscle in asthma may be in part due to the proliferation of resident myocytes, 
plus the addition of cells differentiated from a progenitor pool that expands in 
the NOACE. In the same tissue sections, T cells were shown to infiltrate the 
airway smooth muscle in accordance with asthma severity, and some of them 
were found in microlocalization (juxtaposing) with PCNA+α-SMA+ cells, both in 
the airway smooth muscle bundles and NOACE, suggesting direct contact. 
Such T cell/ PCNA+α-SMA+ cell juxtaposition events was also increased in 
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accordance with the severity of asthma. Furthermore, VCAM-1 expression was 
upregulated in the subjects with asthma in the endothelium, airway smooth 
muscle and NOACE. In the airway myocytes and NOACE, VCAM-1 was 
expressed in the form of defined discoid patches suggesting receptor 
focalization and clustering for cell-to-cell interaction. In multivariate regression 
modeling, T cell infiltration of the airway smooth muscle was the major predictor 
of the airway smooth muscle mass increment, followed by the frequency of α-
SMA+PCNA+ cells in both airway smooth muscle and NOACE. In summary, 
consistently with the prior experimental evidence of direct cell contact mediated 
T cell involvement in airway smooth muscle remodeling, we showed in the 
present study on bronchial biopsies that T cells infiltrate the airway smooth 
muscle and juxtapose proliferating α-SMA+ cells in the airways of subjects with 
asthma. VCAM-1 may participate in mediating such T cell/α-SMA+ cell 
interaction. T cells may deliver morphogenic signals to α-SMA+ structural cells 
or their precursors through a direct, receptor-mediated "synapse" within the 
milieu of chronic inflammation and an associated dysregulation of repair 
responses. 
Role of apoptosis in airway smooth muscle remodeling. All previous work on 
airway smooth muscle remodeling has largely focused on its growth 
mechanisms in terms of hyperplasia/hypertrophy and the migration and 
differentiation of precursor cells. The prior experiments that demonstrated T 
cell-driven airway smooth muscle remodeling in short-term rat experimental 
asthma, also suggested that the growth of airway smooth muscle occurred 
through a combination of hyperplasia and inhibition of myocyte apoptosis. 
Contrary to those experiments, a study on horses with heaves, a naturally 
occurring, allergic airway obstructive disease due to hay sensitization, showed 
that airway smooth muscle cell apoptosis was increased. Such discordant 
results led us to hypothesize that apoptosis is involved in the homeostasis of 
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airway smooth muscle, and may be subjected to regulation through the natural 
history of the disease as airway remodeling occurs. To pursue this hypothesis, 
we first performed a study in murine experimental asthma (unpublished, not 
part of the present thesis), based on allergic sensitization followed by repeated 
allergen bronchoprovocation, with two data collection cutoffs: (i) a short-term 
cutoff reflecting early disease and (ii) a late cutoff reflecting long-term disease. 
At the early cutoff, the mice with experimental asthma showed an unchanged 
baseline frequency of airway smooth muscle cell apoptosis compared with 
control animals, and airway hyperresponsiveness associated with remodeled 
airway smooth muscle with increased mass was already present at this point. 
On the late cutoff, airway smooth muscle cell apoptosis was upregulated in the 
animals with experimental asthma. In all, the data suggested that a baseline 
frequency of apoptosis exists in airway smooth muscle, likely involved in the 
homeostasis of this structure, and that, in response to airway smooth muscle 
remodeling as asthma develops, myocyte apoptosis is upregulated. To provide 
a further, more mechanistic demonstration of this concept, we developed 
another murine model where apoptosis was pharmacologically inhibited during 
the development of experimental asthma, by means of a wide spectrum 
caspase blocking drug. In the animals with experimental asthma, the in vivo 
inhibition of apoptosis led to: (i) chaotic pulmonary mechanics, reflected by an 
unusual response to methacholine challenge where the pulmonary resistance 
(RL) output was an unusual tracing suggesting a sort of airway smooth muscle 
"fibrillation"; and (ii) inusitate, unstructured growth of airway contractile tissue, 
shown in the form of an unusual pattern of airway smooth muscle remodeling, 
consisting of an exaggerated thickening of the airway smooth muscle layer 
along with morphological features suggestive of disorganized growth of this 
structure. In all, the data from these experimental asthma models showed that 
airway smooth muscle cell apoptosis is involved in the homeostasis of this 
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structure, and that an upregulation of myocyte apoptosis occurs in response to 
airway smooth muscle remodeling through the development of the disease. 
Such findings brought us to perform a study on human bronchial biopsies, 
shown in this thesis, in search of further evidence for such involvement of 
apoptosis in the pathology of actual asthma. In this study, we analyzed 
bronchial biopsy tissue sections from 59 subjects with asthma, comprising 7 
subjects with intermittent asthma, 33 with moderate asthma and 19 with severe 
asthma, plus 13 controls subjects. First, we performed in situ terminal 
deoxynucleotidyl transferase mediated dUTP nick end labeling assay (TUNEL), 
and colocalization of this signal with α-SMA. In a subsequent exploratory 
analysis, partially limited by specimen availability, we performed 
coimmunostaining of cleaved poly ADP ribose polymerase (c-PARP), a 
byproduct of caspase activity and apoptosis, with α-SMA. The latter analysis 
comprised tissue sections from biopsies of 5 moderate and 8 severe 
asthmatics, and all 13 controls subjects. Consistently with previous data, the 
airway smooth muscle was increased in the subjects with asthma showing a 
significant gradient from the control subjects through the severe asthmatics. 
Remarkably, a borderline significant increment of airway smooth muscle was 
already present in the subjects with intermittent asthma. An observed greater 
frequency of TUNEL+α-SMA+ cells in the asthmatics did not result statistically 
significant, yet severe asthmatics did show a significant increase in the 
frequency of c-PARP+α-SMA+ cells over the moderate asthmatics and the 
controls. Overall the data suggest, in consistency with the animal models, that 
an upregulation of myocyte apoptosis is involved in the mechanisms of airway 
smooth muscle remodeling, likely playing a regulatory role in response to the 
smooth muscle growth. 
Regulatory T cells (Tregs) and mesenchymal stem cells (MSCs) in bronchial 
biopsies. Research on the role of the adaptive immune responses in asthma 
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had largely focused on effector CD4+ T cells, as central drivers of such 
responses. However, following the discovery of immunoregulatory CD4+CD25+ 
T cells in the 1990s, and also the discovery of the transcription factor FOXP3 as 
a key molecular effector and marker of CD4+ regulatory T cells, a major 
conceptual turnaround on the immune responses occurred, since CD4+ T cells 
were not anymore just effector T cells. This sparked rapid and extensive 
research on the Tregs, yet very scarce and inconsistent data were generated in 
the field of asthma. The hypotheses that initially arose and got generalized was 
that Tregs would be decreased in asthma, and therefore chronic airway 
inflammation would develop as a result of a failure of this regulatory arm. 
However, most of the few studies done were limited to peripheral blood 
analyses showing decreased Treg numbers or impaired responsiveness to 
chemotactic stimuli, and two studies done on bronchoalveolar lavage fluid 
showed decreased or increased Tregs, respectively. In the absence of any 
direct data on Tregs in the airways, we hypothesized that chronic airway 
inflammation does not arise from a primary failure of Tregs but, conversely, 
Tregs may be reactively increased in response to the sustained inflammation 
and may actively participate in inducing airway remodeling through their main 
released cytokine, TGF-β, which is a potent fibrogenic factor. Under this 
hypothesis we conducted an experimental asthma model (unpublished data, 
not part of the present thesis), with three data collection cutoffs representing 
very early disease, an intermediate point of disease development, and long-
term chronicity, respectively. Airway hyperresponsiveness peaked at the 
intermediate point and then plateaued and declined. Concomitantly, IL-10 and 
TGF-β producing Tregs, identified by colocalization of FOXP3 
immunofluorescence with IL-10 and TGF-β in situ hybridization, increased 
gradually and significantly from early disease through long-term disease, and 
this was associated with increased goblet cell numbers, airway epithelial mucus 
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mass and subepithelial fibrosis. In bronchial biopsies, we undertook an 
exploratory analysis on the specimens from 5 control subjects and 29 subjects 
with severe asthma, whereby FOXP3 immunostaining followed by hematoxylin 
counterstain was performed. FOXP3 was exclusively expressed by lymphoid 
cells mostly located in the lamina propria, which were virtually absent in the 
control subjects and increased in important significant numbers in the airway 
wall of the subjects with severe asthma. This outcome is consistent with the 
hypothesis that Tregs are reactively increased in the airway wall of asthmatics, 
and may actively participate in the mechanisms of airway remodeling. As for the 
MSCs, they share along with Tregs the properties of being immunoregulatory 
and simultaneously having the means to participate in tissue repair processes 
and thus in airway remodeling as a dysregulated repair response. The 
effectiveness of MSC transfer to treat graft-versus-host disease led to a hot 
topic for investigations into the potential use of MSCs to treat a variety of 
chronic inflammatory disorders. In the case of asthma, this trend led to rapid 
research that focused on the immunomodulatory properties of MSCs, 
completely overlooking the fact that MSCs have the potential to differentiate 
into mesenchymal tissue structural cells including smooth muscle cells, and 
might thus promote airway remodeling instead of having a therapeutic effect if 
administered as anti-inflammatory agents. In fact, there is accumulated 
evidence that a type of circulating, bone marrow-derived progenitor cell termed 
fibrocyte, get recruited into the airway wall of asthmatics and contributes to 
airway smooth muscle remodeling. A recently published study was conducted 
at our Experimental Pneumology Unit, where adipose tissue-derived MSCs 
from syngeneic donor mice, genetically engineered to permanently express 
green fluorescent protein (GFP) for in vivo tracking, were administered to mice 
with established experimental asthma. The MSCs abrogated airway 
inflammation soon after their administration, yet this therapeutic outcome was 
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followed by a rebound with full reinstatement of airway inflammation after two 
weeks of continued allergen exposure. Conversely, airway 
hyperresponsiveness was significantly attenuated at such late cutoff after MSC 
treatment, and this was accompanied by a significant regression of the airway 
smooth muscle mass, which was an unexpected outcome contrary to the 
original hypothesis. Furthermore, the transferred GFP-labeled MSCs did not 
integrate nor differentiate into any airway wall structures including the airway 
smooth muscle. These promising results prompted us to conduct a pilot study 
to analyze the presence of MSCs in bronchial biopsies, on the basis of STRO-1 
immunostaining, which is a marker of marrow stroma derived MSCs. We 
analyzed biopsy tissue sections from 4 control subjects and 8 subjects with 
severe asthma. There was virtually no existing STRO-1+ cells in the control 
subjects. On the contrary, STRO-1+ cells were present in significant numbers in 
the lamina propria of the subjects with severe asthma. In these subjects, 
STRO-1 antigen clusters were also present in the airway smooth muscle, 
suggesting residual STRO-1 expression by former mesenchymal stem cells that 
had recently migrated, integrated and differentiated as myocytes into the airway 
smooth muscle. This latter outcome, in mismatch with the outcome from the 
previous study on treatment with MSCs in murine experimental asthma, 
suggests that different progenitor cell populations may be recruited during 
airway smooth muscle remodeling in asthma, and cells of stromal MSC origin 
may be involved. In view of such foreseeable complexity, further research and 
solid preclinical development are warranted for any MSC-based asthma 
therapies, and the future may lead us to investigate on the production and 
therapeutic use of MSC-derived mediators rather than employing the MSCs 
themselves. 
Apart from the projects and results summarized here, the Bronchial Biopsy 
Biobank is meeting its commitment of serving projects driven by different 
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qualified principal investigators, with three of such projects running at present in 
different stages of development. In summary, the Bronchial Biopsy Biobank has 
been successfully drawn from its inception as a novel initiative to its 
implementation into practice, and has achieved the following of: fostered 
multicentric collaboration; yielded a sustained flow of quality biopsy specimens 
allowing to generate valid outcomes for specific scientific goals; allowed us to 
bridge outcomes from experimental asthma animal models and in vitro cell and 
molecular biology studies with the generation of supportive clinical evidence, 
which is the ultimate goal of translational research; evolved to meet parallel 
normative developments; and provided supportive logistics, methodological 
knowledge base, training, and specimen handling and analysis services to 
investigator-initiated projects. Furthermore, its logistics, standard operating 
procedures and knowledge base provide readiness for a future, foreseeable 
need of designing and implementing clinical trials aimed at developing 
innovative therapies that target airway remodeling.  
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1. Introduction 
Chronic airway inflammation and remodeling, underlie the clinical 
manifestations of asthma. Data from clinical studies,1 mathematical modeling2, 3 
and experimental asthma4-6 suggest that increased airway smooth muscle is 
involved in airway hyperresponsiveness, airflow obstruction and disease 
severity. Mechanisms proposed for the growth of airway smooth muscle in 
asthma include in situ proliferation,7, 8 and the expansion and migration of a 
subepithelial myofibroblast population.9 More recently, the recruitment and 
differentiation of fibrocytes, i.e. a circulating, bone marrow-derived progenitor 
cell, has also been proposed as a contribution to airway smooth muscle growth 
in asthma.10-18 The cumulative evidence pointing at the importance of airway 
smooth muscle remodeling in asthma pathophysiology has propelled research 
into its mechanisms, yet no therapy targeting remodeling has been developed. 
Most of the knowledge on the cell and molecular pathways leading to airway 
remodeling has been gained from in vitro research and from investigations 
employing animal models of experimental asthma. However, a translation of 
such knowledge to actual human asthma is deemed essential for the discovery of 
therapeutic targets and the development of novel therapies that may attenuate or 
revert airway remodeling. This is essential from the standpoint of descriptive 
studies aiming at human correlates that validate basic experimental data, and 
instrumental for clinical trials that may eventually aim at proving the safety and 
efficacy of airway remodeling-targeted therapeutic advances. On such front, the 
bronchial biopsy is the only existing type of clinical specimen that allows us to 
sample the live airway wall while acceptably preserving its tissular architecture 
for structural analysis through quantitative morphology. However, harvesting 
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and processing bronchial biopsies that sample assessable airway smooth muscle 
for research purposes bears its complexities and requires particular logistics and 
a networking setup. In the present thesis, the process, methodology and 
outcomes from establishing the first specialized Bronchial Biopsy Biobank of 
Spain, a project fostered within the Programa Integrado de Investigación en 
Asma (PII Asma) of the Sociedad Española de Neumología y Cirugía Torácica 
(SEPAR), is presented. Furthermore, specific data sets generated from the 
analysis of bronchial biopsies in pursuit of translating animal model outcomes 
are also shown and discussed.  
 
2. Asthma: a general background 
Since the 60s, there has been an escalation in the prevalence of global 
asthma, as well as morbidity, mortality and economic burden associated with it. 
From data collected through the Global Initiative for Asthma (GINA)19, 20 the 
estimated prevalence of asthma is increasing at a rate of 50% each decade in the 
world. The prevalence doubled in the decade of the 1990s in the European 
Union (EU), to reach by the year 2000 close to 30 million of affected people, 
costing 17,7 billion euros annually in the health systems. In Spain, the 
prevalence of asthma varies from 1% to 4% depending on areas and data 
sources21, 22 or between 5,1% and 7,5% as per the Executive Summary of the 
GINA Dissemination Committee report19 whereby it alone has progressively 
increased.23 For children in the age range of 6 to 7 years old and adolescents, the 
prevalence of asthma symptoms has reached critical values in different areas in 
Spain; 13.6% (children) and 12.2% (adolescents)22, 24 and 16.7% (adolescents).22 
In some countries, asthma prevalence has reached 18%.  
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Advances in the understanding of disease mechanisms in asthma 
physiopathology have resulted in subsequent therapeutic advances, with a 
significant impact in the management and control of the disease. Despite the 
latter, the number of asthmatics continue to grow. The proportion of cases with 
severe, difficult-to-manage asthma known for being refractory despite available 
treatments, accounts for approximately 10% and has not been eradicated.25, 26 In 
the European Union, the population mortality rate has oscillated from 0.78 to 1 
per 100.000 inhabitants in some regions, which amounts to approximately 8 to 
10 deaths per year due to asthma in local populations inhabited by one million 
individuals.  
Hospitalizations due to acute asthma attacks are frequent, with 
approximately 20% of asthmatics having acute episodes requiring emergency 
room visits.27 Hospital admissions from acute attacks among children of all ages 
are also frequent.28 As such, asthma exacerbation sufferers are a financial 
burden, resulting in tripling the costs of health care resources as opposed to 
those who do not exacerbate.27 Episodes of asthma exacerbations can therefore 
impose a large cost for the health care systems worldwide. Furthermore, 
productivity losses caused by poor asthma control has been estimated to account 
for €9.8 billion per year in Europe alone28 From the evidence collected, an 
overall consensus exists regarding the dimension of the problem, and asthma is 
on the rise despite advances in the domain,29 making it an utmost priority for 
research in the health care systems of the European Union and also for the 
pharmaceutical industry.  
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2.1 The asthma concept: a brief historical account 
The word “ásth-ma” (άσθμα) originates from the Greeks and has been 
employed up-to-date to define the disordered chronic inflammatory state which 
affects the respiratory airways. There is evidence from hieroglyphics and other 
sources that asthma preceded the Greeks. Historically, in the year 2600 BC, the 
Chinese medical books were pioneers in trying to describe the clinical 
characteristics of asthma.30, 31 The first known explanation used to describe the 
disease, included fast and laborious breathing as typical of an individual during 
an asthma attack.  The Corpus Hippocraticum, by Hippocrates (460-360 BC), 
pinpointed the medical term “asthma” in his writings and referred to the term as 
being associated with spasms that occurred mostly with occupational work such 
as tailors and metalworkers. Following suit were Aretaeus of Cappadocia and 
Galen of Pergamo, which added on to Hippocrates’ writings in the 1st and 2nd 
centuries AD, and described asthma as bronchial obstruction.32 All the 
aforementioned remained as such until the Middle Ages. In the second century, 
a Roman Doctor named Areteo of Capadocia, wrote in his book on the “Causes 
and symptoms of chronic diseases” which was one of the first descriptions on 
asthma symptoms.   
A Belgian physician from the 17th century, named Jean Baptiste Van 
Helmont (1579 – 1644), a chemist and physiologist who suffered from asthma, 
believed that asthma originated in the “pipes” of the lungs and pointed out that 
the contraction of the lungs was a pathophysiological mechanism associated 
with asthma.30 Bernardino Ramazzini (1633 – 1714), also from the same 
century, detected a relationship between asthma and organic dust, and also 
recognized exercise-induced asthma. In the year 1698, an English asthmatic 
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doctor named Floyer, published the first clinical based evidence on all that 
encompassed asthma symptomatology. One of Floyer’s greatest observation, 
was to attribute bronchospasm as the contraction of muscular fibers wrapping 
the bronchioles. He also speculated on the possible etiological causes of the 
disease to the following contributing factors of hereditary, tobacco, occupational 
and atmospheric in nature.33, 34 Later on, Friedrich Hoffmann (1660-1742) 
contributed books such as “Fundamentals” and “Rational Systems Medicine,” 
with a new perspective on the disease that attracted interest towards 
inflammation of the respiratory airways in asthma. Following, through the XIX 
century, there were two technological advances contributing to the 
understanding of asthma, as well as other respiratory diseases, which were the 
stethoscope and spirometry. The stethoscope was invented in 1819 by a French 
physician, Theophile Hyacinthe Laënec. He was able to describe signs and 
symptoms from processes that differed such as bronchiectasis, emphysema, 
pulmonary infarct, pulmonary abscesses, pulmonary carcinoma and 
bronchopneumonia. As well, the first spirometer prototype was developed and 
presented by John Hutchinson in 1888. Its invention has been greatly used and 
continues to be so in the field of respiratory medicine.35-37 With all this, at the 
start of the XIX century asthma was still considered a disease that encompassed 
any clinical state associated with a respiratory deficiency. It wasn’t until late in 
the century, that Henry Hyde Salter issued a detailed treatise publication of 
asthmatic symptoms, of which he himself suffered.38 Henry Hyde Salter's 
treatise, entitled “On asthma, its pathology and treatment” (1860), comprised the 
best known practices in treating asthma, and defined asthma as “…a paradoxical 
dyspnoea of peculiar nature, generally periodic, with respiratory satisfaction in-
between episodes”. The theory collected was that “during an asthmatic crisis, 
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the peri-bronchial muscles presented with an intense contraction.” As well, there 
was an advanced classification of each external stimuli, that could be associated 
with an asthma crisis. Hyde-Salter was also the first in describing contributing 
characteristics of asthma such as the presence of eosinophils in sputum from 
asthmatic patients, and in defining bronchial hyperactivity.36, 37, 39 
Important advances in Medicine followed at the advent and beginning of the 
20th century. Sir William Osler, who described asthma as a condition producing 
spasms of bronchial muscles, swelling of the bronchial mucous membrane and 
inflammation of the smaller bronchioles,40 provided an early contribution to the 
clinical observational interconnection between pathology and physiology. Other 
contemporary scientists contributed to the advances on the pathogenesis of 
asthma, such as Charles Blackley and Frances Rackemann. Through their 
studies they were able to describe “asthma due to hay” and were the originators 
of non-allergic types of asthma in the years 1870 and 1910 respectively.36, 37, 39 
The constriction of airway smooth muscle was experimentally performed and 
documented by Brodie and Dixon in 1903.41 In the year 1906, experimental 
exposure to purified allergens was found to reproduce the symptoms of hay 
fever42 and that led to the characterization of asthma as an allergic 
hypersensitivity to foreign antigens. Worth noting, is recognition for work done 
by Richet and Portier on their description of anaphylaxis, and Von Pirquet for 
his nomenclature for antigenic hypersensitivity as “allergy” as well as his 
collaboration with Schick for relating it to antigen-antibody interaction.43, 44 In 
1910, Meltzer brought up the origin of allergic asthma, and in 1921 Cooke 
refurbished the knowledge obtained in the last era and demonstrated the 
relationship between domestic dust and allergic symptoms that gave way to the 
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association of Dekker between asthma and house dust mites (HDM).45-47 All the 
aforementioned advances led to the hypothesis that allergen administration in an 
attenuated fashion that is continuous, could attenuate the response mediated by 
its antibodies, responsible for allergic development, which laid the fundamental 
basis for the later development of immunotherapy.  
The discovery of a serum substance, in 1921, which demonstrated passive 
transfer of “allergy” to a specific allergen,48 led to the identification of IgE49 and 
provided a critical link in characterizing asthma as an allergic disorder. In the 
first half of the 20th century, Paul Ehrlich described aniline stains for 
eosinophils (eosin) and mast cells (toluidine blue)50, 51 that favored 
histopathological studies of different diseases; primarily allergic diseases which 
includes asthma. These advances, together with technical advances in optical 
microscopy, led to a better understanding of how allergen exposure can trigger 
the release of chemical mediators from airway mast cells (early reaction), which 
in turn can lead to the recruitment of eosinophils, basophils and mononuclear 
cells (late reaction).52, 53 A late response in asthma was also linked to the 
enhanced airway reactivity to irritant stimuli. Mast cells were attributed to a 
primary role in triggering IgE-dependent inflammation in asthma in the 1970’s 
and 80’s,54 and a broad range of pro-inflammatory substances (histamine, 
prostaglandin D2, cysteinyl-leukotrienes, tryptase, chymase, heparin and etc.) 
were identified as mast cell products participating in the asthmatic reaction. 
Concurrently, there was a growing interest in the role of T lymphocytes in 
allergic responses,55 that led to the identification of a special subset of T cells 
capable of secreting cytokines (IL-4, IL-5, IL-13) which selectively interact with 
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mast cells, basophils and eosinophils, and are responsible for the recruitment, 
priming and survival of the primary effector cells of the allergic cascade.56   
Sir William Osler’s definition at the Ciba Foundation Guest Symposium in 
1959, which was considered as obsolete, was perfected thanks to the advances 
made in asthma research over the years. It has thus been redefined as “a disease 
characterized for its variable occlusion of the respiratory airways, of which 
profoundly alters in a spontaneous way or in its response to a specific 
treatment.” This definition was expanded by an American Thoracic Society 
Committee in 1962 to make reference to the increase in response of the 
respiratory airways from diverse stimuli, introducing the term bronchial 
reactivity.57 
Since the introduction of the Global Initiative for Asthma (GINA) in the 
1990s, significant improvements in asthma care have been achieved thanks to 
the guidelines in asthma management provided. The GINA defined asthma as a 
“chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation causes an associated increase in 
airway hyper-responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in the early 
morning. These episodes are usually associated with widespread but variable 
airflow obstruction that is often reversible either spontaneously or with 
treatment.”19 
The main clinical manifestations of asthma are wheezing, cough, chest 
tightness, dyspnea, bronchoconstriction and airway hyperresponsiveness, which 
are variable in the asthmatic population. Also, different clinical-epidemiological 
“phenotypes” can be defined according to the disease history, clinical 
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manifestations, inflammatory profile and response to therapy. Airflow 
obstruction can be variable and episodic in asthma, which can be associated with 
triggering factors such as infections, allergens and inflammatory peaks, or can 
be persistent (associated to airway structural changes), leading in the latter case 
to an irreversible deterioration of lung function.58 Airway remodeling has 
recently contributed to the understanding of asthma disease mechanisms and 
become defined as structural alterations that can develop in association with 
chronic inflammation, which plays a key role in the clinical manifestations of 
the disease and causes the clinical signs.59, 60  
Chronic airway inflammation can contribute towards airway remodeling and 
reversible episodes of airflow obstruction that may evolve towards chronic 
obstruction and progressive, irreversible deterioration of lung function. The 
repetition of several contributing factors from infections to pollution, allergens 
and meteorological conditions (changes in weather), may trigger acute asthmatic 
episodes that may also contribute to the progression towards a chronic decline in 
lung function.61 Despite clinical and basic knowledge advancement over the 
years on the understanding of asthma, there is a perceived complexity 
underlying the disease. 
2.2 Evolution of the asthma therapeutic armamentarium and contemporary 
clinical guidelines 
As with understanding and defining what is understood as asthma, the 
treatments used to alleviate its associated symptoms have also evolved through 
history. For many years, the usage of the Datura stramonium plant due of its 
anticholinergic properties and its xanthine contents, and other anticholinergics 
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(atropine) that were purified from the base of the Atropa belladonna, were 
common remedies for asthma attacks.62 Because of the slow mode of action 
from these anticholinergics and their secondary adverse effects, subsequent drug 
research for treatments on asthma focused on finding and isolating substances 
that were more effective and less harmful. In 1888, Albrecht Kossel managed to 
isolate theophylline (1,3-dimethylxanthine) from the coco grains, which can also 
be found naturally in coffee or in tea. The importance of this discovery was not 
fruitful until 1921, where its relaxant properties on the smooth muscle were 
discovered.63 Following, was the synthesis of aminophylline, which took over 
the usage of anticholinergics despite its non-superior effects, and it was not until 
the 1980s that the toxic effects of methylxanthines were understood.     
Despite the discovery of adrenergic agonists prior to methylxanthines, the 
therapeutic development of this drug class was much slower. Although the 
usage of a catecholaminergic agonist dates approximately 500 years ago, as an 
old Chinese remedy derived from the Ephedra sinica (Ma Huang) plant, 
adrenaline was not discovered until 1900 and was isolated and purified in 
1901.64, 65 Adrenaline was soon used as a bronchodilator in asthmatic patients, as 
an oral administration compound that was poorly effective. Alternative modes 
were then investigated such as via subcutaneous by 190366 and inhaled aerosol 
forms by 1910,67 that improved the symptoms of patients, but with secondary 
cardiac effects. 
The discovery of alpha and beta adrenergic receptors in the 1960s led to the 
discovery of drugs that were more specific, such as isoprenaline (isoproterenol), 
of easy usage and ample accessibility for asthmatics but with greater side 
effects, which manifested in an increase in the incidence of deaths due to asthma 
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crises between 1963 and 1968 in England, Wales, Scotland, Ireland, Australia 
and New Zealand.68 Following the latter failure, the use of isoproterenol was 
dropped and, thanks to the discovery of β1 and β2 adrenergic receptors in 1968, 
drugs that were more selective such as salbutamol and terbutaline were 
developed. In the 1980s, β2-adrenoreceptor agonists of long duration of action 
(long-acting β2-adrenergic agonist, LABA) were developed such as salmeterol 
and formeterol.69 Lately, a long-acting anticholinergic agent originally 
developed for chronic obstructive pulmonary disease (COPD), tiotropium 
bromide, has been approved for asthmatics already on treatment with a LABA 
plus inhaled corticosteroid who are not sufficiently controlled as per the 
frequency and severity of their exacerbations.70 This latest addition represents a 
long turnabout from a historical standpoint, where a modernly developed 
anticholinergic agent has come to expand the asthma bronchodilator toolbox.  
Aside from inhaled bronchodilators, a pivotal advance for the treatment of 
asthma was the development of inhaled corticosteroids although the deployment 
of this drug class was slow. Cortisone was identified in 1936, but its anti-
inflammatory properties as a steroid were only known by the years 1940 to 
1956, whereby the safe administration along with long-term usage of this drug 
was achieved, and its effectiveness in asthma demonstrated.71, 72 The ample 
usage of corticosteroids for the treatment of asthma evolved through the 1970s 
with the development of beclomethasone as the first inhaled steroid, followed 
later by others such as budesonide and fluticasone propionate.73 Years later, a 
study involving asthmatic patients of recent diagnosis demonstrated that the 
early usage of inhaled corticosteroids, compared to β2-adrenergic agonists alone, 
reduced bronchial hyperreactivity and the deterioration of pulmonary function.74 
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Advances in the treatment of asthma with inhaled corticosteroids and in 
combination with bronchodilators, were complemented from the 
pharmacological developments that focused the therapy on the pathway of 
inflammatory mediators derived from arachidonic acid, more specifically the 
leukotrienes, molecules discovered in 1940 by Kellaway and Trethewie. The 
blockade of leukotrienes showed its benefits on inflammation, bronchial 
hyperreactivity and airway remodeling and as such, commercialization in the 
1990s of the first inhibitors of the synthesis of leukotrienes, such as zileuton, 
and the first leukotriene receptor antagonists such as pranlukast, zafirlukast and 
montelukast, begun.69, 75 
In the last 20 years, studies on the immunological mechanisms underlying 
asthma and the application of new molecular biology-based technologies 
brought advances that translated into the development of a novel drug class, the 
"biologicals" or humanized monoclonal antibodies (the "umabs"). This is the 
case of omalizumab in the asthma field, an anti-IgE monoclonal antibody, 
approved in 2003 for severe atopic asthmatic patients with high levels of total 
serum IgE, that are insufficiently management for their disease despite the 
current therapies previously mentioned.76 After Omalizumab, the humanized 
monoclonal antibody technology has been employed to generate a number of 
new "umabs" directed to a variety of immunological pathway targets, now 
undergoing clinical development. This involves agents such as mepolizumab 
and reslizumab targeting IL-5, benralizumab targeting the IL-5 receptor, 
lebrikizumab and tralokinumab targeting IL-13, dupilumab targeting the alpha 
subunit of the IL-4 receptor which is bound by both IL-4 and IL-13, and 
QGE031B, an improved anti-IgE antibody.  
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Another advance, already approved for clinical practice, came from the field 
of interventional respirology: bronchial thermoplasty.77 In bronchial 
thermoplasty, radiofrequency energy is delivered through bronchoscopy aiming 
at reducing the amount of airway smooth muscle. The immediate effect of 
delivering radiofrequency energy to the airways is a heat injury. While all types 
of airway structural cells are susceptible to such immediate injury, normal 
anatomy is preserved and, with time, there is complete reconstitution of the 
airway wall constituents with the exception of smooth muscle. Therefore, one 
obvious effect of bronchial thermoplasty is a reduction of airway smooth muscle 
mass,78-80 and improved asthma control was reported in a randomized clinical 
trial.81 
 Using the modern, currently available therapeutic resources, both the GINA 
and GEMA asthma management guidelines have assembled asthma treatment 
through a stepwise approach aimed at asthma control, i.e. treatment is subjected 
to reviewing along with disease follow up and can be stepped up or down 
according to asthma control monitoring. Therapeutic step 1 is applicable to the 
so-called "intermittent asthma" and consists of on-demand use of inhaled, short-
acting β2-agonists such as salbutamol or terbutaline. Step 2 is the lowest 
therapeutic stage for those with mild persistent asthma requiring minimum 
maintenance therapy, and consists of regular, low-dose inhaled corticosteroids. 
For higher asthma severity stages, or as the goal of asthma control requires 
increased therapy, subsequent steps combine increased doses of inhaled 
corticosteroids along with the addition of second controller medications such as 
LABAs, leukotriene modifiers, and long-acting muscarinic bronchodilators 
(tiotropium bromide currently approved). At the top of currently approved 
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therapies, there is the use of systemic corticosteroids as part of the maintenance 
treatment, and/or omalizumab where indicated (GINA step 5, or GEMA steps 5 
and 6).20, 22 
 
3. Asthma immunobiology: basic principles 
The main aim of the present thesis is to present the development of a 
specialized bronchial biopsy biobank as a tool to chiefly analyze airway 
remodeling in human airway specimens. Airway remodeling is a final outcome 
underlying asthma severity and its clinical features, and is closely engaged in its 
mechanisms with the cornerstone feature that defines asthma physiopathology: 
chronic airway inflammation. Results from specific applications of the bronchial 
biopsy biobank to translational hypotheses stemming from animal models of 
experimental asthma are also presented as part of this thesis. For such reasons, 
the present section is focused on an overview of the immune system 
involvement in asthma (Fig. 1) and serves to introduce its close counterpart on 
the next section: airway remodeling. 
Gray’s Anatomy
50-100 m2
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 23 - 
Figure 1 (previous page). The respiratory system as an immunological organ. Our lungs 
contain by far our largest surface area exposed to the outer environment (about 50-
100 m²), extensively greater than our digestive tract or our skin. Such surface needs 
continued surveillance relying on the immune system. In fact, specialized cells of the 
immune system are continuously sampling every particulate matter that enters our 
conductive airways and lung parenchyma, and defense versus tolerance decisions are 
being constantly made. Indeed, immunological tolerance is not a passive outcome by 
default, but an active response subjected to complex regulation. The micrograph 
shown in the lower-right corner of the figure was obtained from an induced sputum 
sample of a patient with supposedly difficult-to-control asthma, and shows a 
macrophage fully engorged with phagocytosed bacteria. Figure composition elements: 
(i) Anatomical illustration: Gray's Anatomy, 1858 classical edition (Gray H., Vandyke 
Carter H.) under Creative Commons Attribution License; (ii) Macrophage micrograph: 
original, unpublished. 
 
3.1 Role of adaptive immune responses in the development of asthma  
The sequence of immunological mechanisms that underlie airway 
inflammation was best studied in asthma of allergic origin, whereby active 
participation of the adaptive immune system is present (Fig. 2).82-85 Generally, 
the immune response that in the form of hypersensitivity originates allergy, 
comes about as a result of a sensitization and later re-encounter with its antigen 
(in this case the allergen). During the process of allergic sensitization, the 
allergen is captured and processed by a specialized antigen-presenting cell 
followed by its presentation to naive T cells (a denomination that is given to 
CD4+ T cells when they have not yet been activated as a result of antigen 
presentation), which carry receptors that are specific for recognition of the 
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Dendritic cells
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Specific response
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Figure 2. Overview of the induction of an adaptive immune response. The immune 
system comprises an innate arm in charge of immediate, continued protection through 
nonadaptive, nonspecific responses, with no immunological memory. The first line of 
defense is provided by physical barriers such as the respiratory epithelium with its 
mucous lining and ciliary sweeping. Beneath such barrier, there is a dense network of 
dendritic cells, the most "professional" antigen presenting cells, which scan the 
antigens that enter our airways with the aid of prolongations across the epithelium. 
The lower-left corner micrograph shows an example of immunohistochemical 
detection of dendritic cells (red signal), fully surrounding the murine airway shown in 
the picture. When dendritic cells pick up antigen, they detach from the subepithelial 
network, undergo maturation and process the antigen as they migrate to the regional 
draining lymph nodes, where they present processed antigen peptides associated with 
MHC-II molecules. There they are scanned by naive CD4+ T cells that continuously 
circulate across the secondary lymphoid organs. Their TCR bears a predetermined 
specificity and, when an encounter occurs with a dendritic cell presenting a matching 
peptide/MHC-II complex and appropriate costimulatory signals are delivered, CD4+ T 
cell activation is triggered. Upon activation, the T cell will secrete cytokines such as IL-2 
and IL-4, which will further promote its proliferation and differentiation in an autocrine 
fashion. The activated CD4+ T cell, now an effector helper T cell, undergoes clonal 
expansion, generates effector and memory subpopulations, and modifies its leukocyte 
adhesion receptor expression so as to change its trafficking and exit the bloodstream at 
sites of inflammatory activity. Airway epithelium and lymph node: Creative Commons 
Attribution License. Micrograph: Lagranderie M et al. Immunology 2003;108:352-64. 
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processed antigen presented on major histocompatibility complex (MHC) class 
II molecules.  
Although different cells have the capacity to perform MHC class II-restricted 
antigen presentation such as macrophages, B cells, dendritic cells and possibly 
certain structural cells, the more "professional" and potent cells in their capacity 
to initiate and maintain the inflammatory response are the dendritic cells. In the 
airways, a dense population of dendritic cells exist that are present in the form of 
a subepithelial web with intraepithelial prolongations (Fig. 2),86 and that upon 
stimulation of the airways with allergens, its density is drastically increased.87-89 
Before an encounter with an allergen occurs, these dendritic cells are found in 
an immature state, expressing on their cell surface small traces of B7 co-
stimulating molecules (CD80 y CD86) and MHC molecules that are incapable 
of stimulating the naive T cells. The detection of foreign antigen presence by 
different mechanisms based on the surface receptors of dendritic cells, leads to 
the activation of these, which results in detaching from the subepithelial surface, 
and migrating to peripheral lymphoid tissues as they acquire an active state. The 
signal traversing these surface antigen "detectors" induces changes in the 
chemokine receptor profile of the dendritic cell surface, as seen in the case of 
CCR7 receptor, of which its de novo expression allows dendritic cells to be 
attracted by the chemokines CCL19 and CCL21 secreted by lymphoid tissues.  
The mature dendritic cells that have migrated to the lymphoid tissues lose 
their capacity to engulf new antigens, and this is followed by presenting on their 
cell surface large amounts of MHC molecules of Class I or II depending on the 
antigen that is being processed. Almost simultaneously, high levels of co-
stimulating B7, B7.1 (CD80), B7.2 (CD81) and CD40 receptors are also initially 
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presented, which interact with counterreceptors of naive T cells,87, 88 as well as 
adhesion molecules such as DC-SIGN (dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin, CD209), ICAM-1 (intercellular 
adhesion molecule-1), ICAM-2, LFA-1 (lymphocyte function-associated 
antigen-1, CD54), LFA-3 (CD58)90 and chemokines such as DC-CK (dendritic 
cell-derived CC chemokine CCL18),91 essential for the attraction of naive T 
cells. The migration of naive T lymphocytes from the blood circulatory 
pathways to the peripheral lymphoid tissues, where dendritic cells are found 
already matured as antigen presenting cells, is dependent on their union and 
interaction with vascular endothelial cells via leukocyte adhesion molecules and 
chemokine gradients (such as of CCL21), which are detected through their 
receptors (i.e. CCR7) that naive T lymphocytes have on their cell surface.  
Out of the adhesion molecules considered most important, we may 
underscore the selectins, integrins, immunoglobulins and molecules similar to 
mucins. The selectins, particularly L-selectin (CD62L), express themselves on 
the cell surface of naive T lymphocytes to mediate their recruitment from the 
blood stream to the peripheral lymphoid tissues. The interaction of L-selectin 
with molecules similar to mucins on the endothelial vascular cell surface 
(vascular addressins) such as CD34 and GlyCAM-1 (glycosylation-dependent 
cell adhesion molecule-1),92 mediates the displacement of the T cell over the 
epithelial surface (rolling). In order for a lymphocyte to cross the endothelial 
barrier and enter the lymphatic nodules, the participation of other leukocyte 
adhesion receptors of the interim family is needed, such as LFA-1 (leukocyte 
functional antigen-1), CD2, VLA-4 (very late activation antigen-4) and the 
ICAM (Intercellular Adhesion Molecule)-1, ICAM-2 and ICAM-3.93-95 Once a 
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naive T lymphocyte enters a lymph node, it directs itself to the T cell zone 
following CCL21 and CCL19 chemokine gradients. It is at this location where T 
cells scan the surface of the dendritic cells, in search of processed antigen 
peptides presented in association with MHC molecules. When a naive T 
lymphocyte encounters a dendritic cell presenting a processed peptide that 
matches its predetermined specificity, the process of T cell activation is 
initiated. For such encounter to occur, there needs to be an interaction occurring 
between both cells through a series of surface adhesion molecules involving 
LFA-1, ICAM-3 and CD2 in the T cell side, and ICAM-1, ICAM-2 and DC-
SING in the dendritic cell side.  ICAM-3 and DC-SING are considered the most 
important overall. By means of this transitional union, naive T cells can scan the 
surface of antigen presenting cells in search of MHC molecules carrying 
processed antigen peptides. When a matching encounter takes place, the union 
of the MHC/peptide complex with its T-cell receptor (TCR) with predetermined 
specificity induces a change in the LFA-1 adhesion receptor, increasing its 
affinity for its specific ligands and stabilizing the union between the T cells and 
the antigen presenting cell for several days. For complete effector T cell 
activation to occur, and for such T cell to enter rapid cell cycle and clonal 
expansion, the delivery of a so-called "second signal" is needed. The "second 
signal" is provided by the union of B7 co-stimulating molecules expressed by 
the dendritic cell with their CD28 ligand on the T cell surface, which induces the 
synthesis of IL-2 (an essential T cell growth factor) by the T cell itself, and the 
expression of the α chain of its own receptor (CD25). This upregulated receptor 
makes a trimer structure by joining β and γ chains, which results in a fully 
conformed, high affinity IL-2 receptor able to promote T cell clonal expansion 
upon binding IL-2 in an autocrine fashion.96, 97  
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After the activation phase mediated by IL-2, CD4+ T activated cells can 
switch among different differentiation pathways (Fig. 3) to give way to effector 
T cells of various types, termed T-helper (Th)1, Th2, Th17 and various T 
regulatory cells (Treg) which suppress the response mediated by the former. The 
differentiation of T CD4+ cells into diverse effector subtypes depends on 
specific conditions, such as the local cytokine milieu before and after antigen 
presentation, the expression of co-stimulating molecules,98 the concentration, 
density and nature of the antigen protein, and the presence of certain ligands. In 
the context of asthma, the differentiation of T CD4+ cells towards an effector 
Th2 phenotype is responsible for the allergic airway inflammation82, 99-103 via the 
production of cytokines, such as IL-4, IL-5, IL-9 and IL-13.56, 84 From the 
signals that potentiate the differentiation towards the Th2 phenotype, IL-4 is 
essential as a priming signal and for Th2 cell clonal expansion, 104-106 and also 
acts as an inhibitory signal for the differentiation towards Th1. IL-4 intracellular 
signaling activates the STAT6 (Signal Transducer and Activator of 
Transcription 6) transcription factor via a signal cascade through 
phosphorylation of its tyrosine residue by kinases Jak1 and Jak3 (members of 
the Janus kinase family).  STAT6, following its activation and translocation to 
the nucleus, promotes the expression of other transcription factors such as 
GATA-3 (Trans-acting T-cell-specific Transcription factor-3) and c-Maf 
(transcriptional factor musculoaponeurotic fibrosarcoma oncogene) followed by 
NF-ATc (Nuclear Factor of Activated T cells, cytoplasmic) and AP-1 (Activator 
Protein-1), all potent activators of the Th2 type cytokine genes such as IL-5, IL-
4 and IL-13. The production and secretion of IL-4 maintains the Th2 phenotype 
and its continuous expression106-110 acting as a feedback system, in an autocrine 
fashion. The origin of the IL-4 "primer" cytokine previous to its production by 
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activated Th2 cells is not fully clear. Some studies showed that, in the dendritic 
cells, certain molecules from the Jagged family are able to perform as ligands 
for the Notch receptor on the surface of the CD4+ T cells. The signals from this 
receptor demonstrated in vitro, increased the transcription of the IL-4 gene from 
their own T cells, inducing a polarization towards Th2.111-113 Another possible 
source of initial IL-4 is the subpopulation of natural killer NK1.1+ cells, a minor 
cellular subtype of natural killer T (NKT) cells that express a marker called 
NK1.1 on its cell surface and has affinity for CD1d, a non-polymorphic antigen-
presenting molecule that binds self and foreign lipids and glycolipids.114  NKT 
cells may have a relevant role in asthma, yet still uncertain. Under certain 
conditions, NKT cells have the capacity to produce large amounts of Th1 (IFN-
γ) as well as Th2 (IL-4 and IL-13) cytokines. In particular, the iNKT cells (NKT 
cells that express an invariant T-cell receptor α chain) were shown to be 
necessary for the induction of Th2 allergic responses, airway inflammation and 
airway hyperresponsiveness in mouse models of experimental asthma,115-117 and 
were also found infiltrating the bronchial mucosa of subjects with asthma.118, 119 
Overall, NKT cells seem capable of promoting the development of asthma in a 
direct and indirect manner, by stimulating the T CD4+ cells to produce Th2 
cytokines or redirecting its secretory phenotype towards Th2 once they reach the 
airway subepithelial region.120 Another cytokine candidate for the initiation of 
polarization of Th2 in cases of allergic diseases, is TSLP (Thymic Stromal 
Lymphopoietin), which is secreted by bronchial epithelial cells, activated 
bronchial smooth muscle cells and activated mastocytes,121 and has receptors 
present in dendritic cells, monocytes and T lymphocytes.122 Despite the lack of 
full understanding on the mechanisms by which this cytokine is able to stimulate 
CD4+ T cells for the development of a Th2 phenotype, it is believed that the 
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process is based on a direct action on the CD4+ T cells123 via the induction of 
IL-4 expression dependent on STAT6, and on the stimulation of dendritic cells 
which overexpress co-stimulating molecules and produce CCL17 (C-C motif 
chemokine ligand 17), a chemokine attractant of T helper 2 lymphocytes.124 
Once the CD4+ T cells have been activated by antigen presenting dendritic 
cells and have differentiated to Th2, one of their acquired functions is the 
capacity to stimulate B cells in the lymphoid tissues. B cells present on their cell 
surface a series of immunoglobulins that act as surface receptors (B-cell antigen 
receptor, BCR) allowing for a large detectable range of different molecules 
(proteins, glycoproteins, polysaccharides, viral and bacterial particles) and, upon 
ligand binding, they may act as antigen presenting cells (by capturing, 
processing and presenting an antigen on surface MHC-II), or giving way to a 
cascade of internal signals similar to T cells. In the first scenario, the 
antigen/MHC-II complex can be recognized by effector Th2 cells previously 
stimulated with the same antigen, causing the release of different cytokines that 
promote B cells to proliferate and differentiate into specific antibody secretory 
cells and into memory B cells. Such interaction between T and B cells occurs 
within peripheral lymphoid tissues, where B cells are attracted in a similar 
manner as described for naive T cells via the activation of adhesion molecules of 
LFA-1 type and the expression of chemokine receptors such as CCR7. The 
activation of B cells, as with naive T cell activation, requires the secretion of 
effector molecules and the expression of new molecules of superficial adhesion 
on the part of Th2 cells. One of utmost importance is the CD40 ligand (CD40L 
or CD154), expressed on the surface of the T cells, whose counterreceptor, 
CD40, is found on the B cells. This interaction stimulates, together with the 
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continuous production of IL-4 by the Th2 cells, B cell proliferation and the 
somatic hypermutation that determines the immunoglobulin isotype to be 
produced, and the increase in surface expression of B7 co-stimulator molecules 
that concurrently maintain the growth and differentiation of T cells towards the 
Th2 phenotype.114, 125 Other signals are also produced through additional 
receptor contact between the B cells and T cells, as occurs between CD30 
(CD153)/CD30, 4-1BB (CD137)/4-1BB ligand, and ICOS (inducible co-
stimulator)/B7-RP ligand.126-128 As a whole, these activation signaling cascades, 
together and followed by the secretion of IL-5 and IL-6, promote the activation 
of B cells, which suffer various proliferation cycles until differentiating into 
antibody-producing plasma cells.  
In general, the humoral responses mediated by T cells induce IgM antibody 
secretion from B cells, followed by a switch in their immunoglobulin class via a 
recombination process that affects the C-terminal regions of the heavy chains of 
the immunoglobulins. This process is influenced by cytokines, secreted by T 
helper lymphocytes and, in the case of Th2 cells, the secretion of IL-4 induces a 
change towards IgE class and inhibits the expression of the rest of the 
immunoglobulins.129 The IgE secreted by plasma cells links through its constant 
fraction to high affinity receptors (FcεRI) located on the surface of resident 
mastocytes in the airways and to low affinity receptors (FcεRII, CD23) present 
in lymphocytes, eosinophils, platelets and macrophages. Mastocytes are 
important for the inflammatory responses after an infection occurs and are 
mostly found in vascularized connective tissues below epithelial surfaces. The 
binding of IgE to high affinity FcεRI receptors carried by mastocytes, and the 
cross-linking of two or more of these receptors, activates the mastocytes in the 
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presence of specific allergens and cause a rapid release of pre-synthesized 
inflammatory mediators stored in their cytoplasmic granules, as well as de novo 
synthesis and secretion of other pro-inflammatory molecules that follow.130, 131 
The main mediators released by mastocytes are: histamine, certain cytokines 
(TNF-α, IL-4, IL-5 and IL-13), arachidonic acid metabolites or eicosanoids 
(prostaglandins, leukotrienes, thromboxanes), and growth factors such as 
platelet activating factor (PAF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF), which together mediate an immediate allergic response in the 
airways and cause airflow obstruction.132, 133 These inflammatory mediators 
promote T effector and memory cells to migrate to the airways and infiltrate the 
airway wall, which promotes the late allergic response that follows several hours 
later along with prolonged airflow obstruction. The late responses play an 
important role in the sustained effects that underlie asthma including persistent 
T cell and eosinophilic infiltration, and airway hyperresponsiveness.134, 135 
The cytokines liberated by cells that participate in the adaptive immune 
response system in asthma present different effects in the airways. IL-5 is 
principally secreted by CD4+ Th2 cells and to a lesser degree by mastocytes and 
eosinophils, and promotes the recruitment of eosinophils to the airways, their 
survival and activation during the inflammatory process136, 137 as well as the 
accelerated production of their precursors by the bone marrow.138 The presence 
of active eosinophilic infiltration causes epithelial damage and the liberation of 
pro-inflammatory mediators. IL-4 and IL-13 jointly with IL-9 stimulate B cells 
to produce specific IgE and work on the epithelium and airway smooth muscle 
cells to cause an increase in mucous secretion, cytokine production, airway 
remodeling and airway hyperresponsiveness.139-141 
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Figure 3. Effector T cell activation pathways and current targets for biological 
therapies. Post-thymic, circulating T cells have two root subpopulations, i.e. CD4+ and 
CD8+, which can both acquire effector or regulatory functions. Only effector pathways 
are shown in this diagram. Naive CD4+ T cells are activated under concurrent 
presentation of processed antigen peptide on MHC-II molecules (“signal 1”), 
engagement of costimulatory receptors (“signal 2”) and priming cytokine signaling 
from the antigen presenting cell (“signal 3”). The main, “professional” antigen 
presenting cell is the dendritic cell (Dendr), although macrophages (Mac) and B cells 
(B) may also do so. Tissue structural cells (Estr) can facultatively express MHC-II 
molecules, although their MCH-II restricted antigen presenting capabilities are unclear. 
Upon activation, CD4+ T cells undergo clonal expansion and differentiate into different 
effector phenotypes defined as per their cytokine expression. The fundamental 
functional branching comprises the Th1 and Th2 arms, a discovery from the 1980s that 
nowadays continues providing a valid, comprehensive scheme for a key mechanism of 
the adaptive immune responses. Th1 cells are specialized in driving the defense 
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against intracellular microbes (e.g. Mycobacterium tuberculosis), and their main action 
is to activate macrophages through the so-called “classical activation pathway”, chiefly 
mediated by IFN-γ. Activated macrophages release highly destructive TNF-α and IL-8, 
an important neutrophil (Neut) chemoattractant. Th2 cells command the defense 
against various types of extracellular noxae including large, multicellular eukaryotic 
parasites. Through IL-4 and IL-13, they induce immunoglobulin class switch on B cells, 
which upon full activation become IgE producing plasma (Plasm) cells. Specific IgE 
circulates and, through its constant epsilon Fc fraction, gets anchored on FcεRI (high 
affinity) or FcεRII (low affinity) receptors, the former chiefly expressed by resident 
mastocytes (Mast) that underlie the skin and mucosal surfaces. IgE crosslinking by 
antigen rencounter triggers mastocyte degranulation and de novo synthesis of other 
proinflammatory mediators such as cysteinyl-leukotrienes. Through IL-5, Th2 cells also 
promote eosinophil release from the bone marrow and their recruitment to the site of 
inflammation, activation and degranulation. CD8+ T cells are primarily cytotoxic and, 
upon MHC class I-restricted antigen presentation, kill tissue cells (e.g. infected by 
viruses or with neoplastic transformation). In the field of respiratory pathophysiology, 
cytotoxic CD8+ T cells are involved in the production of pulmonary emphysema 
through the induction of type-I pneumocyte apoptosis. Subsequently to the seminal 
discovery of the Th1/Th2 branching, other CD4+ effector T cell subpopulations were 
defined. It is of relevance for asthma the Th17 cells which, through the secretion of 
the IL-17 cytokine family, stimulate macrophages through non-classical routes to 
produce IL-8 and attract neutrophils. The Th17 cells also crosslink and potentiate the 
Th2 responses. The upper, “Th2 domain” of the diagram pertains to the 
immunobiological pathways of allergic asthma and rhinitis, of which a grater in-depth 
understanding has historically been gained. The lower, “Th1 domain” provides a view 
of some pathways involved in COPD and autoimmunity. Lately, advances on the 
understanding of the variety and complexity of the immunobiological pathways 
involved in asthma yielded the concept of a plural “asthma” disease (syndrome?) 
comprising different physiopathological mechanisms or “endotypes”. The green 
shaded crescent overlaps the spectrum of the immunobiological pathways involved in 
asthma as shown in this simplified diagram. This illustration also depicts the biological, 
“umab”-based therapies that are approved (omalizumab) or under current advanced 
clinical development, and their targets. All such therapies are clustered within the 
“Th2 domain”, and an “orphan area” is left below, comprising pathways leading to 
steroid-resistant, neutrophilic asthma, where no current clinical development exists 
for novel therapies. Overall, the upcoming impact of the new umab-based therapies 
on the management of asthma in “real world” clinical practice, and the extent and 
importance of the severe non-Th2 asthma pheno-endotypes left with no current 
therapeutic development, are undetermined. Figure source: original, unpublished. 
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3.2 The innate immune system’s role in asthma: tolerance versus activation 
Advances towards deciphering the implications of the adaptive immune 
system with a focus on T cell participation and the generation of immunological 
memory, were of great importance in understanding the mechanisms that 
underlie the perpetual inflammatory process of the airways and the clinical 
manifestations of asthma. On the other hand, the knowledge of the mechanisms 
that truly originate the asthmatic process is still fuzzy. Little is understood on 
the reasons why the capturing, processing and antigen environmental factors 
unknown to T cells that should result in tolerance, end causing an allergic 
sensitization and its consequent effects. It should be noted, that not all asthmatic 
phenotypes develop as a consequence of an allergic response to one or more 
allergens. For unclear reasons, an adaptive immune response similar to an 
allergic response can get activated out of context in what concerns atopy and the 
inability to identify the allergenic agent.86, 99, 142 Because the adaptive immune 
response requires the participation or previous development of an innate 
immune response, the role of the innate immune system has recently gained 
interest in the origin of asthma. Overall, the immune response begins with a 
non-specific role on innate immunity, which could be followed by a second 
specific response that is potent and with the capacity for memory, led by the 
adaptive immune response. Much of the stimulating signaling system present in 
antigen presenting cells participates in the activation and clonal proliferation of 
lymphocytes with antigen specificity induced during an innate response. During 
this response, the cells of the innate system liberate large amounts of different 
cytokines, which will largely determine the type of adaptive response needed 
alongside the pathogen which caused the immune cascade.  
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The first barrier to the innate immune system are the epithelial tissues. Apart 
from their role as a mechanical barrier, epithelial tissues produce chemical 
substances with antimicrobial properties that attack the bacterial membranes. 
This helps in the recognition by phagocytic cells that also take part in the innate 
immune system. Some epithelia host bacterial commensal flora with capacity for 
antimicrobial peptide secretion. In the case of the respiratory epithelium, its 
barrier is quite evolved in that it produces mucous that is continuously dragged 
towards the oropharynx by the ciliated cells. If a pathogen passes the epithelium 
barrier, a series of mechanisms are activated for its recognition and elimination 
by the innate immune system. The recognition of pathogens as they interact with 
the epithelium barrier, as the first line of defense of the innate immune system, 
occurs due to the existence of foreign surface molecules of repeated structural 
pattern (carbohydrates, lipids, lipoproteic acids, lipopolysaccharides, CpG 
dinucleotides, etc.) known as pathogen-associated molecular patterns (PAMPs), 
and recognized by pattern recognition receptors (PRRs) that can be found in the 
form of free proteins or on the surface area of phagocytic cells. An example of a 
soluble PPR that participates in the first line of defense is the type of lectin 
called mannose-binding protein (mannose-binding lectin, MBL), which 
recognizes particular carbohydrate patterns found on the surface of a large 
number of pathogenic microorganisms. The binding of MBL to its targets results 
in microbial opsonization and activation of the complement system through a 
recently discovered pathway, the "lectin pathway". As for cell surface PRRs, an 
important example is the mannose macrophage scavenger receptor (a lectin type, 
calcium dependent transmembrane protein that recognizes carbohydrates on the 
surface of viruses and bacteria). Next, and very importantly, if a microbial 
pathogen breaches the epithelial barrier it encounters the Toll-like receptors 
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(TLRs). TLRs are a class of single membrane-spanning protein PRRs mostly 
expressed by dendritic cells and macrophages, capable of recognizing different 
types of microbial components.143-145 At present, 11 human and 12 murine TLRs 
have been identified that express themselves on the cell surface of mastocytes, T 
lymphocytes, mononuclear phagocytes and primarily dendritic cells.  Some of 
these act as cell surface receptors, while others are capable of detecting the 
presence of pathogens that have been digested through phagocytosis or 
macropinocytosis. Usually they are found as homodimers, but they can also 
form dimers such as in the case of TLR-4, or heterodimers with other cell 
surface proteins such as CD-14 and MD-2 ("lymphocyte antigen 96") that 
collaborate in the recognition of bacterial LPS.146-149  
The majority of TLRs signal through protein adaptors such as MyD88 
(myeloid differentiation primary response 88), inducing the activation of 
transcription NFκB (nuclear factor kappa light-chain enhancer of activated B 
cells). NFκB then translocates into the nucleus and promotes the transcription of 
proinflammatory genes and the liberation of cytokines and chemokines. 
Depending on what pathogen has been detected, signaling via TLRs may favor 
or prevent the development of allergic responses by inducing the expression of 
particular costimulatory surface receptors and the release of different cytokines 
by dendritic cells and macrophages, which mark the polarization of naive T 
cells. For example, the expression of B7.2 (CD86) and the interaction with its 
ligand OX40 (CD134) favors the Th2 phenotype, whereas IL-12 production and 
the expression of costimulatory molecule B7.1 (CD80) induce a Th1 profile. In 
the case of Treg development, further discussed in section 3.3, the costimulatory 
molecule ICOS (Inducible T-cell COStimulator) and the production of IL-10 
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appear to play a key role.145, 149-152 The discovery of the role of TLRs in the 
modulation of the activation of T cell effector pathways led to the development 
of the “hygiene theory”, which postulates that exposure to certain viral 
infections or bacterial products early in life can be a protective factor for the 
subsequent development of allergies throughout life, because such exposure 
balances the immune system towards a Th1 response profile.153 The occidental 
lifestyle limits this natural tuning of the immune system and its responses, 
because exposure to microbes has been reduced to a minimum which, according 
to the hygiene theory, favors an immune deviation towards Th2 responses, and 
this is involved in the increased prevalence of allergic diseases in industrialized 
countries.150 The hygiene theory does however have important faults. There is 
evidence that exposure to respiratory infections at an early age is a risk factor 
for the development of asthma. Also, the hygiene theory does not explain why 
there has been a concomitant increase in the prevalence of autoimmune diseases 
mediated by Th1 cells along with allergic diseases.154, 155 The chronic exposure 
to microbial products in rural zones or poorly industrialized during fetal 
development or infancy may play a significant protective role during 
development against allergy as a consequence of chronic cell stimulation of the 
innate immune system. It is believed that the reduction of microbial exposure 
favors a deviation of the adaptive immune responses towards Th2 cell 
phenotypes.111, 156-158 The low microbial load may also produce a reduction in 
immunological suppression as a consequence of a decrease in activity from 
regulatory T cells, thus facilitating both Th1 and Th2 immune responses 
responsible for the increase in the prevalence of autoimmune diseases as well as 
allergic disorders.154, 159  
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 39 - 
The recognition of PAMPs on the cell surface of certain bacteria and viruses, 
mediated by TLR receptors present on the cell surface of dendritic cells 
macrophages, NK cells and others, results in the ignition of an immune response 
with the liberation of a cytokine cascade including TNF-α, IFN-α, IFN-γ, IL-1, 
IL-6, IL-10 and IL-12, which all favor effector T cell differentiation into Th1 
phenotype.159-161 Conversely, early secretion of IL-4 during antigen presentation 
in the absence of IL-12 and IFN-γ leads to the activation of transcription factors 
STAT-6, c-maf and GATA-3, favoring further IL-4 secretion and the production 
of IL-5 and IL-13, leading to a Th2 response.162 One of the identified TLRs that 
allow for polarization towards the Th2 phenotype is TLR-2, which once bound 
to its ligand suppresses the expression of IL-12. 163 TLR-4 also favors effector T 
cell differentiation towards Th2 depending on the ligand exposure dosing, which 
in this case is the lipopolysaccharide of the bacterial wall from gram-negative 
bacteria.164  
3.3 Regulatory T cells  
In the 1970s, Gershon et al. found that T cells had the ability to grant 
tolerance to recipient animals when they were transferred from an antigen 
tolerant donor.165 These were characterized as cells that had immunomodulatory 
activity as shown by skin allograft experiments. These cell types were named 
“suppressor T cells,”166 but the lack of specific markers for the identification and 
isolation of these cell subsets, and poor clarity in their definition, led to their 
abandonment for more than two decades. Meanwhile, some researchers that 
worked on “suppressor T cells” revealed mechanisms underlying different 
pathologies and defined in vitro and in vivo features,167-170 yet the lack of 
consistent data led to the discontinuation of this research area,171 and the 
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“suppressor” terminology was avoided.172 It wasn’t until the 1990s, that 
Sakaguchi et al. described a T cell subset that could restore thymus-ablated mice 
into a healthy tolerant state.173, 174 Their work demonstrated that thymectomized 
mice with a severe autoimmune syndrome could be rescued after adoptively 
transferring a CD4+CD25+ T cell subpopulation from healthy animals. In vitro 
studies by other investigators followed, demonstrating inhibitory properties of 
such CD4+CD25+ T cells on CD4+ effector T cell activation.175 The in depth 
characterization of an immunoregulatory function from the CD4+CD25+ T cell 
subset was achieved by Hori et al., Fontenot et al. and Khattri et al. once entered 
into the 21st century.176-178 These studies showed that the forkhead box P3 
(FOXP3) transcription factor was responsible for the induction of 
immunoregulation by CD4+CD25+ T cells in the inhibition of T effector 
responses against self-antigens. Indeed, defects in the FoxP3 gene located in the 
X chromosome, cause the immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX),179an autoimmune inflammatory disease 
caused by uncontrolled activation and expansion of CD4+ T cells.180 Defects in 
the FoxP3 locus is also shown as linked with a fatal lymphoproliferative 
disorder in mice ("scurfy" phenotype).181 
Studies on mice have shown that the glucocorticoid-induced tumor necrosis 
factor receptor family related gene (GITR) is needed for Treg mediated 
suppression of effector T cells in vitro.182 Although FOXP3 is a strong Treg cell 
marker in mice, this has become less clear in humans and the identification of 
Treg cells has turned complicated.183 In fact, cells devoid of FOXP3 expression 
that otherwise exert regulatory functions have been recently described,184-186 as 
well as non-regulatory cells with transient FOXP3 expression.187-189 Slight 
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upregulating of FOXP3 expression by TCR activation has also been reported, 
without leading to any immunoregulatory function.190 Nevertheless, FOXP3 is a 
marker of significant value to identify Treg cells in humans, along with other 
FOXP3-associated markers that are being progressively defined such as low IL-
7 α-subunit receptor expression (CD127LOW)191 and tumor necrosis factor 
receptor 2 (TNFR2).192  
The Treg cells can be characterized as a heterogeneous group deriving from 
distinct developmental origins whose role is to maintain immune homeostasis, 
prevent autoimmunity and moderate inflammation. Treg cells have different 
phenotypes such as regulatory effector-memory phenotypes, characterized by 
CCR6 expression, that regulate effector-memory phenotypes and are believed to 
function as a counterbalance to the common effector memory T cells.193 A range 
of suppressor capabilities can be found in the Treg population. Depending on 
what defect has occurred in the development and function on Tregs, different 
autoimmune diseases can arise. 194-196 
The FOXP3 transcription factor, as a key to immune regulation, is in itself 
subjected to complex regulation controlling its expression. Recent studies have 
shown epigenetic regulatory mechanisms acting at the FoxP3 locus197 and, 
upstream the gene locus, there is a conserved CpG-rich element working as a 
FoxP3 enhancer. This Treg regulatory region is demethylated in natural Treg 
(nTreg) cells that have stable FOXP3 expression.198 However, FOXP3 
expression can be attained regardless this regulatory mechanism, since TGF-β 
induces FOXP3 expression in CD4+CD25- cells located in peripheral tissues, 
with no epigenetic changes.198 Thus, regulatory T cell function appears to 
require FOXP3 expression but not lineage commitment,199 yet this is complex 
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because certain immunological cell types lacking FOXP3 expression have also 
shown regulatory properties during immune responses.200  
Currently, despite attempts in describing “suppressor cell types” over the 
years, there is still a lack of definite molecular markers for immunoregulatory 
cell identification. Immunoregulatory cell subtypes cannot be simply explained 
as a regulatory/non-regulatory phenotype issue. Depending on the tissue 
environment, regulatory properties cannot be attributed to just one cell type, but 
attributed to different cell subtypes working together in exerting an overall 
regulatory function. Also, Treg cells are believed to not only exert tolerance to 
self antigens or attenuate late immune responses, but also early immune 
responses when faced with viral infections.201 Defective Treg function has been 
described as involved in the persistence of chronic infection,202 and in the failure 
of anti-tumor responses that result in disease progression for certain types of 
tumors.202  
FOXP3+ Treg cells are important sources of the immunomodulatory 
cytokines IL-10 and TGF-β.203-206 IL-10 and/or TGF-β are secreted by Treg cells 
depending on the nature of the encountered pathogen and its tissue environment, 
so as to control infections or inflammatory diseases.207, 208 Both IL-10 and TGF-
β are implicated in various diseases involving Treg cells.208 The exact functions 
and milieu that regulate the production of Treg immunomodulatory cytokines 
such as IL-10 and TGF-β are still unclear. Complex pathways seem to be 
involved in the expansion and regulation of Tregs. As for effector T cells, IL-2 
acting in a paracrine fashion is needed for Treg expansion,209, 210 yet it is not 
needed for the regulatory function.211 Also, the interaction between B7 and 
CD28, crucial for lymphocyte survival in the thymus, is pivotal in controlling 
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autoimmune diseases via a mechanism requiring the expression of cytotoxic T 
Lymphocyte Antigen 4 (CTLA4).212 CTLA4 binds to B7 and acts as a CD28 
homologue, but it transmits inhibitory signals on T cell activation.213 TCR 
stimulation in naive T cells can stimulate the transient expression of CTLA4,214 
which can prevent self-reactive pathogenic T cells from acting.215 FOXP3 is 
capable of upregulating CTLA4 expression on the surface of nTregs.210, 216, 217 
CTLA4 expression permits nTreg cells to interact with the B7 molecule 
expressed on antigen presenting cells, and downregulate effector T cell 
activation.218 Treg cells can in fact interact with dendritic cells via CTLA4, 
inducing the production of immunosuppressive molecules that suppress effector 
T cells.219, 220  
In regards to Treg cell subsets, whether a key common pathway or multiple 
redundant or non-redundant pathways participate in the initiation and 
maintenance of immunological tolerance is unclear. Vignali et al. proposed a 
mechanism of tolerance induction from the integration all such aforementioned 
mechanisms, using a model by which Tregs adopt one or other inhibitory 
pathways depending on the environmental context.208 Unfortunately, there has 
not been any experimental proof on this theory and further research is needed. 
The first Tregs discovered and characterized were the nTregs, i.e. 
CD4+CD25+FOXP3+ T cells naturally arising from the thymus. Recently, 
various inducible (iTreg) subsets have been described that differentiate in 
secondary lymphoid organs under different cytokines and antigen exposure 
scenarios. Various FOXP3-expressing and non-expressing Tregs arising from 
distinct developing origins have been described up to present. However, despite 
their origin and features, iTreg cell subsets share common functions to maintain 
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tolerance by suppressing potential effector responses against innocuous 
antigens, and controlling the normal immune response against infections.  
3.4 Airway inflammation  
Chronic airway inflammation is one of the key features of asthma,221 even in 
cases where no evidence of pulmonary function deterioration is present as seen 
in subclinical cases with apparent symptomatic remission.222 Chronic 
inflammation is associated with airway remodeling and severity of symptoms, 
although one needs to account for clinical variability. A number of studies have 
looked at the distribution of inflammation within the airway tree and this has 
generated discordance, where some attest to the airways being mostly affected 
centrally while others show inflammation predominates peripherally.223-227 
Chronic inflammation in asthma is a complex event where there is active 
participation of leukocytes, overall CD4+ T lymphocytes, eosinophils, 
macrophages, mastocytes, as well as structural cells of the airways such as 
epithelial cells, fibroblasts and smooth muscle cells. 
3.4.1 The inflammatory process  
Once a pathogen enters and is identified as such, the inflammatory response 
that follows results in an increase in immune system cells and effector 
molecules, in the aim of helping the first line of defense for the destruction of 
the foreign agent. This creates a physical barrier to contain the pathogen and 
limits access through blood flow to the rest of the organism, therefore promoting 
the repair and healing of the affected zone. During the inflammatory process, 
leukocytes migrate through the blood stream into the tissues attracted by the 
cytokines and chemokines that are secreted by macrophages and other cells from 
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the surroundings. Along with increased vascular permeability and the formation 
of edema, there is an increase in blood viscosity and hemodynamic changes. 
This results in a decrease in blood flow which favors the location of leukocytes 
in the periphery of postcapillary veins allowing their interaction with vascular 
endothelial cells. Next step towards the formation of inflammatory infiltrates is 
leukocyte extravasation. This process constitutes the first reversible union 
between adhesion molecules expressed in the endothelium as a result of 
induction by cytokines, inflammatory mediators and bacterial components such 
as TNF-α, LPS, histamine, leukotrienes, etc., and leukocyte adhesion receptors. 
Amongst the most important adhesion molecules found, are the selectins, 
integrins, molecules of the immunoglobulin superfamily, and glycoproteins 
similar to mucins. Under the action of chemokines, induced changes occur in the 
leukocyte integrins, and the interaction of these with endothelial adhesion 
molecules is promoted. These unions create a strong hold with leukocytes onto 
the endothelial wall, which allows for the continued process of extravasation. By 
means of the interaction of adhesion molecules and the secretion of matrix 
metalloproteases (MMPs), the leukocytes are capable of degrading the basal 
membrane proteins of the endothelium and displace across it via diapedesis, to 
reach the interstitial space into the tissues. The expression of adhesion 
molecules on the surface of leukocytes as well as endothelial cells is increased 
in the airways of asthmatic patients,228-231 Leukocytes can then migrate across 
the tissues, following chemokine gradients.232-235  
In cases where acute inflammation does not resolve, a prolonged response 
ensues the development of chronic inflammation, where the processes involved 
in the inflammation itself cause sustained damage and elicit dysregulated tissue 
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repair responses. Chronic inflammation may result as a consequence of 
persistent infection due to microorganisms or other foreign agents of low 
toxicity, prolonged exposure to endogenous or exogenous toxins, autoimmune 
reactions or allergic sensitization, resulting in a final common outcome of late 
hypersensitivity reaction. In general, chronic inflammation is characterized by 
the presence of mononuclear leukocyte infiltrates and the destruction of the 
lesioned tissue, which then is replaced by scarred connective tissue, a process 
led by angiogenesis and fibrosis.236 The types of cells mostly encountered in 
chronic inflammatory infiltrates depend on the immune response profile. In the 
case of Th1 adaptive responses, seen as a result of persistent infections by 
intracellular pathogens and in most forms of autoimmune disease, the infiltrates 
characteristically contain lymphocytes and activated macrophages. Such process 
is perpetual in time due the continued expression of cellular adhesion molecules 
and the release and cytokines and chemotactic factors,237 largely from 
macrophages that migrated and got immobilized within the inflammatory zone. 
Such activated macrophages produce damage, degradation and tissue fibrosis. In 
Th2 responses, elicited for the defense against extracellular noxious agents such 
as parasites and in atopic hypersensitivity, the inflammatory infiltrates contain 
lymphocytes and eosinophils with the possibility of additional recruitment of 
mastocytes and basophils.  
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3.4.2  Main inflammatory cells and mediators involved in asthma  
The principal inflammatory cells that play a central role in leading chronic 
inflammation in atopic asthma are the effector, Th2 CD4+ T cells, which may be 
directly involved in the mechanisms of airway remodeling. 17, 102, 238 In order to 
trigger the adaptive immune response, CD4+ T cell activation by the antigen 
presenting cells is needed. The main antigen presenting cells are the dendritic 
cells, that form a network beneath the basement membrane of the respiratory 
epithelium, capable of detecting inhaled airborne antigens and capturing them. 
In the upper airway, the density of dendritic cells is high (600-800 cells/mm2) 
and decreases through the intrapulmonary airways (75 cells/mm2) in most 
peripheral airways.239 Whatever macromolecules escape the tight barrier 
junctions among the respiratory epithelial cells are retained and processed by 
dendritic cells. Dendritic cells evolve to mature phenotypes that then migrate to 
the peribronchial, hilar and mediastinal lymph nodes and probably to non-
encapsulated clusters of secondary lymphoid tissue called bronchial associated 
lymphoid tissue. Within these locations, dendritic cells present processed 
peptides to naive CD4+ T cells, which in the presence of all necessary 
costimulatory signals elicits T cell activation towards a Th2 phenotype.240 
Innocuous agents induce antigen specific tolerance instead of a defensive 
immune response. In asthma, conversely, CD4+ T cells activated into a Th2 
phenotype secrete IL-4, IL-5 and IL-13 as main response driving cytokines and 
this results in the induction of IgE synthesis by activated B cells, eosinophil 
recruitment and mucus production. Th2 cells also enhance mast cell activity and 
further stimulate the Th2 response through IL-9.241, 242 The genes encoding the 
major Th2 proinflammatory cytokines map all in close proximity to 
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chromosome 5 in humans,243 and polymorphisms in this region are liked to the 
development of atopy and airway hyperresponsiveness.244 The granulocyte 
majorly involved in the inflammatory infiltrates found in asthma is the 
eosinophil, recruited by effector Th2 cells via IL-4, IL-5 and IL-13. Eosinophils 
are in turn important producers of the fibrogenic mucus inducer cytokine IL-
13.245 IL-13 is key in airway remodeling and its expression is increased in the 
lungs of asthmatics that have greater remodeling,246 as well as and in 
experimental murine asthma models.247 IL-13 is also involved in the 
development of pulmonary fibrosis248 and mucus hypersecretion.82 Neutrophilic 
inflammation can also be present in asthma and is usually refractory to treatment 
with corticosteroids. The immunobiological pathways leading to neutrophilic 
airway inflammation differ from those of typical atopic asthma and may involve 
Th1 and Th17 responses, which lead to the production of cytokines and 
chemokines that are neutrophil attractants such as IFN-γ, IL-17 and IL-8. 
Neutrophilic asthma can run on its own as a dominant response or may combine 
with a Th2 response, leading to mixed inflammatory profiles.249 It has been 
observed that highly activated Th17 cells can be found in bronchial biopsies of 
patients with asthma and that the increased levels of IL-17 mRNA correlate with 
the neutrophil numbers.250, 251 In turn, Th17 cells have the ability to potentiate 
Th2 responses through a crossover pathway and further attracts eosinophils to 
the area of inflammation.252 As for Th1 responses, their role in asthma is 
unclear. Th1 and Th2 responses have long been known to cross-inhibit each 
other. The adoptive transfer of OVA-specific Th1 cells reverses Th2 derived IL-
4 production, eosinophilia in bronchoalveolar lavage (BAL) and airway 
hyperresponsiveness in experimental asthma,253 but opposite results have also 
been reported.254 In a murine allergic asthma model, the  recruitment of Th1 
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cells has been suggested to be a prerequisite for Th2 cell recruitment.255 Th1 
cytokines, particularly IFN-γ and TNF-α have also been shown to aggravate 
inflammatory events in asthma.256  
Chronic respiratory airway inflammation of asthmatics is characterized by 
the generation of large quantities of cytokines and chemokines as a consequence 
of cellular activation that takes place in the immunological cascade process. The 
most important cytokines involved in atopic asthma, those from the Th2 
phenotype such as IL-4, IL-5, IL-9 and IL-13,257, 258 will now be discussed in 
greater detail. IL-4 is crucial for the differentiation of effector CD4+ T cells 
towards the Th2 phenotype and, together with IL-13, induces the 
immunoglobulin class switch to IgE on B cells, thus providing an essential 
pathway for antigen detection by mastocytes and basophils via the induction of 
the expression of the high affinity FcεRI receptor and the anchoring of IgE on 
the surface of such cells.259 Additionally, IL-13 has other actions including the 
induction of hyperplasia and hypertrophy of mucus secreting cells in the airway 
epithelium, the increase of airway smooth muscle contractility and the 
recruitment of monocytes, macrophages, T cells and eosinophils.82, 257 IL-5 
regulates the differentiation, maturation and migration of eosinophils in 
peripheral blood, as well as their activation and survival.136, 260 Finally, IL-9 can 
show various inflammatory effects on the airways, such as promoting the 
proliferation of T cells in the absence of antigens, increasing IgG and IgE 
production and the expression of their specific surface receptors on mastocytes 
thus contributing to mastocyte proliferation, activation and liberation of 
inflammatory mediators contained in its cytoplasm, which participate in the 
hyperplasia of goblet cells and other significant aspects of airway 
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remodeling.261-263 IL-9 production during the first phase of Th2 mediated 
responses secondarily contributes to IL-8 production by macrophages and 
smooth muscle cells, which together with IL-17 stimulates the attraction of 
neutrophils to the airways of certain asthmatics.264 Other interleukins stemming 
from the Th2 profile, implicated in certain asthmatic phenotypes, are the IL-10, 
IL-17, IL-22, IL-33, IL-1β and TNF-α. In the case of IL-10, a polymorphism has 
been identified that seems to be associated with a severe asthmatic phenotype,265 
even though it is a cytokine that is fundamentally a suppressor of responses 
mediated by T cells against inhaled allergens.266 IL-17 is secreted by T 
lymphocytes with a Th17 activation phenotype and participates in the 
recruitment of neutrophils, being increased in severe asthma cases and possibly 
responsible for corticosteroid-resistant asthmatic phenotypes.250, 267 IL-22 is a 
member of the IL-10 family and is secreted by Th1, Th22, Th17, cytotoxic T 
cells and NKT cells, and is also associated with severe asthma phenotypes.268, 269 
IL-33 is a recently identified member of the IL-1 family and seems to be 
involved in allergic inflammation via basophil activation and the liberation of 
IL-4, IL-13 and IL-8. Its expression is also linked to refractory and severe 
asthmatic phenotypes.259, 270 Finally, IL-1β and TNF-α are capable of 
stimulating the activation of endothelium, leukocytes and fibroblasts, induce 
acute systemic reactions, participate in neutrophil recruitment and induce many 
airway remodeling features, which also contribute to persistent severe asthmatic 
phenotypes and corticosteroid resistance.271-277   
In what concerns chemokines, their production and expression also relates to 
asthma severity. The IL-8 cytokine is at the same time a prominent chemokine 
(CXCL8) with a central role in neutrophil attraction. Other relevant chemokines 
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are MCP-1 (monocyte chemotactic protein-1 or CCL2), eotaxin (CCL11), MIP-
1α (macrophage inflammatory protein-1α, CCL3) and RANTES (regulated on 
activation, normal T cell expressed and secreted, CCL5), all of them mostly 
implicated in eosinophil recruitment.278-282 The MCP-1 chemokine also 
participates in the activation of mastocytes resulting in the synthesis and release 
of leukotriene LTC4, and in the differentiation of T cells towards the Th2 
phenotype.283 
At the cellular level, airway inflammatory infiltrates are most frequently 
characterized by the presence of eosinophils, CD4+ T cells with Th2 phenotype 
and activated mastocytes. During the development of the inflammatory 
response, there is an increase in the numbers of hematopoietic progenitor cells in 
the bone marrow.138 The activation of eosinophils in the airways causes the 
release of their cytoplasmic granular contents as detailed below. With respect to 
mastocytes, it has lately been reported that the airway smooth muscle in 
asthmatics is infiltrated by these cells, and this has led to a "myositis" theory in 
asthma.85, 284, 285 The migration of mastocyte precursors to the airway smooth 
muscle bundles may be in part due to the expression of stem cell factor (SCF) or 
the expression of chemokines specific for mastocyte surface receptors, more 
specifically CCR3, CXCR1, CXCR3 and CXCR4.286 The activation of the 
mastocytes infiltrating the airway smooth muscle causes the release of their 
cytoplasmic granule contents, particularly rich in histamine, and the synthesis 
and release of eicosanoids (prostaglandin D2 and cysteinyl leukotrienes). These 
mediators along with the presence of other proinflammatory molecules present 
in the milieu such as proteins of the complement system (C3a and C5a), 
enzymes released by other leukocytes, neuropeptides (Substance P) and 
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cytokines (IL-1 and IL-8),287 may produce acute bronchoconstriction, edema, 
increased mucous production and endothelial cell activation.134, 135, 284, 288 
Mastocyte degranulation additionally liberates enzymes such as tryptase, which 
potentiates the effect of histamine on airway smooth muscle contraction,289 and 
is also a potent fibrogenic factor and a mitogen for epithelial cells.290 Alveolar 
macrophage activation has  also been pointed out as a participant mechanism in 
the asthmatic inflammatory cascade, also associated with late allergic responses, 
in certain asthma phenotypes.291, 292 Macrophages contribute to airway 
remodeling through the secretion of growth factors such as platelet-derived 
growth factor (PDGF), basic fibroblast growth factor (bFGF) and TGF-β, all of 
which are implicated in the promoting fibrosis.293 They also synthesize and 
secrete metalloproteinases (MMP-9)294 capable of degrading macromolecules of 
the extracellular matrix such as elastin. They can also release eicosanoids, 
oxygen reactive species, cytokines and chemokines (macrophage inflammatory 
protein-1α, MIP-1α)295 that cause deleterious effects on the airways. Finally, the 
presence of Th2 cells plays an important role as the cells that lead chronic 
inflammation and airway remodeling.56, 99, 102, 112, 137, 221, 255, 296, 297 Studies 
involving adoptive transfer of antigen-specific CD4+ T cells with Th2 effector 
functions, showed that these cells, upon antigen airway challenge, are necessary 
to drive inflammation, late allergic responses, remodeling and airway 
hyperresponsiveness.102, 298-302  
Beyond cytokines and chemokines, other molecular systems also participate 
in mediating the chronic inflammatory cascade in asthma. This includes plasma 
proteins such as the complement system, the kinin-kallikrein system and the 
coagulation system.  
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The complement system is composed of a series of proteins that act as 
opsonins, i.e. they covalently bind to the surface of pathogens and facilitate 
phagocytosis. They also participate in the recruitment of inflammatory cells by 
generating protein fragments of chemotactic nature and in the degradation of 
pathogens through the creation of pores in the bacterial wall. Regarding asthma, 
the most relevant of the complement system components are the C3a and C5a 
proteins, generated from proteolytic fragmentation of their C3 and C5 precursors 
and also known as anaphylotoxins, which are capable of inducing and increasing 
vascular permeability, leukotriene release, chemotaxis, opsonization and cell 
death. In addition, C5a is a potent inductor for the activation of mastocytes in 
the absence of antibody stimulation.303  
The kinin-kallikrein system is a protease cascade that is activated as a 
consequence of tissue damage in the aim of liberating inflammatory mediators, 
bradykinin as most notable. Bradykinin is an important vasodilator and 
inflammatory mediator able to increase vascular permeability and promote 
plasma protein flow in the area of tissue damage, and participates in mediating 
the sensation of pain.304, 305  
The coagulation system also participates in the inflammatory process and 
acts as a contention barrier that is activated as a result of endothelial damage. As 
with the kinin-kallikrein system, the coagulation system can also activate itself 
in the absence of tissue damage by endothelial cell activation in the presence of 
pathogens. This system can divide itself into two convergent pathways that 
culminate with the activation of thrombin and the formation of the fibrin clot. 
The intrinsic coagulation pathway is initiated as a consequence of the activation 
of Hageman factor (factor XII), which also induces the fibrinolytic system 
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(plasmin production and fibrin degradation occur) and the activation of the 
complement system. The role of thrombin, one the main proteases of the 
coagulation system, is to break fibrinogen found in a soluble state, transforming 
it into insoluble fibrin. Fibrin binds to protease-activated receptors expressed in 
platelets, endothelium cells, smooth muscle cells and other cell types, and such 
union causes a cascade of various responses that induce inflammation, such as 
the expression of P-selectins, chemokine production, leukocyte adhesion 
molecule expression, production of platelet activating factor (PAF), generation 
and release of nitric oxide, and cyclooxygenase (COX)-2 induction with the 
consequent production of prostaglandins.306, 307   
The metabolites of arachidonic acid is another family of important mediators 
in the inflammatory process of the airways. This family of mediators is also 
known as eicosanoids due to their molecular structure, and includes the 
prostaglandins, leukotrienes, lipoxins and resolvins.308-310 Prostaglandins are 
generated by the COX-1 and inducible COX-2 enzymes. The most important 
prostaglandins within the inflammatory process in asthma are prostaglandin 
(PG) E2, PGD2 and PGE2α, which by causing vasodilation and increased 
vascular permeability potentiate the formation of edema. PGI2 or prostacyclin, 
although anti-inflammatory, also induces vasodilation and increases vascular 
permeability, and prevents the formation of the platelet plug involved in 
hemostasis as part of blood clot formation. Chiefly opposed to PGI2 in its 
functions, thromboxane (Tx) A2 is a potent inductor of platelet aggregation. The 
leukotrienes (LT) are synthesized from arachidonic acid through the 
lipoxygenase pathway. In asthma pathophysiology, the most relevant of these 
molecules are the so-called cysteinyl leukotrienes because of having a cysteine 
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amino acid in their structure, and this includes LTC4, LTD4 and LTE4. The 
cysteinyl leukotrienes were formerly called, as a whole before they were 
individually identified, slow-reacting substance of anaphylaxis (SRS-A). They 
are powerful proinflammatory mediators with chemotactic properties, also 
capable of directly inducing vasoconstriction, increased vascular permeability 
and bronchospasm. The other arachidonic acid derivatives, lipoxins and 
resolvins, are negative regulators of leukotrienes and participate in the resolution 
of inflammation by inhibiting cytokine production and the recruitment and 
activation of leukocytes.311, 312 Finally, although not an arachidonic acid 
derivative, PAF is a phospholipid proinflammatory mediator of importance in 
asthma. It is produced by a number of cells including platelets, basophils, 
mastocytes, neutrophils, macrophages and endothelial cells and, in addition to 
platelet aggregation, promotes vasoconstriction, bronchoconstriction, increased 
vascular permeability, leukocyte-endothelial adhesion, chemotaxis, generation 
of oxygen reactive species and the synthesis of other inflammatory mediators, 
mainly eicosanoids.313 
The liberation of nitric oxide (NO) by macrophages and other phagocytic 
cells during the degradation of noxious agents induces vasodilation, reduces 
platelet aggregation and adhesion and acts as an endogenous leukocyte 
regulator, also inhibiting potent inflammatory inductors such as products 
released from the degranulation of mastocytes.314, 315 The measurement of the 
NO fraction in orally exhaled air (FeNO) has reached the regular clinical 
practice as a useful tool for asthma follow-up. In asthma, the exhaled NO is 
mainly produced by the inducible NO synthase (iNOS), and iNOS expression is 
in turn upregulated by IL-4 and IL-13 through STAT-6 activation in the 
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bronchial epithelium. Therefore, the FeNO primarily reflects Th2 driven 
inflammation and eosinophilic infiltration of the airways, and is a suitable 
marker for predicting the response to inhaled corticosteroids and to monitor their 
therapeutic effect in this asthma phenotype.316 
As a result of their activity, macrophages and granulocytes also release their 
granule contents, which comprise a large variety of proinflammatory mediators 
and other substances, such as enzymes and oxygen reactive species, which are 
directly destructive on tissues. It is at this point that the anti-protease systems of 
the blood serum and interstitial fluids must act as a compensatory 
mechanism.317, 318 The activation of eosinophils in the airways leads to the 
release of cytoplasmic granular components such as protein toxins (major basic 
protein, MBP; eosinophilic cationic protein, ECP; eosinophil-derived 
neurotoxin, EDN), oxygen free radicals, eicosanoids, Th2 type cytokines, 
growth factors, elastase and metalloproteinases. All such mediators can cause 
epithelial damage, increased vascular permeability, hyperreactive airway smooth 
muscle319 and structural alterations involved in airway remodeling.320-322 
Oxygen reactive species can contribute to potentiate the expression of cytokines, 
chemokines and leukocyte adhesion molecules upon release at low 
concentrations, and their release in large quantities produces tissue damage and 
increases vascular permeability by causing endothelial cellular lesions, 
inactivation of anti-protease systems, extracellular matrix destruction.317, 323  
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4. Airway remodeling 
4.1 The structure of the airway wall 
Air enters the upper airways through the nose or mouth and passes into the 
intrathoracic airways that begin with the trachea, which then bifurcates into the 
left and right main bronchi. Subsequently, the intrapulmonary airways divide 
into several generations of bronchi, then bronchioles (which lack supportive 
cartilage in their wall), terminal bronchioles and finally the respiratory 
bronchioles (where the respiratory epithelium alternates with scattered alveolar 
openings). This tree-like structure of conducting airways ends into the lung 
parenchyma, which is where gas exchange occurs, made up of respiratory 
bronchioles, alveolar ducts, alveolar sacs and alveoli. At the histological level, 
the airways consist of several tissue layers that differ in composition from the 
trachea to the small bronchioles. The airway wall is made up of respiratory 
epithelium, which is a pseudo-stratified ciliated cylindrical epithelium, where all 
cells are anchored to the basement membrane, but not all reach the lumen. This 
epithelium is composed of basal cells, ciliated cylindrical cells whose cilia are 
joined by dynein arms, a protein that gives consistency and promotes ciliary 
movements, and goblet cells that contain mucus granules. Underlying the 
respiratory epithelium basement membrane, is the lamina propria, a layer that 
consists of conjunctive tissues rich in elastin fibers, that provides a space for the 
distribution of blood, lymphatic vessels and nervous fibers. The respiratory 
epithelium and the lamina propria together are called mucosa. Beneath the 
mucosa, is the submucosa. The tracheal submucosa is a layer of dense 
connective tissues containing mucous and serous glands that secrete mucin and 
polypeptide substances to the airway lumen. It also hosts the tracheal cartilage, a 
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smooth muscle layer and finally the adventitia, a loose connective tissue layer 
containing adipose cells that surround the trachea.  
Looking at the neurophysiology of the lungs, these are mainly innervated by 
the sympathetic and parasympathetic pathways that contribute to determine the 
bronchial airway tone through bronchodilator and bronchoconstrictive stimuli, 
respectively. Although the sympathetic system has less direct innervation on the 
airways than the parasympathetic, the bronchial smooth muscle cells express β2-
adrenergic receptors that can be stimulated by circulating catecholamines that 
produce smooth muscle relaxation and bronchodilation. On the other hand, the 
parasympathetic system innervates the airways more profusely and induces 
bronchoconstriction via cholinergic stimuli.  
4.2 Structural alterations of the airway wall in asthma 
Airway remodeling in asthma is defined as permanent structural 
abnormalities of the airway wall, associated with chronic airway 
inflammation,60, 324 that can form the basis for airway hyperresponsiveness, 
airflow obstruction and asthma severity.325 Airway remodeling may begin in the 
early phases of asthma prior to the onset of symptoms. The changes that can 
occur in airway remodeling comprise alterations affecting all layers of the 
airway wall (Fig. 4). Following such changes by layer order, thickening of the 
respiratory epithelium is the first event.326 Some studies have highlighted a 
possible role for the airway epithelium in the pathogenesis of asthma, related to 
epithelial dysfunction and breakdown of the epithelial tight junction integrity.151, 
327, 328 Evans et al. introduced the concept of epithelial-mesenchymal trophic 
unit (EMTU), which involves a close interaction between the airway epithelium 
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and the underlying mesenchymal tissues in controlling the airway 
microenvironment during processes such as lung development, repair, and 
regulation of inflammatory responses.329 Abnormalities in the airway epithelium 
of subjects with asthma may lead to a dysregulated interaction between the 
epithelium and subjacent mesenchymal elements such as fibroblasts, thus 
altering the EMTU function. Fibroblasts have the ability to differentiate into 
myofibroblasts, which secrete extracellular matrix proteins and proinflammatory 
mediators. An increased epithelium fragility and damage during chronic 
inflammation may as well lead to epithelial cell activation and the unleashing of 
proinflammatory and tissue repair mediators (cytokines, exotoxins, growth 
factors, extracellular matrix proteins, and metalloproteases), which can 
contribute to chronic inflammation and airway remodeling.330  
Other possible reasons for respiratory epithelium thickening are goblet cell 
hyperplasia and hypertrophy resulting in mucous hypersecretion. There is also 
an increased amount and size of mucous glands. Mucous glands are present in 
the peripheral bronchioles of asthmatics, where they are normally absent, and 
can make up a higher proportion of the submucosa in fatal asthma compared 
with normal subjects.331 In asthma, mucous glands can also have dilated 
secretory ducts that eventually leak air, causing interstitial emphysema as a 
possible complication.332 Higher mucous viscosity can significantly decrease 
mucociliary clearance,333 thus plugging small airways and causing a poor 
response to inhaled bronchodilators.334 The overproduction of mucus may cause 
mucous plugs in the airways of all sizes,335 and lead to atelectasis, where data 
showed that more than 50% of the airways can be occluded by mucous plugs 
during a fatal asthma attack.336  Hyperplastic increases in goblet cell numbers is 
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associated with mucous hypersecretion. Goblet cell hyperplasia and secretory 
hyperactivity have been attributed to inflammatory mediators such as IL-9337 
and IL-13.139, 337, 338   
The airway epithelium basement membrane is formed by the basal lamina 
and the lamina reticularis (a net of reticular fibrils, type VII collagen and 
microfibrils), both synthesized by conjunctive tissue cells. The thickening that 
occurs in the lamina reticularis, a feature of subepithelial fibrosis in asthmatic 
airways, is caused by the increased deposition of extracellular matrix and 
alterations in its turnover. 339 The extracellular matrix located in the 
subepithelial region, is made up of type I and III collagen fibers, fibronectin and 
proteoglycans. 59, 340, 341 Subepithelial fibrosis may occur if there is airway 
epithelium dysfunction and loss of integrity, resulting in possible repair 
impairment to injury.328 Subepithelial fibrosis may oppose airway smooth 
muscle contraction and limit its effect on airway narrowing.342  
A network of capillaries pertaining to the systemic circulation runs in the 
lamina propria and is implicated in the inflammatory process. There is also 
angiogenesis leading to neovascularization with altered permeability, facilitating 
edema that contributes to the airway narrowing and airflow obstruction.336, 343 
Various endothelial growth factors may be implicated in angiogenesis, such as 
VEGF, bFGF, PDGF and hepatocyte growth factor (HGF).59  
Next layer is the airway smooth muscle, which is increased in asthma 
through a combination of hyperplasia and hypertrophy, and a probable 
contribution of circulating precursor cells as discussed below. Such an increase 
of airway smooth muscle mass is the most prominent feature of airway 
remodeling, and clinical and experimental data suggest that the increased 
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smooth muscle mass plays a key role in the mechanism of variable airflow 
obstruction and airway hyperresponsiveness, which are cardinal features of 
asthma. The airway smooth muscle can also play a proinflammatory role 
through the secretion of several mediators.344 For such reasons, the increase of 
airway smooth muscle has been the airway remodeling feature most extensively 
studied and is the main focus of the research line from which the data presented 
in this thesis stemmed. Thus, next sections are dedicated to review the current 
knowledge on the mechanisms or airway smooth muscle remodeling and its 
implications in asthma physiopathology.   
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Figure 4 (previous page). The components of airway remodeling. The sketch compiles 
and illustrates the histopathological features of airway remodeling (right) compared 
with the normal airway wall (left). Airway chronic inflammation and altered injury-
repair mechanisms lead to persistent structural changes that prime the airways to 
undergo obstruction in the presence of doses of contractile stimuli that would not 
have such hyperresponsive effect in a normal airway. Such structural abnormalities 
alter the mechanics of airflow regulation in such way that obstruction, variable or 
persistent, may be elicited even if the airway smooth muscle was intrinsically normal 
from the cell biology standpoint. The structural abnormalities involved in airway 
remodeling include or result in: increased mucous content (1) as a result of a bronchial 
epithelial hyperplastic response (2) that involves the mucus-producing goblet cells 
along with an increase in the number and size of submucosal glands; subepithelial 
fibrosis (3), comprising a thickened basement membrane, and a thickened lamina 
propria as a result of an overall increased deposition of extracellular matrix 
components, which amplify the luminal obstruction caused by a given degree of 
smooth muscle shortening; (4) although not strictly a feature of airway remodeling, 
persistent inflammatory infiltrates and edema are often present; (5) neo-
vascularization; (6) a thickened airway smooth muscle layer as a result of myocyte 
hyperplasia and hypertrophy, likely involving a contribution from the recruitment and 
differentiation of circulating progenitor cells, and a probable regulation of myocyte 
apoptosis; and (7) a thickened and loose airway adventitia, which decreases the 
airway-distending forces that rely on the airway-parenchymal mechanical inter-
dependence. Figure source: original of D. Ramos Barbón, published in Ramos-Barbón 
D. et al. Clin Rev Allergy Immunol 2004; 27: 3-22. 
 
4.3 Mechanisms of airway smooth muscle remodeling 
Despite the demonstrated and known fact from experimental animal models4-
6, 345-348 and bronchial human samples336, 343, 349-354 that smooth muscle is 
increased in asthma, the mechanisms of airway smooth muscle remodeling are 
still unclear. There are various proposed pathways behind the increase in airway 
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smooth muscle mass, whereby the remodeling outcome likely results from a 
combination of all such possible mechanisms: increase in the size or 
hypertrophy of resident myocytes;354, 355 hyperplasia activated due to an increase 
in cell proliferation or because of a decrease in apoptosis;1, 83, 356 and the 
recruitment and differentiation of mesenchymal progenitor cells.10-13, 15-17, 357-359   
4.3.1 Hypertrophy of airway smooth muscle cells  
The presence of airway myocyte hypertrophy as a contributor to the 
thickening of the smooth muscle layer is still controversial. Studies that have 
focused on the detection of increased smooth muscle in bronchial biopsies of 
patients with different severity gradients, demonstrated that the increase in 
cellular size is associated with disease severity as well as the increase in 
contractile protein expression such as myosin light chain kinase (MLCK).1, 85, 355 
In vitro studies on airway smooth muscle cells from non-asthmatic subjects 
showed that the mTOR (mammalian target of rapamycin) protein124 and TGF-
β360 promote the activation of cascade signaling needed for myocyte 
hypertrophy.  
4.3.2 Hyperplasia of airway smooth muscle cells 
Most of the data regarding the mechanisms of airway smooth muscle 
remodeling have been obtained from experimentally induced asthma animal 
models. Animal models which used mice, rats and guinea pigs with repeated 
sensitization with ovalbumin, have shown an increase in smooth muscle mass 
due to hyperplasia.102,360-365 More recently, proliferation of resident airway 
smooth muscle cells has been demonstrated in human bronchial biopsies as 
shown in Part II of the Results section in the present thesis.17 The mechanisms 
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causing airway smooth muscle cell hyperplasia are under investigation and may 
comprise a complex array of different players. Most likely, chronic 
inflammation and the associated, dysregulated repair responses are overall 
responsible for inducing airway myocytes to enter active cell cycle in asthma, 
and many molecular mediators may be involved including cytokines, growth 
factors, eicosanoids, etc. Effector T cells infiltrate the airway smooth muscle 
and may induce myocyte proliferation in a direct fashion through direct, 
receptor-mediated cell contact.17, 102 Mastocytes also infiltrate the airway smooth 
muscle, and the release of a number of mastocyte mediators in close proximity 
may play a role as well.85, 284, 285 During the degranulation process of mastocytes 
and in response to repair initiated by the bronchial epithelium as a consequence 
of the inflammatory process, there is a liberation of growth factors such as 
epidermal growth factor (EGF), PDGF, TGF-β and leukotriene D4 which all 
acts as direct mitogens for smooth muscle cells both in vivo and in vitro.366-371 
PDGF also participates in the stimulation of fibroblasts for collagen production 
and further liberation of mitogenic signals.366 Other mediators, such as bFGF are 
produced by epithelial cells during tissue repair and regeneration processes and 
causes an upregulation of PDGF receptor in airway smooth muscle cells.372 IL-
1β stimulates the production of PDGF which, in association with IL-5, reduces 
the relaxing actions of prostaglandin E2 (PGE2) and isoproterenol, therefore 
affecting the contractility of airway smooth muscle and favoring 
hyperresponsiveness to acetylcholine.373-376 Other growth factors such as insulin, 
insulin-like growth factors (IGFs) can also act on airway myocytes.377 
Contractile agonists such as histamine, thromboxane A2 (TxA2), LTD4, 
thrombin and serotonin, also act as mitogens and induce myocyte 
proliferation.378-380 Endothelin-1 (ET-1) is capable of increasing the response of 
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airway smooth muscle cells to other mitogens through its union to G-protein 
coupled receptors (GPCR) present in the myocyte membranes.381-383  
4.3.2.1 Airway myocyte apoptosis  
Apoptosis, as a highly regulated and controlled process of programmed cell 
death, is involved in crucial events involving the respiratory system such as 
morphogenesis and immune regulation (Fig. 5). There is hardly any literature on 
studies that examined apoptosis of airway smooth muscle cells. Up to date, 
studies that looked at apoptosis in asthma have focused on its role in the process 
of leukocyte elimination once inflammation has resolved, as with the case of 
eosinophils and T lymphocytes when faced with corticosteroid treatment,384 and 
the effect of defective apoptosis of these cells in the maintenance and 
development of airway inflammation. Recent studies have proposed whether 
certain inflammatory cells (CD4+ T lymphocytes and eosinophils) in close 
connection with smooth muscle cells, have effects on the modulation of 
apoptosis of myocytes from the airways of asthmatics.385 In any case, most 
studies on bronchial smooth muscle cell apoptosis were done on non-asthmatic 
subjects,386-388 and only one study was done on asthmatic patients, with 
inconclusive results.389 In a study on Brown Norway rats based on adoptive 
transfer of CD4+ T lymphocytes from OVA sensitized donors and subsequent 
airway antigen challenge of the recipients, there was an increase in airway 
smooth muscle mass along with increased myocyte proliferation and decreased 
apoptosis.102 This outcome suggested that activated T cells had the capacity to 
induce changes in the homeostatic control of airway smooth muscle by 
promoting the inhibition of myocyte apoptosis and contributing to survival and 
proliferation. Conversely, studies involving large animals with spontaneous 
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Figure 5 (previous page). Apoptosis pathways, simplified scheme. Cell apoptosis can be 
initiated through two types of routes termed intrinsic and extrinsic pathways 
respectively, which later converge at the level of the final effector mechanisms. 
Central to such effector mechanisms are the caspases, a cascade of cysteine proteases 
subjected to sequential activation, that ultimately carry out the degradation of the 
cell. A wide variety of cell injury sources (e.g. cell membrane damage, heat, radiation, 
nutrient deprivation, hypoxia) may initiate the intrinsic pathway through the 
activation of proapoptotic proteins (e.g. BAD, BAX, BAK) that target the regulation of 
mitochondrial permeability and may lead to the release of cytochrome c. Once 
cytochrome c is leaked out of the mitochondria, it binds with Apoptotic protease 
activating factor-1 (Apaf-1), which in turn binds pro-caspase-9 to form a protein 
complex known as apoptosome. The apoptosome cleaves pro-caspase-9 to release 
active caspase-9, which then activates the effector caspase-3. The extrinsic pathway is 
initiated through the binding of cell surface receptors of the TNF receptor family such 
as Fas, TRAIL receptor and the TNF receptor by their ligands, i.e. Fas-L, TRAIL and TNF-
α. Receptor activation leads to the recruitment of pro-caspases 8 and 10 through 
adaptor proteins associated to the intracellular receptor domain, to form the death-
inducing signaling complex (DISC), where the caspase activation cascade is initiated. 
Active caspases 8 and 10 are released and subsequently activate caspases 6 and 7, to 
also finalize with the activation of caspase 3. The extrinsic pathway may also deliver 
cross-linking intracellular signaling to the mitochondrial pathway (not shown in the 
diagram). Caspase 3 is finally responsible for chromatin condensation and DNA 
fragmentation, leading to cell death. Figure elements: mitochondrion, cell nucleus and 
DNA molecule are from Blausen Gallery 2014 under Creative Commons Attribution 
License. Original figure composition, unpublished.  
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obstructive respiratory disease, particularly horses with heaves, showed opposite 
results. Horses may develop, in a spontaneous and natural manner, a type of 
airway obstructive disease as a consequence of being exposed and sensitized to 
hay. This disease termed heaves is characterized by chronic airway 
inflammation, airway hyperresponsiveness and structural changes of the airway 
wall similar to what takes place in asthmatic humans. Data obtained from 
studies on heaves showed a significant increase in airway smooth muscle mass 
along with increased myocyte proliferation yet, as opposed to the experimental 
asthma study in rats,102 that was accompanied by a significant increase in airway 
smooth muscle cell apoptosis.365   
Overall, consistent data on airway smooth muscle cell apoptosis are lacking, 
both on its role in regulating homeostatic cell turnover, and on its probable 
involvement in the pathological remodeling of this structure in asthma. Multiple 
agents may participate including cytokines, growth factors and other immune 
response mediators, produced by the airway myocytes themselves or by 
inflammatory cells, and further mechanisms may be involved such as 
interactions with the extracellular matrix, mechanical stress and direct effects of 
activated T cells.356, 390 A cell may initiate apoptosis signaling through two 
pathways, basically: (i) the so-called "intrinsic" or mitochondrial pathway 
initiated at the mitochondria; and (ii) the "extrinsic" pathway, which is initiated 
by cell surface receptor-mediated signal transduction from external stimuli. Both 
pathways converge into a final cascade of cleavage and activation of enzymes, 
the caspases, which are the final effectors that initiate DNA fragmentation in the 
cell nucleus. In vitro studies showed that both airway and vascular smooth 
muscle cells express the inductor receptor for cell death Fas (Fas cell surface 
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death receptor), whose union with its ligand (FasL) leads to apoptosis. It is 
therefore believed that this receptor, a member of the TNF family, may have a 
role in controlling the number of airway myocytes.386, 391 Fas activation is 
followed by the recruitment of other signaling molecules including the Fas-
associated death domain (FADD), procaspase-8 and procaspase-10 to form a so-
called death-inducing signaling complex (DISC). After DISC formation, the 
activation of caspase-8 ensues, which can be sufficient to unlock the rest of the 
caspase cascade. If apoptosis signaling is initiated from the mitochondria, the 
fragmentation of Bid (an anti-apoptotic proteins of the Bcl-2 family) gives way 
to the release of cytochrome c from the mitochondria and the formation of a so-
called apoptosome via the union of apoptotic protease-activating factor-1 (Apaf-
1), with procaspase-9 being activated and promoting the continuation of the 
caspase cascade activation. The final effector caspases act on nuclear substrates 
such as poly(ADP-ribose) polymerase (PARP)392 which is involved in DNA 
repair and is cleaved as part of the process of apoptosis, releasing cleaved PARP 
(c-PARP) as a byproduct. PARP appears to be otherwise implicated in the 
process of airway inflammation associated with asthma and other respiratory 
disorders, due to its modulating capacity on the expression of various pro-
inflammatory mediators such as TNF-α, other interleukins, adhesion molecules, 
etc.393  
4.3.3 Recruitment and differentiation of circulating progenitor cells  
There is evidence that airway smooth muscle remodeling may in part occur 
through the recruitment and differentiation of circulating progenitor cells, which 
may differentiate into fibroblasts, myofibroblasts and ultimately airway smooth 
muscle cells.10-16, 18 Mechanisms suggested for airway smooth muscle growth in 
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asthma may in fact involve the migration and differentiation of subepithelial 
myofibroblasts,10, 11 which may originate from circulating, bone marrow-
derived, α-SMA expressing progenitor cells termed fibrocytes.12, 16 Studies on 
bronchial biopsies showed increased subepithelial myofibroblasts10, 11 and fibro-
cyte localization upon allergen challenge in the bronchial mucosa of 
asthmatics.12 In murine asthma models, fibrocyte recruitment to the airways, and 
their differentiation to α-SMA+ myofibroblasts, was demonstrated.12, 15, 18 Other 
studies strengthened the clinical evidence of fibrocyte involvement in airway 
remodeling,13, 14, 16 and provided direct evidence that fibrocytes are present in 
the airway smooth muscle bundles in asthmatics of all severities.16  
The evidence that a circulating progenitor cell such as the fibrocyte may 
participate in airway smooth muscle remodeling through its integration and 
differentiation in the smooth muscle layer has a particular relevance in view of a 
theoretical use of mesenchymal stem cells (MSCs) as a treatment for asthma. As 
MSCs recently propelled extensive research on regenerative medicine due to 
their ability to differentiate into a variety of structural tissue cells,394 further 
knowledge gained on the biological properties of MSCs, particularly their 
immunoregulatory effects and good tolerance upon allogeneic infusion,395, 396 
expanded their potential uses into the treatment of severe immune mediated 
diseases. This new field rapidly evolved to the clinical trial setting, with 
encouraging results obtained for graft-versus-host disease397 and a growing 
number of trials running at present.398 Such outcomes also attracted interest on a 
potential use of MSCs as an asthma therapy for subjects with severe, refractory 
asthma. However, the use of MSCs as an anti-inflammatory therapy for asthma 
is uncertain and may face significant limitations due to the building evidence 
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that airway remodeling may at least in part occur through the recruitment and 
differentiation of circulating progenitor cells.10-16, 18 MSCs administered for 
therapeutic purposes in asthma may therefore bear a to a potential where they 
may reduce airway inflammation, yet they may serve as building blocks for 
airway remodeling. 
 
5. Investigative procedures on lung structure: the role of 
bronchial biopsy and its related methodological aspects 
5.1 Overall contribution of bronchial biopsies to asthma knowledge 
A large amount of the data generated on asthma disease mechanisms has 
been generated from animal models mostly employing small laboratory rodents, 
i.e. rats and mice, with obvious advantages and some controversial limitations.7, 
356, 399, 400 Yet the knowledge gained from those approaches needs in any case to 
be contrasted and verified for the actual human asthma, if clinically relevant 
translation is to be attained.  
Data obtained from human lung tissue specimens have provided extensive 
information since almost a century349 regarding the phenomenon of airway 
remodeling and inflammation present in asthma. However, such knowledge was 
for many decades gained from postmortem lung specimens, which have been 
useful for basic descriptions on histopathology but bear major, obvious 
limitations related to the effects of immediate degradative processes that hamper 
the use of antibody-based techniques to detect specific targets, plus an overall 
distortion of lung architecture preventing reliable quantitative analyses, and the 
impossibility of harvesting viable biological material for studies based on 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 72 - 
explant or cell culture. The source of knowledge on lung histology and the 
histopathology of respiratory diseases, asthma in particular as for the focus of 
the present work, was virtually limited to the collection of postmortem 
specimens for many decades until the development of fiberoptic endoscopic 
techniques starting in the 1970s,401 and autopsy material has long ago been 
rendered almost useless for the requirements of modern knowledge advances.  
The possibility to obtain bronchial biopsies in healthy control individuals, 
asthmatic patients and patients with other respiratory conditions has advanced 
our knowledge on the pathogenesis of asthma up to current times and continues 
doing so, still far from reaching the boundaries of its possibilities as of today. 
Endobronchial biopsy is indeed considered a benchmark to non-invasive 
sampling methods such as sputum induction for data validation and 
interpretation,402 and also for the validation of noninvasive assessment of airway 
wall structure through imaging techniques403-405 and the development of 
endobronchial ultrasonography (EBUS) applications.406 The advantage of 
bronchial biopsy over any other sampling techniques from live subjects is that it 
is the only procedure that provides airway structural information at the 
microscopic scale, therefore allowing for the examination of the different 
bronchial wall compartments such as the epithelium, the subepithelial 
connective tissues of the lamina propria, the airway smooth muscle layer, 
mucous glands, and the microvasculature of the bronchial circulation, as well as 
the detailed microlocalization of inflammatory infiltrates. Early studies on 
bronchial biopsies from asthmatics provided evidence of extensive 
inflammatory infiltrates in the airway wall, even in mild asthmatics and cases of 
subclinical disease. This included the finding of mucosal infiltration by 
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eosinophils showing morphologic evidence of activation, mast cell 
degranulation and extensive deposition of collagen beneath the epithelial 
basement membrane.407 Compelling evidence of infiltration of the airway wall 
tissues by eosinophils was provided, as well as the first hints on the variability 
of inflammatory infiltrates among different asthmatics, and the persistence of 
background airway inflammation in stable asthma.407-410 This set of early studies 
included the examination of bronchial biopsies under electron microscopy, with 
consistent results.408 Further studies have been instrumental to provide evidence 
of hyperplastic airway smooth muscle growth in patients with just mild-to-
moderate asthma,1 and to pinpoint increased markers of epithelial cell 
proliferation and activation,411 increases in type-III collagen deposition, airway 
smooth muscle cell hypertrophy and fibroblast numbers,355 and differences in 
cytokine expression412 as characteristics that distinguished severe from mild 
asthma. Increases of airway smooth muscle mass to a greater extent and a 
shortened distance from the outer edge of the smooth muscle layer to the airway 
epithelium were also selectively seen in airway tissue from subjects with severe 
asthma, suggesting remodeling features associated with disease severity.413 
Bronchial biopsies also allowed to sub-classify severe, refractory asthmatics into 
different phenotypic subsets as per the intensity of eosinophilic inflammatory 
infiltration, and relate the greater presence of eosinophils with larger 
subepithelial fibrosis and a history of life-threatening asthma attacks.414  
Beyond all such descriptions, studies on bronchial biopsies were also 
determinant for a deeper advancement of knowledge into disease mechanisms. 
An early insight into airway wall inflammation associated the presence of 
activated CD4+ T cells with eosinophilic inflammation.221 Another of such 
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outcomes was the "myositis" theory, whereby mast cells infiltrate the airway 
smooth muscle of asthmatics, and closely interact with it through their mediators 
to induce airway hyperresponsiveness, the release of further inflammatory 
mediators and ultimately airway smooth muscle growth.85, 371 One more advance 
into the disease mechanisms brought by the analysis of biopsies has been the 
buildup of evidence on the participation of circulating, recruited progenitor cells 
in the hyperplastic growth of airway smooth muscle.10-12, 16 Furthermore, 
bronchial biopsies provide valuable information not only regarding the 
pathophysiology of asthma but also about treatment-induced changes in 
inflammation and remodeling,415-417 and can also be used to isolate and culture 
resident cells and study their phenotype and responses to in vitro 
experiments.385, 389, 418, 419 
Some reports on bronchial biopsies led to controversy in terms of validity 
and confirmation of formerly published findings. Examples of such 
controversial findings pertain to the association between increased connective 
tissue deposition and asthma severity,420, 421 the loss of airway epithelium422, 423 
and the relationship between remodeling and airway hyperresponsiveness.424 
The work by Laitinen et al. in 1985422 was pioneering in obtaining bronchial 
biopsies from asthmatics, through the use of a rigid bronchoscope. 
5.2 General principles behind bronchial biopsy obtention and processing 
The use of bronchial biopsies for endpoint-oriented research outcomes 
implies procedural goals such as obtaining quality immunohistochemical or 
immunofluorescent staining, nucleic acid detection through techniques such as 
in situ hybridization, and structural representativeness and preservation 
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standards so as to generate reliable, quantitative morphology data. Such goals 
affect every step of the whole process, starting from biopsy location and the 
harvesting technique during bronchoscopy, continuing through tissue fixation 
and preservation options, transportation and storage logistics, the different 
techniques employed for specific antibody or nucleic acid probe-based target 
detection, and up to the production of reliable quantitative data through 
microscopic image analysis. For those reasons, review material and consensus 
guidelines have been published covering various of such aspects plus safety 
issues.402, 425-431 
In 1990, a joint workshop was held by the U.S. National Institutes of Health 
National Heart, Lung, and Blood Institute, the National Institute of Allergy and 
Infectious Diseases, the American Academy of Allergy and Immunology, the 
American College of Chest Physicians, and the American Thoracic Society to 
issue official guidelines on the investigative use of bronchoscopy, lavage and 
bronchial biopsies in asthma and other airway diseases.426, 427 By reviewing 
extensive data from more than 200 published articles during the previous 5 
years, the workshop participants concluded that bronchoscopy, and 
bronchoscopic techniques including bronchial biopsy, can be safely performed 
for investigative purposes in asthmatics when appropriate precautions are 
observed. The safety record included investigative bronchoscopic procedures 
carried out in asthmatics with FEV1 values <60% predicted, and bronchoscopy 
with instrumentation, including biopsy, performed before and after a variety of 
bronchial provocation procedures involving local instillation of antigen, non-
isotonic solutions, air pollutants, and other stimuli such as exercise and 
hyperventilation. The safety of repeating bronchoscopic procedures in the same 
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asthmatic individuals was also established. The workshop participants also 
previewed, as later history confirmed, that the research potential for 
investigative bronchoscopy and instrumentation of the airway was considerable, 
and that such approaches would continue to provide valuable information about 
the pathogenesis of airway diseases. From the methodological standpoint, the 
workshop statement acknowledged that the techniques used to obtain fluid and 
tissue biopsies varied widely, so no detailed specific recommendations were 
made. Therefore, the resulting guidelines were mostly focused on establishing 
the safety of bronchoscopy and bronchoscopic instrumentation in asthmatics. In 
regard to bronchial biopsies it was pointed out, based on the accumulated 
experience, that three to six, 2-mm diameter biopsies could be obtained in a 
single bronchoscopy session from one or more segmental or subsegmental 
carinae. The workshop neither attempted to issue specific recommendations on 
tissue processing after biopsy collection, beyond the general statement that 
technical skills and laboratory resources are especially important in processing 
the small biopsy specimens, which require careful histological preparation and 
processing since the type of analyses performed on the specimens from 
investigative bronchoscopy are not routine clinical procedures. Finally, a closing 
remark on limitations was made. Beyond the invasive nature of bronchoscopy as 
its main limitation for research purposes, and the added difficulty to obtain 
specimens from acutely ill or exacerbated asthmatics, it must be taken into 
account that bronchial biopsies are limited to larger airways and may not reflect 
the findings in smaller, peripheral airways.  
Following the 1990 workshop and its resulting guidelines, continuing 
investigations using bronchial biopsy, paralleled by the development of 
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improved resources for specific target detection on tissue sections plus the 
advancement of microscopy technologies, led to a variety of choices and issues 
pertaining to the collection and processing of the biopsies, which determine and 
may limit the future work can be done on the stored specimens. A review of 
such aspects follows:  
5.2.1 Factors affecting bronchial biopsies at collection point 
In order to get reliable and meaningful research data, it is crucial to obtain 
quality biopsies. Factors that contribute to overall quality are: bronchoscopic 
instrumentation, expertise, number of biopsies obtained, location, size and 
morphological integrity. Although not official guidelines, experience 
accumulated after the 1990 workshop led to issuing authoritative review work 
stating further standards.402, 428-430 Samples must have a subepithelial depth of at 
least 0.3 to 0.5 mm excluding crush artifact cartilage or blood clots resulting 
from the forceps bite-and-pull action. Due to the possibility of hemorrhage, it is 
recommended that biopsy sampling is unilateral (i.e. right or left lung only) and 
biopsies should be obtained from visible carinae up to subsegmental bronchial 
level (i.e. second, third and fourth airway generations), moving from a distal to 
proximal direction at random. With the 1990 workshop having established the 
safety of collecting up to 6 bronchial biopsies in a single bronchoscopy session, 
a minimum of 2 biopsies per session is recommended to ensure at least one good 
sample for analysis.  
No published data or recommendations exist on the choice of the biopsy 
forceps model for optimum sampling of the airway wall and best preservation of 
structural integrity, and the specific forceps employed is most often not quoted 
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in the reports. A large body of published data sets report findings limited to 
subepithelial level (i.e. alterations of the bronchial epithelium, basement 
membrane thickening, subepithelial fibrosis, and inflammation within the 
epithelium and lamina propria). Regarding the particular aims set for the 
development of the specialized bronchial biopsy biobank presented in this 
thesis, and as for the goals of the research projects derived from, or served by, 
the biobank, sampling assessable airway smooth muscle is a main objective that 
poses some technical issues that later will be discussed. 
5.2.2 Issues on bronchial biopsy processing for specimen preservation 
Immediately upon collection, bronchial biopsies must be processed for tissue 
preservation, for the purpose of storage and later staining and analysis. This 
process starts in the bronchoscopy room, at the very moment when the biopsy 
forceps is pulled out of the bronchoscope and the biopsy is released and dropped 
into its first recipient containing a particular fluid. From this point a spectrum of 
technical possibilities opens, each with its own advantages, limitations and 
logistics implications. Further discussion on the chosen strategy for the 
bronchial biopsy biobank presented here will be done later in the corresponding 
sections. 
Various methods are available for the preservation of freshly obtained 
tissues, such as is the case of the bronchial biopsies.428, 429, 432 A tree-branch 
diagram in Fig. 6 facilitates a snapshot view of the different choices, and their 
main advantages and issues are summarized in Table 1.  
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Specimen
Frozen
Room
Temperature
Prefixed,
OCT protected
Unfixed,
OCT protected
Snap frozen
 Paraformaldehyde
 Methanol-acetone
 Acetone
Formalin/paraffin
Acetone/methacrylate  
Figure 6. Decision tree diagram for the immediate processing and preservation 
of tissue specimens. A detailed explanation is provided in the main text. Figure 
source: original. 
 
The first decision node is: frozen specimens versus room temperature-
preserved specimens. Since tissue fixation with chemicals may hamper the 
detection of particular targets in subsequent processes, frozen specimens have 
the advantage that prior fixation is not necessary and, upon retrieval of the 
frozen tissue block, tissue sections can then be fixed according to the needs of 
particular purposes, so virtually anything can be detected. However, working 
with frozen biopsies implies significant disadvantages related to on-site logistics 
and morphological quality. The main reason for such disadvantages is that 
tissues cannot be snap frozen if their structure needs to be preserved, because 
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Table 1. Comparison of tissue processing and preservation methods 
abrupt freezing disintegrates the specimen. The procedure to freeze tissue 
specimens with preservation of their structure implies: immersing the tissue in 
optimal cutting temperature (OCT) medium inside an appropriate block cast; 
bringing its temperature down progressively through immersion in methanol, 
which must be readily precooled in liquid nitrogen; and expediting the transfer 
of the specimen to a -80ºC freezer. All such procedure requires readily available 
laboratory support at the bronchoscopy site, and an ultrafreezer storage facility 
where the freezers should ideally be equipped with remote alarm and 
temperature-tracking probes to prevent disastrous losses in case of failures of 
electricity supply or freezer breakdown. Alternatively, the tissues can be fixed 
prior to freezing, usually in paraformaldehyde. Due to its spontaneous 
N/A: non-applicable. OCT: optimal cutting temperature embedding medium. PCR: polymerase 
chain reaction. Table source: original. 
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degradation within hours, the preparation and maintenance of a para-
formaldehyde supply also requires on-site laboratory support and an ultrafreezer 
facility for its preservation. Prefixation in paraformaldehyde conditions and 
limits the ulterior use of the specimens, since it is a cross-linking fixative (see 
comment on formalin below). In both cases, frozen tissue blocks yield poorer 
quality tissue sections for morphological analysis.  
As for the procedures for tissue preservation at room temperature, the most 
common and classical method is formalin fixation followed by embedding in 
paraffin blocks. "Formalin" consists of chemically stabilized, PBS-buffered 4% 
formaldehyde in its working solution form (it is often called "10% formalin" in 
the laboratory jargon because it is a 1/10 dilution of a commercially available 
40% formaldehyde solution). An upfront advantage of formalin fixation is its 
simplicity at the biopsy collection point; the bronchoscopist only has to drop the 
biopsy in a cryotube or Eppendorf tube preloaded with formalin. No immediate 
laboratory support nor special logistics are required, and the fixation runs on its 
own at room temperature. Tissue sections from formalin-fixed, paraffin-
embedded specimens yield excellent morphological quality, superior to that of 
frozen tissues. The drawback of formalin fixation is that formaldehyde is a 
cross-linking fixative; that is, it establishes covalent chemical bonds that fold 
and distort the tertiary structure of proteins, and this may render particular 
epitopes spatially inaccessible to primary antibodies that are directed to them for 
detection. As a result, some primary antibodies that work for 
immunohistochemistry or immunofluorescence on frozen tissues, as well as 
some antibodies that work for flow cytometry or for Western blot on extracted 
proteins, may not work on formalin-fixed tissues. This inconvenience can often 
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be overcome by applying the so-called antigen retrieval techniques (see 
explanation on the next section). The effect of formalin on the performance of 
subsequent immunohistochemical or immunofluorescent detection procedures is 
time-sensitive and therefore, differently from the processing of specimens for 
regular pathology examination in the clinical setting, the time of fixation must 
be controlled and standardized. Formalin fixation yields significant tissue 
autofluorescence in comparison with other fixatives commented below, a feature 
that used to be considered a drawback for immunofluorescent techniques. 
However, the strength of modern fluorochromes now overcomes this problem 
by providing a very good signal-to-noise ratio on formalin-fixed tissue sections, 
and the tissue autofluorescence may indeed become an advantage because it 
provides a background of histological reference for signal localization. A major 
advantage of formalin fixation over non-prefixed frozen specimens is the 
preservation of nucleic acids, which allows for subsequent in situ hybridization 
techniques, e.g. for the detection of mRNA species. Furthermore, formalin-
fixed/paraffin-embedded biopsies can later be subjected to additional processing 
for electron microscopy.  
To avoid the cross-linking effect of formaldehyde and paraformaldehyde, 
other fixatives can be used such as acetone or methanol-acetone. Acetone-fixed 
specimens can be embedded and preserved in room-temperature glycol 
methacrylate blocks, which yield tissue sections providing excellent 
morphological quality.428 However, such alternative fixatives must be precooled 
down to -20ºC for their use and handled under a fume hood for volatile organic 
compounds, and therefore require laboratory infrastructure at the bronchoscopy 
site. Glycol methacrylate embedding is not compatible with conventional tissue 
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processors and microtomes, and therefore requires its own, costly equipment for 
tissue processing and sectioning. As a further disadvantage, acetone-based 
fixation does not preserve nucleic acids, therefore rendering the biopsies not 
valid for in situ hybridization procedures.  
5.2.3 Staining and specific detection techniques on bronchial biopsy 
tissue sections 
Nowadays, classical histochemical staining techniques432 readily provide 
important information for the analysis of bronchial biopsies and lung tissue 
sections in general, including specimens from experimental animal models. 
Commonly employed histochemical stainings in the field of asthma research are 
hematoxylin-eosin, Masson's trichrome and periodic acid-Schiff (PAS). 
Hematoxylin-eosin staining allows for a general histopathological examination 
along with the evaluation of biopsy quality and tissue integrity, and is very 
sensitive for the detection of eosinophilic inflammatory infiltrates. It is possible 
in fact to perform quantitative morphology to determine the numerical density of 
eosinophils, on the basis of hematoxylin-eosin staining. Masson's trichrome 
provides an overall staining of extracellular matrix components and is useful to 
detect subepithelial fibrosis. PAS staining detects mucous substances and is used 
to evaluate the hyperplasia and hypertrophy of mucus-producing goblet cells 
and the overall mucus load in the airway epithelium. 
Antibody-based technologies allow for the detection of specific protein 
targets through the techniques of immunohistochemistry and immuno-
fluorescence.432 The basic difference between both families of techniques is 
determined by how the visible signal is produced: in immunohistochemistry, an 
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enzymatic reaction produces a colored precipitate that can be viewed using 
regular bright-field microscopy, whereas for immunofluorescence the signal is 
produced by fluorochromes and the signal is viewed with a fluorescence 
microscope equipped with an excitation lamp source and filters to select and 
narrow the excitation and emission wavelength. As for the rest, 
immunohistochemistry and immunofluorescence share the same general 
principles. Briefly, a primary antibody, which can be monoclonal or polyclonal, 
is added to the tissue section in order to bind a particular antigen that the 
antibody targets. Monoclonal antibodies target a specific antigen epitope, 
whereas polyclonal antibodies may bind several different epitopes in the same 
antigen. Polyclonal antibodies may offer greater sensitivity but they may be 
subjected to manufacturing batch-to-batch variation, since they are extracted 
from the blood of large sensitized animals (i.e. from rabbit onwards). 
Monoclonal antibodies offer specificity to a particular epitope, are produced in 
vitro from hybridoma cell lines that provide a limitless supply, and are 
invariable. In the early development of immunohistochemical and 
immunofluorescence techniques, the primary antibodies were directly labeled 
with enzymes or fluorochromes and the signal strength was poor for microscopy 
applications. Antibodies directly labeled with fluorochromes perform well for 
flow cytometry and are extensively used in this field. As for microscopy, later 
developments provided strong signal amplification systems by means of 
secondary anti-immunoglobulin antibodies, large molecular enzyme 
conglomerates and modern, powerful fluorochromes. All such resources allow 
us now to obtain a great signal-to-noise ratio in the processed tissue sections, 
and to perform multiple labeling for the simultaneous detection and 
colocalization of different targets (Fig. 7).  
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Figure 7. Coimmunostaining employing modern detection systems. Two different 
antigens (e.g. Ag1, a nuclear enzyme; Ag2, a cell surface receptor) can be targeted for 
detection with specific monoclonal antibodies, respectively. Modern immunostaining 
systems performed in sequence allow for sharp differential detection even if both 
primary antibodies (1 and 2 respectively) are from the same species and pertain to the 
same immunoglobulin class and subclass (e.g. both can be a mouse IgG1 monoclonal 
antibody). Specimen incubation with each primary antibody can then be followed (the 
diagram represents one of various systems available) by a biotinylated secondary 
antibody (3, e.g. a horse anti-mouse IgG polyclonal antibody). As next step, an avidin-
biotin alkaline phosphatase complex (4) is added. This complex forms very large 
molecular conglomerates that firmly bind the secondary biotinylated antibodies. 
Lastly, a development reaction is performed by adding an alkaline phosphatase 
chromogen substrate that forms a colored, blocking precipitate (5). Using a system 
sequence such as the one depicted here, up to three different epitopes can be 
coimmunostained in the same tissue section, and clearly differentiated along with a 
histological counterstain such as methyl green (i.e. four different signals can be 
simultaneously obtained and analyzed on the same specimen). This strategy allows for 
a rich and versatile exploitation of valuable bronchial biopsy tissue sections (see Part II 
in the Results section of the present thesis as an example of this application). Figure 
source: original, unpublished. 
 
As pointed out in section 5.2.2, tissue preservation with cross-linking 
fixatives such as formalin may render some epitopes undetectable, and this 
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problem can often be solved by employing antigen retrieval techniques. Antigen 
retrieval consists of unfolding the proteins distorted by the covalent bonds 
produced by the cross-linking fixatives, so that the hidden epitopes get 
uncovered and exposed to the primary antibodies that target them for detection. 
This can be achieved by enzymatic cleavage with trypsin or other enzymes, or 
by physical procedures where intense energy is applied to the tissues through 
techniques such as microwaving or high-pressure heating ("pressure 
cooking").433-435 The techniques and technical parameters vary, and establishing 
a successful antigen retrieval technique for a particular epitope may need 
empirical, trial-and-error testing. The outcome may vary from fully successful to 
not feasible; therefore, some epitopes for which specific antibodies are 
commercially available may not be detectable in tissues processed with cross-
linking fixatives. 
Finally, in situ hybridization techniques allow for the detection of specific 
nucleic acid sequences by targeting them with labeled, complementary 
probes.436 This procedure can be applied for the detection of genomic DNA 
sequences or to detect RNA species, the latter usually applied to study gene 
expression at post-transcriptional level by detecting specific mRNA. For the 
purpose of these techniques, thermocyclers adapted to process microscope slides 
are commercially available.  
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6. Summary and rationale 
Asthma is a research priority due to its global burden, caused by its 
increasing prevalence, its cost on the health systems and the existence of a 
percentage of asthmatics comprising large populations in absolute numbers, who 
suffer from severe disease, and/or disease refractory to maximum available 
therapy. To add complexity, asthma comprises a not well understood spectrum 
of clinical variants ("phenotypes") and involves varying physiopathologic 
mechanisms ("endotypes") corresponding to its clinical variability. A large 
clinical trial pipeline is currently running for the development of novel asthma 
therapies, with a particular emphasis on "biologicals" (i.e. humanized 
monoclonal antibodies, "umabs"). 
Under such variable "asthma syndrome", a chronic inflammatory condition 
of the airways underlies. The immunobiology of adaptive immune responses has 
been extensively investigated and better understood during the 20th century, and 
also its role in atopic asthma. Knowledge on the involvement of the innate 
immune system, and its complex implications in triggering effector versus 
tolerogenic immune responses, is currently in progress. The diversity of the 
immunobiological pathways involved in asthma is now being characterized and 
its classification is being attempted, yet an overall, integrated view of the 
immunobiology of asthma is still lacking. Associated with chronic airway 
inflammation, airway remodeling is also an important feature of asthma 
pathophysiology. Airway remodeling is understood as a dysregulated response 
of tissue repair mechanisms that leads to abnormal structural changes of the 
airway wall, including hyperplasia and hypertrophy of mucus producing cells in 
the airway epithelium, an increase in the number and size of mucous glands, 
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subepithelial fibrosis, neovascularization and increased airway smooth muscle. 
All such alterations together lead to a thickened airway with altered physiology, 
where the increase of airway smooth muscle is considered central to the 
mechanisms of airway hyperresponsiveness and  airflow obstruction. Airway 
smooth muscle is increased through a combination of hyperplasia and 
hypertrophy, and proposed mechanisms for airway smooth muscle growth in 
asthma include in situ proliferation of airway smooth muscle cells, and the 
recruitment and differentiation of a type of circulating, bone marrow-derived 
progenitor cell, the fibrocyte. Fibrocytes participate in the physiological 
mechanisms of tissue repair and, in asthma, they may be recruited to the 
inflamed airways where they may differentiate into myofibroblasts and 
myocytes, and get integrated into the airway smooth muscle bundles. In all, 
airway remodeling is believed to underlie the clinical manifestations and the 
severity of asthma. Therefore, the analysis of airway remodeling is of obvious 
importance for the advancement of knowledge on asthma, yet not an easy 
research goal. 
Data on the disease mechanisms of asthma, the discovery of potential 
therapeutic targets and the effects of proposed novel therapies arise from various 
sources including experimental animal models and in vitro studies, and 
ultimately need translation to actual asthma to achieve clinical meaningfulness. 
To this regard, bronchial biopsy is the only clinical sampling procedure that 
yields structural information from the airway wall under the microscope, and at 
ultrastructural level if needed. Therefore, bronchial biopsy is the benchmark to 
analyze airway remodeling in asthma. However, bronchoscopic instrumentation 
and the collection and processing of bronchial biopsies that yield valid data for 
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research purposes in asthma, is subjected to procedural requirements and issues 
that make this aim be a special field apart from regular clinical practice. In 1991, 
official guidelines were published establishing the general principles for safe 
bronchoscopy and bronchoscopic instrumentation in asthmatics, for research 
purposes. Beyond the guidelines, a broad spectrum of technical choices opens, 
affecting the entire process from biopsy collection during bronchoscopy to 
quantitative morphology under the microscope, and comprising a variety of 
biopsy handling and processing procedures, each with its applications, 
advantages and limitations, where no particular road map exists. 
Notwithstanding the relevance of airway remodeling to asthma and its therapies, 
the airway wall structure and its alterations are generally being under-analyzed 
due to the need of bronchial biopsies for such purpose and the associated 
requirements and difficulties. However, it is foreseeable that, as the growing 
pipeline of novel therapies aimed at difficult-to-control or severe, refractory 
asthma develops, the demand of knowledge on airway remodeling will be on the 
rise and clinical trials may eventually request expertise to incorporate bronchial 
biopsy procedures and the analysis of outcomes related to airway wall structure. 
Due to the necessity and importance of bronchial biopsy for asthma research, 
and to the gap that to this respect existed in Spain, we aimed at developing a 
structured, multicentric Bronchial Biopsy Biobank with systematic logistics and 
optimized, standard operating procedures (SOPs). The work presented in this 
thesis compiles the deployment of such biobank as part of the Asthma Integrated 
Research Program (Programa Integrado de Investigación en Asma, PII Asma) 
of the Sociedad Española de Neumología y Cirugía Torácica, SEPAR.  
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The core aim of the Bronchial Biopsy Biobank is to service specific 
scientific goals pertaining to research projects from qualified investigators. The 
Experimental Pneumology Unit that fostered the development of the Bronchial 
Biopsy Biobank, currently hosted at the Biomedical Research Institute and 
Respiratory Department of the Hospital de la Santa Creu i Sant Pau, Barcelona, 
holds a translational research line with a primary focus on airway inflammation 
and remodeling, where data from animal models of experimental asthma are 
combined with work on the human bronchial biopsies. In this thesis, results 
from applying the Bronchial Biopsy Biobank to specific scientific goals of this 
research line will also be presented. This pertains to the interaction between T 
cells and airway myocytes, the role of apoptosis in airway smooth muscle 
remodeling, the involvement of Treg cells in asthma, and the potential 
implications of mesenchymal stem cell therapies for asthma. Next section 
compiles the hypotheses and objectives for the overall work presented in the 
thesis. In the Results section, each part dedicated to the exploitation of the 
Bronchial Biopsy Biobank for specific research project goals will be headed by 
a summarized background presented as "Introduction", in order to lead the 
results and facilitate the reading flow. 
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Hypotheses 
General hypothesis on Bronchial Biopsy Biobank development 
The collection, shipping and processing of bronchial biopsies obtained from 
bronchoscopy procedures indicated as per clinical practice, in a multicenter 
fashion, in adherence to specifically developed standard operating procedures, 
shall yield a sustainable flow of quality specimens comprising assessable airway 
smooth muscle, valid for non-preset, wide-spectrum research objectives 
comprising accurate histopathological evaluation, specific epitope target 
detection, complex colocalization procedures, and the generation and analysis of 
quantitative morphology data. 
 
Specific hypotheses on asthma immunobiology from Bronchial Biopsy 
Biobank specimen analyses 
1. A direct, receptor-mediated, T cell/airway smooth muscle cell contact 
involved in the mechanism of airway smooth muscle cell hyperplasia as 
predicted by experimental asthma modeling, is present in human asthma and 
subjectable to demonstration in bronchial biopsy tissue sections. 
2. A baseline frequency of airway smooth muscle cell apoptosis involved in 
homeostasis, and its upregulation in response to airway smooth muscle 
remodeling as demonstrated in experimental asthma modeling, have a 
correlate in human asthma that is subjectable to demonstration in bronchial 
biopsy tissue sections. 
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3. FOXP3+ regulatory T cells, reactively increased in response to chronic 
airway inflammation as demonstrated in experimental asthma modeling, 
infiltrate the airway wall in increased numbers in human asthma and this is 
subjectable to demonstration in bronchial biopsy tissue sections. 
4. STRO-1+, non-fibrocyte mesenchymal stem cells, are not involved in airway 
wall infiltration nor airway smooth muscle remodeling in human asthma as 
predicted by experimental asthma modeling, and this is subjectable to 
demonstration in bronchial biopsy tissue sections. 
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Objectives 
1. To develop and implement the logistics and standard operating procedures 
for multicentric collection of bronchial biopsies and associated 
demographics and clinical data, under the premises of: (i) maximized 
procedural simplicity at the bronchoscopy site, and (ii) specimen processing 
and preservation suitable for a widest possible spectrum of subsequent 
investigational procedures, so as to establish a specialized Bronchial Biopsy 
Biobank as a stable, sustainable structure able to serve specific research 
projects as part of the Asthma Integrated Research Program (PII Asma) of 
the Sociedad Española de Neumología y Cirugía Torácica (SEPAR). 
2. To set up and perform coimmunostaining of bronchial biopsy tissue sections 
for the colocalization of T cells, α-SMA+ cells and proliferating cell nuclear 
antigen (PCNA), and generate quantitative morphology data, in order to 
obtain evidence of a direct T cell/airway smooth muscle cell contact 
mechanism involved in the induction of myocyte proliferation in asthma. 
3. To analyze airway smooth muscle cell apoptosis in biopsy tissue sections by 
colocalization of in situ terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) and/or immunostaining of other byproducts of 
apoptotic activity as pertinent, with α-SMA+ cells, and to generate 
quantitative morphology data so as to provide evidence of the role of 
myocyte apoptosis in airway smooth muscle remodeling, in asthma. 
4. To perform exploratory immunostaining of FOXP3 on bronchial biopsy 
tissue sections, and to generate quantitative morphology data, so as to 
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provide preliminary evidence on the presence and frequency of FOXP3+ 
regulatory T cells in human asthma.  
5. To perform exploratory immunostaining of STRO-1 on bronchial biopsy 
tissue sections, and to generate quantitative morphology data so as to discern 
whether STRO-1+ mesenchymal stem cells are recruited into the airway wall 
of subjects with asthma. 
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1. Bronchial Biopsy Biobank deployment 
1.1 Overall organization and regulatory standards 
The Bronchial Biopsy Biobank is a self-renewing structure with a dynamic 
specimen inventory, where the biopsies are regularly collected and contributed 
in a multicenter fashion, and tissue sections are used for the scientific goals of 
specific projects. Such projects may be led by independent principal 
investigators involved in the Bronchial Biopsy Biobank network, or can be run 
by third-party investigators from academic or industrial entities upon project 
approval by the Biobank Scientific Committee. 
In compliance with the 14/2007 Law of July 3rd, 2007 on Biomedical 
Research437 and its terminology, this structure originally envisioned and termed 
as "Bronchial Biopsy Biobank" before the 2007 Law is currently a biobank 
subset incorporated and hosted in the institutional biobank of the Hospital de la 
Santa Creu i Sant Pau Biomedical Research Institute (see Appendix 1), with 
registry number B.0000722 in the Registro Nacional de Biobancos of the 
Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, 
Government of Spain. As per the 14/2007 Law and its definitions, the 
"Bronchial Biopsy Biobank" is not a "collection", nor is restricted to the legal 
limitations of a "collection", since it is part of a registered institutional biobank. 
For this reason, with no detriment to the 14/2007 Law specifications and for the 
purposes of the present doctoral thesis and derived works, the original 
denomination of "Bronchial Biopsy Biobank" is maintained. From this point 
onward, the Bronchial Biopsy Biobank is referred to in italics solely to reflect 
this terminology allowance. As per law specifications, the Scientific Committee 
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that issues project authorization for the use of tissue sections from the Bronchial 
Biopsy Biobank by third-party investigations is, as an independent body, that of 
the institutional biobank of the Hospital de la Santa Creu i Sant Pau Biomedical 
Research Institute. The proprietary of the Bronchial Biopsy Biobank is the 
Integrated Asthma Research Program (PII Asma) of SEPAR (juridically 
SEPAR), and its Executive Committee holds authority on the biobank. Dr. 
David Ramos Barbón, the Bronchial Biopsy Biobank founder and developer, is 
its principal investigator in terms of further development and scientific direction. 
Nadia S. Brienza, a Certified Clinical Research Coordinator (CCRC) by the 
international Academy of Clinical Research Professionals (ACRP) with license 
number 151454 is the Bronchial Biopsy Biobank project manager from its 
inception. The Bronchial Biopsy Biobank project has been approved by the 
institutional Ethics Review Board of all participating centers, and all subjects 
have signed an informed consent form (see Appendix 2).  
1.2 Subjects 
1.2.1 Bronchial Biopsy Biobank subject groups 
Bronchial biopsies are collected during bronchoscopies that are performed 
under indication as per regular clinical practice, in the following groups of 
subjects: 
a) Asthmatics: diagnosed as per GEMA or GINA, aged from 18 to 75 years, 
capable of authorizing informed consent, in good general condition, with no 
concomitant systemic disease except for atopic manifestations when present, 
and with a normal blood coagulation test. The biopsies are collected during a 
bronchoscopy indicated for: (a.1) the diagnosis of an intercurrent, focal 
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pulmonary condition including, but not limited to, a lung mass module 
(preferably of peripheral location), atelectasis, hemoptysis of unknown origin, or 
the finding of malignancy in a sputum smear; or (a.2) differential diagnosis as 
required, due to asthma severity or refractoriness. For case (a.1), the biopsies 
will be harvested from a lung region distant from the focal area under study. 
b) Control airway wall group: these are non-asthmatic subjects where a 
bronchoscopy is indicated for the diagnosis of a focal lung condition, including 
all possibilities listed for group (a.1) in the asthmatics. Subjects must be 18 to 
75 years old, capable of authorizing informed consent; must be in good general 
condition with absence of any known systemic disease; must have no history of 
asthma nor symptoms suggesting asthma; must not have any known allergies; 
must not have cardiovascular disease; must have spirometric FEV1 ≥80% of its 
predicted value with a FEV1/FVC ratio ≥70%; and must have a normal blood 
coagulation test. Bronchial biopsies are collected from areas with no visible 
pathology upon bronchoscopic examination, and distant from any area of focal 
pathology under study. 
c) Control airway inflammatory pathology group: these are subjects 
suffering from an inflammatory airway disease different from asthma, such as 
sarcoidosis, idiopathic eosinophilic bronchitis or COPD, where a bronchoscopy 
is performed under medical indication, for diagnostic or follow-up purposes. 
Subjects must be 18 to 75 years old, capable of authorizing informed consent; 
must be in good general condition with absence of any systemic disease 
manifestations except for those related to sarcoidosis, eosinophilic bronchitis or 
COPD; must have no history of asthma nor findings suggesting asthma; must 
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not have any known allergies; must not have cardiovascular disease except for 
COPD related findings; and must have a normal blood coagulation test. 
▪ Note on sarcoidosis: on inclusion, bronchoscopy and initial case report form 
(CRF) submission, all cases of suspected or confirmed sarcoidosis are 
classified as group (c) by default. All clinical phenotypes of probable or 
confirmed sarcoidosis must be considered, including those in radiological 
"stage I" (with hilar or mediastinal lymphadenopathies in the absence of 
pulmonary infiltrates). Upon histopathological examination of the bronchial 
biopsy tissue sections, those specimens showing no bronchial involvement 
(i.e. no evidence of granulomatous inflammation affecting the airway wall) 
will be redirected to group (b), control airway wall group. 
▪ Note on smoking: due to the possibility of projects aimed at analyzing 
interactions between cigarette smoking and asthma, all subjects are 
considered for inclusion regardless of their smoking status, whether never 
smokers, active smokers or ex-smokers, and their smoking history is 
quantitatively recorded as packs-years, as well as the end-of-smoking date in 
the case of ex-smokers. Subsequent selection of biobank samples for 
analysis, or stratified data analysis where applicable, are to be performed 
according to the hypothesis, study design and objectives of the specific 
research projects exploiting the biobank. 
▪ Exclusion criteria: (i) any disability that prevents from understanding and 
signing the informed consent form; (ii) any general contraindication for 
bronchoscopy and/or bronchial biopsy as per standard clinical practice; and 
(iii) the presence of any known pulmonary disease (except for the focal 
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condition under investigation where applicable), or any comorbid condition 
(except for those considered in group (c) of control airway inflammatory 
pathology) that might affect asthma disease activity or airway physiology, 
immunobiology and/or histopathology overall, such as HIV infection, 
metastatic cancer, congestive heart failure or other conditions upon 
investigator's judgment. 
1.2.2 Classification of asthmatics 
The classification of asthmatic subjects by disease severity may vary upon 
the design and goals of projects serviced by the Bronchial Biopsy Biobank. For 
the study of T cell/myocyte interaction (see Results section Part II) and the role 
of apoptosis in airway smooth muscle remodeling (see Results section Part III), 
in order to keep consistency with the pre-classification of a subset of biopsy 
tissue sections provided by McGill University, the subjects with persistent 
asthma where classified as severe as per the American Thoracic Society 
Workshop on Refractory Asthma,25 or as moderate as per criteria reported 
elsewhere,413 as follows: 
▪ Severe asthmatics. At least one of the 2 of the following major criteria had 
to be met: (a) treatment with daily oral corticosteroids for more than 50% of 
the previous 12 months or (b) treatment with high-dose inhaled steroid 
(≥1000 mg of fluticasone or equivalent per day) and at least one other add-
on therapy (long-acting β2-agonist, leukotriene receptor antagonist, or 
theophylline) continuously over the previous 12 months. In addition, at least 
2 or more minor criteria had to be present: (a) daily use of short-acting β2-
agonist; (b) persistent airflow obstruction, as per prebronchodilator FEV1 of 
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less than 70% and an FEV1/FVC ratio of less than 80% of predicted value; 
(c) 1 or more urgent care visits in the previous 12 months; (d) 3 or more 
corticosteroid bursts in the previous 12 months; (e) prompt deterioration with 
less than 25% dose reduction of steroids; or (f) a near-fatal asthma event in 
the last 3 years.  
▪ Moderate asthmatics. All of the following criteria had to be met: a) well-
controlled asthma on at least 200 mg/day of fluticasone or equivalent but not 
exceeding 1000 mg/day, with or without the use of a long-acting β2-agonist; 
(b) 2 or less corticosteroid bursts in the previous 12 months and none in the 
past 3 months (the total number of days taking oral corticosteroids could not 
exceed 30 days in the previous 12 months); (c) FEV1 >70% of predicted 
value and >90% of the individual’s best from the previous 2 years; and (d) 
no more than 1 nonscheduled urgent care or clinic visit in the previous 12 
months. 
For the studies shown in Parts II to V of the Results section, all subjects 
included were nonsmokers or ex-smokers of at least 2 years with a smoking 
history of less than 5 packs-years.  
1.3 Multicenter logistics 
All site collaborators are issued kits providing all necessary documents and 
expendables for biopsy collection, packing and shipping, which are renewed 
upon usage following site investigator's alert. Each kit, designed to provide 
supplies for 10 patients, includes: an autoclavable, reusable Olympus 35C 
biopsy forceps; a set of screw-cap cryotubes preloaded with fixative; approved 
shipping materials for biological specimens in compliance the International Air 
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Transport Association (IATA) regulations, pre-labeled with the destination 
address; a document filing binder; informed consent formularies; and the 
necessary CRF documents. The fixative-preloaded tubes were originally issued 
as a double set containing a series of tubes with formalin and another series with 
an alternative fixatives under testing (FineFix®, Fisher Scientific, Madrid, 
Spain). In the early development of the biobank logistics, the tubes containing 
FineFix® were discontinued and all tubes were subsequently provided with 
formalin (see Results section). Screw-cap cryotubes were chosen for biopsy 
transportation, despite the absence of any freezing procedures, to best guarantee 
tight sealing of the specimen and fixative. The site collaborators are also 
provided with a card containing a DHL Express account number and contact 
telephone for shipment pickup, and direct cell phone numbers of the Bronchial 
Biopsy Biobank project manager and principal investigator. 
The documents contained in each kit (see Appendix 3) include:  
▪ A kit contents log form for verification and registry upon kit packing and 
shipping, of which a copy is filed at the Bronchial Biopsy Biobank site 
(“Registro kit de colaboración” in appendix). 
▪ A summarized protocol where the study groups, inclusion/exclusion criteria, 
instructions for filling and filing informed consent, registry and CRF 
documents, details on biopsy collection and shipping, carrier contact and 
support contact ("Protocolo" document in appendix). 
▪ A checkup document for inclusion/exclusion criteria, subject group 
assignment and indication for bronchoscopy ("Documento 1" in appendix). 
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▪ A CRF document for demographics and clinical data ("Documento 2" in 
appendix). 
▪ A bronchial biopsy registry provided with a tracheobronchial tree diagram 
to record the numbering and anatomical location of the biopsies, and 
comments and incidences if applicable ("Documento 3" in appendix). In this 
document, an optional checkmark section is available for the collaborating 
investigator to request a return shipment of stained biopsy tissue sections for 
analysis by site pathologist. 
▪ A registry document for subject reversible coding to be filed at the biopsy 
collection site. This is the subject anonymization document, where the 
coding series are pre-numbered and assigned by the Bronchial Biopsy 
Biobank project manager ("Registro de anonimización reversible" in 
appendix). The Bronchial Biopsy Biobank site keeps a registry of the 
anonymization number series sent to the collaborating centers with each kit. 
Upon biopsy collection, the collaborating investigator or his/her support 
personnel call DHL Express to arrange a pickup for overnight shipment to the 
Bronchial Biopsy Biobank site, including: (i) the cryotubes containing the 
biopsies in fixative solution, labeled with the assigned subject number as per the 
anonymization registry and the biopsy sequence number, inside the approved 
sealed bag and pack; and (ii) copies of Documents 1, 2 and 3. DHL has the 
shipping destination address already encoded in the Bronchial Biopsy Biobank 
client account, which is billed for the service. The collaborating investigator 
must file at his/her center site the signed informed consent form, the original 
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Documents 1, 2 and 3, the DHL airway bill ("albarán de recogida") and the 
anonymization registry. 
1.4 Biopsy collection and processing 
Bronchial biopsies are collected as per the 1990 workshop statement on the 
use of bronchoscopy and bronchoscopic instrumentation for research purposes 
in asthma and other airway diseases,426, 427 and subsequent recommendations.427 
A maximum of 6 biopsies can be collected during a single bronchoscopy 
procedure, and a minimum of 2 whenever possible, preferably from the carinae 
of the first subsegmental bronchial generation, unilaterally, and from the 
opposite lung or lung regions distant from any focal pathology under diagnostic 
investigation where applicable. The biopsies must be collected using the 
Olympus 35C forceps provided in the investigator's kit, which requires the use 
of a bronchoscope with and instrumentation channel of 2.8 mm minimum 
diameter. 
Upon extraction through the bronchoscope, each biopsy is immediately 
released from the forceps into a fixative-containing cryotube, and the tube 
labeled with the subject's number assigned from the anonymization registry and 
the sequential biopsy number as indicated in registry Document 3. The biopsies 
are then shipped along with the corresponding documents as specified in section 
1.3. 
The biopsy tissues are fixed for a controlled time period during the overnight 
transportation by DHL. Upon receipt at the Bronchial Biopsy Biobank site, and 
at 24 hours after the recorded biopsy collection time, tissue fixation is stopped 
by transferring the biopsies to 70% ethanol. Each biopsy is then transferred to a 
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histology cassette, inside a special sponge wrapping designed to prevent the loss 
of very small tissue specimens during processing. The cassettes containing the 
biopsies are then placed into the 70% ethanol station of a tissue processor with a 
customized program to initiate processing at this station instead of a formalin 
station, and tissue processing for dehydration and paraffin embedding runs 
overnight. On the following day, the paraffin-embedded biopsies are casted into 
paraffin molds and the resulting paraffin blocks are ready for storage and 
sectioning. By means of a microtome, six 5-µm thick tissue sections are cut 
from each freshly obtained block and laid on SuperFrost Plus adherent 
microscope slides. One of the tissue sections is stained with hematoxylin-eosin 
for general histopathological examination and assessment of biopsy quality, and 
the remaining slides are stored. When requested, additional tissue sections are 
stained and mounted, and shipped back to their center of origin for pathology 
examination. Feedback on histopathological findings of potential clinical 
relevance, and biopsy quality, is also reported to the participating site 
collaborators.  
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2. Immunostaining of biopsy tissue sections for specific project 
goals 
Bronchial biopsy tissue sections were immunostained for the specific 
purposes shown in the Results section Parts II to IV as follows: 
2.1 Colocalization of T cells, smooth muscle α-actin (α-SMA) and 
proliferating cell nuclear antigen (PCNA) 
Triple immunostaining was performed for the simultaneous detection of 
CD3, smooth muscle α-actin (α-SMA) and proliferating cell associated nuclear 
antigen (PCNA). For this purpose, tissue sections (5 μm thick) were 
deparaffinized through xylene, ethanol and Tris-buffered saline (TBS) and 
processed for high temperature epitope unmasking using commercially available 
equipment (Antigen Retriever 2100®, Electron Microscopy Sciences, Hatfield, 
Pennsylvania, USA) and accompanying retrieval buffer. The procedure was 
followed by quenching of endogenous peroxidase in 3% hydrogen peroxide for 
5 minutes, membrane permeabilization in 0.2% Triton X-100 (Sigma-Aldrich, 
Madrid, Spain) and blocking with 5% normal horse serum (Vector Laboratories, 
Burlingame, California, USA) in TBS with 0.1% Tween-20 (Sigma-Aldrich). 
The specimens were then incubated with monoclonal (mAb) rabbit anti-human 
CD3 (clone SP7, LabVision, Fremont, California, USA; 1:150 dilution), 
followed by ImmPRESS®-peroxidase secondary antibody (Vector Laboratories) 
and development with diaminobenzidine (DAB) substrate (Vector Laboratories). 
PCNA was detected next, using primary mAb Ab-1 (Calbiochem/Merck, 
Darmstadt, Germany; 2.5 μg/mL) followed by secondary biotinylated horse anti-
mouse IgG antibody (5 μg/mL), alkaline phosphatase avidin-biotin complex 
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(ABC-AP), and development with 5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium (BCIP/NBT) chromogen (all products from 
Vector Laboratories). Alpha-SMA was detected last using primary mAb 1A4 
(Sigma-Aldrich; 2 μg/mL), secondary biotinylated horse anti-mouse IgG 
antibody, AP-ABC, and development with Vector-Red chromogen (Vector 
Laboratories). The specimens were then counterstained with methyl green 
(Sigma-Aldrich), dehydrated through 1-butanol and xylene, and mounted in 
permanent medium (VectaMount, Vector Laboratories). Primary antibodies 
were diluted in 2.5% horse serum with 0.2% Tween-20, in TBS. Secondary 
antibodies were diluted in 5% human serum (Sigma-Aldrich) with 0.2% Tween-
20, in TBS. Chromogen substrates were added 0.1% Tween-20. 
2.2 Colocalization of vascular cell adhesion molecule 1 (VCAM-1) leukocyte 
adhesion receptor on α-SMA expressing cells 
Double immunostaining was performed to colocalize VCAM-1 (CD106) on 
α-SMA expressing cells. Tissue sections were processed for epitope unmasking 
with trypsin (porcine pancreas trypsin tablets, Sigma-Aldrich, diluted as per 
product specifications), for 30 min at 37ºC, followed by membrane 
permeabilization and blocking with 5% normal horse serum (Vector 
Laboratories). The specimens were then incubated with 0.9 µg/mL mouse mAb 
anti-human CD106/VCAM-1 (clone 1.4c3, LabVision), followed by secondary 
biotinylated horse anti-mouse IgG antibody, AP-ABC complex, development 
with BCIP/NBT, and  α-SMA detection. After completion of multiple 
immunostaining, the specimens were counterstained with methyl green (Sigma-
Aldrich), dehydrated through 1-butanol and xylene, and mounted in permanent 
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medium. Primary and secondary antibodies and chromogen substrate working 
solutions were prepared as specified in section 2.1. 
2.3 In situ analysis of airway smooth muscle cell apoptosis 
To evaluate airway smooth muscle cell apoptosis on biopsy tissue sections, 
the following techniques were applied: 
2.3.1 Terminal deoxynucleotidyl transferase mediated dUTP Nick End 
Labeling (TUNEL) assay 
The TUNEL assay detects the DNA fragmentation pattern that results from 
apoptosis. In this technique, the terminal deoxynucleotidyl transferase (TdT) 
enzyme polymerizes digoxigenin-labeled deoxyuridine 5-triphosphate (dUTP) 
nucleotide tails added to the nicked 3'-OH DNA ends. The resulting 
digoxigenin-labeled oligonucleotides are then detected using anti-digoxigenin 
mAbs, as in an immunohistochemical technique. The whole procedure was 
performed using a commercially available kit (ApopTag® Peroxidase In Situ 
Apoptosis Detection Kit, Chemicon® International, Millipore, Madrid, Spain) 
following the manufacturer's instructions. Tissue sections were first 
deparaffinized and rehydrated through immersion in three xylene, two 100% 
ethanol, two 95% ethanol and two 70% ethanol sequential baths, to end in a 
TBS bath. From this bath the microscope slides were dried with absorbent towel 
paper without touching the tissue, then marked in their reverse side with a 
diamond pen (Dako, Barcelona, Spain), and the biopsy tissue sections circled 
with a hydrophobic pen (Super Pap Pen®, Dako). Next, the tissues were 
pretreated with 20 µg/mL proteinase K (Sera Laboratories International Ltd., 
West Sussex, UK) for 30 minutes at 37°C inside a humid chamber, to digest the 
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DNA-associated proteins. Proteinase K digestion was stopped with two distilled 
water washes. Endogenous tissue peroxidase activity was then quenched by 
incubation in a commercial peroxidase blocking solution (Dako) for 10 minutes, 
and the slides were then washed twice in TBS for 5 minutes. The slides were 
then placed horizontally inside the humid chamber and an Equilibrium Buffer 
from the ApopTag® kit was then applied at 4°C for an hour. Then, the 
specimens were incubated in a 30% dilution of the TdT enzyme in an ApopTag® 
Reaction Buffer, at 37°C for an hour. The TdT enzyme reaction was arrested by 
immersion in an ApopTag® Stop Buffer, followed by 3 washes in TBS. Back 
into the humid chamber, a peroxidase-labeled anti-digoxigenin antibody (part of 
the ApopTag® kit as well) was applied on the tissues for 30 minutes at room 
temperature. After incubation, the antibody excess was eliminated through TBS 
washes and a 3,3'-diaminobenzidine-nickel chromogen substrate (DAB-Nickel 
Substrate Kit, Vector Laboratories) was applied for signal development under 
microscopic monitoring. Upon optimal signal strength, development was 
stopped by immersion and washed in distilled water.  
2.3.2 Immunodetection of active caspase-3 
Caspase-3, a member of the cysteine-aspartic acid proteases, is one of the end 
effectors of apoptosis. It is present in the form of an inactive zymogen and its 
activation by either the extrinsic (death ligand) or intrinsic (mitochondrial) 
pathways in the apoptotic cell leads to chromatin condensation and DNA 
fragmentation. Caspase-3 is activated by proteolytic cleavage into two subunits 
of 17 and 12 kDa respectively, which can be detected with specific antibodies 
by immunohistochemical procedures as done in the present work. For this 
purpose, biopsy tissue sections were deparaffinized and rehydrated as per the 
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procedure described in section 2.3.1. This was followed by an antigen 
unmasking procedure, by means of digestion with 1 mg/mL trypsin (Sigma-
Aldrich) for 30 minutes at 37°C. Trypsin action was stopped with distilled 
water, and the tissue cell membranes were then permeabilized with 0.2% Triton 
X-100 (Sigma-Aldrich) in TBS for 20 minutes. Following washing in TBS 
twice, the tissue sections were blocked with 5% goat serum (Vector 
Laboratories) in 0.1% Tween-20, in TBS. Next, endogenous tissue biotin was 
blocked with a commercial solution (Vector Laboratories) and the tissue 
sections were incubated with a mAb to active caspase-3 (rabbit monoclonal IgG, 
Millipore) at 1:50 dilution in 2.5% goat serum, with 0.2% Tween-20 in TBS, for 
45 minutes at room temperature. Following primary antibody incubation and 
washing, a secondary, biotinylated goat anti-rabbit antibody (Vector 
Laboratories) was applied at 5 µg/mL with 5% human serum (Sigma-Aldrich) 
and 0.2% Tween-20 in TBS, for 30 minutes. ABC-AP incubation for 30 minutes 
and signal development with BCIP/NBT chromogen substrate followed. 
2.3.3 Immunodetection of poly ADP ribose polymerase (PARP) 
fragmentation 
PARP, an evolutionarily conserved enzyme that participates in DNA repair, 
is fragmented by caspases in apoptotic cells. Therefore, cleaved PARP (c-
PARP) is a side product of apoptotic activity, and is detectable by specific 
antibodies. To detect c-PARP in biopsy tissue sections, the specimens were first 
deparaffinized and rehydrated as previously stated, and then submitted to 
epitope unmasking with the Antigen Retriever 2100 equipment, using a pH 6 
citrate buffer (Dako). Following distilled water and TBS washes, the tissue 
sections were permeabilized in 0.2% Triton X-100 in TBS, blocked with 5% 
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goat serum in a 0.2% Tween-20 TBS solution, and endogenous biotin was 
neutralized, as in section 2.3.2. The primary antibody, and anti-c-PARP rabbit 
mAb clone E51 (Abcam, Cambridge, UK), was applied at 1:50 dilution in 2.5% 
goat serum and 0.2% Tween-20 in TBS, at room temperature for an hour. The 
secondary antibody was a biotinylated goat anti-rabbit IgG antibody, applied at 
5 µg/mL concentration with 5% human serum and 0.2% Tween-20 in TBS, for 
30 minutes at room temperature. ABC-AP complex and signal development 
with BCIP/NBT chromogen substrate followed as stated in previous sections. 
The detection of apoptosis or side products of apoptosis employing the 
techniques described in sections 2.3.1 through 2.3.3 was in all cases followed by 
signal colocalization with α-SMA expressing cells. For this purpose, following 
chromogen development of the first signal with DAB-nickel or BCIP/NBT as 
applicable, the tissue sections were blocked with 5% horse serum (Vector 
Laboratories) in 0.2% Tween-20 TBS for 30 minutes and then cleared with 
TBS. The specimens were then incubated with 2 μg/mL primary mAb clone 
1A4 to α-SMA in 2.5% horse serum, 0.2% Tween-20, TBS. The secondary 
antibody was a biotinylated horse anti-mouse IgG (Vector Laboratories) at 5 
µg/mL in 5% human serum, 0.2% Tween-20, TBS. Incubation with ABC-AP 
complex followed, and signal development was performed with Vector Red 
chromogen substrate. Methyl green was then used as a histological counterstain, 
and the specimens were dehydrated and mounted in VectaMount permanent 
medium as in section 2.1.  
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2.4 Immunodetection of FOXP3+ lymphocytes 
To detect FOXP3-expressing lymphoid cells as a criterion for the 
identification of Treg cells, biopsy tissue sections were immunostained using a 
primary mouse anti-human FOXP3 mAb (Abcam) at 1:1000 dilution. The 
specimens were first deparaffinized and rehydrated as in previous sections, and 
then subjected to a heat antigen retrieval procedure using commercial equipment 
(Pre-Treatment Module for Tissue Specimens, PT Link, Dako). As a detection 
system, EnVision® FLEX+ Mouse Linker kit reagents and DAB chromogen 
development (all products from Dako) were used in a Autostainer Link 
equipment (Dako). The tissue sections were then counterstained with 
hematoxylin, and mounted in permanent medium.  
2.5 Immunodetection of STRO-1+ cells 
Immunoreactivity to the STRO-1 mAb was used as a criterion to identify 
mesenchymal stem cells in biopsy tissue sections. The specimens were 
deparaffinized and rehydrated as in previous sections. A mouse IgM mAb to 
STRO-1 (Abcam) was used as primary antibody, followed by detection with 
EnVision® FLEX+ Mouse Linker and DAB chromogen development in Dako 
Autostainer Link equipment, and then  hematoxylin counterstain and mounting 
in permanent medium as in section 2.4. 
2.6 Quantitative morphology  
Digital micrograph files were obtained by means of a bright-field Olympus 
BX61/BX62 microscope (Olympus Corporation, L’Hospitalet de Llobregat, 
Barcelona) equipped with an Olympus DP70 digital camera. The images were 
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captured with Olympus Plan achromatic objectives, selecting in each case the 
objective that would optimally comprise the entire biopsy tissue section at 
maximum magnification (i.e. 10x and 20x objectives in practice). For the 
calibration of image real-size dimensions, a micro-ruler microscope slide (Leica 
Biosystems, Barcelona, Spain) was also digitally captured with the same 
objectives and image acquisition settings. Image calibration and analysis was 
performed using ImageJ v1.47 software (National Institutes of Health, Bethesda, 
USA, available at http://imagej.nih.gov/ij/). Alpha-SMA was measured as the 
digitally extracted α-SMA+ surface area referenced to the biopsy surface area. 
The resulting α-SMA+ surface/surface area density (SS), a dimensionless index, 
was determined as airway smooth muscle mass when the measured α-SMA+ 
surface area corresponded to airway smooth muscle bundles as per histological 
identification, and as non-organized airway contractile elements (NOACE) 
when the measured α-SMA+ surface area corresponded to these structures (see 
Results section Part II). The numbers of T cells, α-SMA+PCNA+ cells, T cell/α-
SMA+PCNA+/- juxtaposition events, TUNEL+ cells, active caspase+ cells, c-
PARP+ cells, FOXP3+ cells and STRO-1+ cells were referenced to the biopsy 
surface area. All such cellular events were counted on direct examination under 
the microscope using the necessary magnification (i.e. 40x or 100x objectives). 
For the study of the interaction between T cells and α-SMA+ cells, a 
juxtaposition event was defined as an interface between a T cell and an α-SMA+ 
cell suggesting cell-to-cell contact, observed as such within a defined focal 
plane at 1000x magnification using an oil-immersion objective.  
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2.7 Data Analysis 
The Bronchial Biopsy Biobank is a dynamic, self-renewing structure with no 
predetermined, closed sample size. Sample size estimates pertain to the specific 
studies stemming from the Bronchial Biopsy Biobank. In most instances, the 
lack of previous data on parameter variability and expected size of effects does 
not make a priori sample size calculation feasible, and the studies are therefore 
necessarily exploratory. Group sizes are in such instances established 
empirically and/or depending on available specimens. The accumulated 
literature on bronchial biopsies overall, suggests that a sample size of 15 
subjects per study group is safely sufficient for the analysis of most outcomes. 
In case of detecting a borderline significant tendency for a particular parameter, 
a retrospective analysis of statistical power is possible. 
Data set values are expressed as mean ± standard error of the mean (SEM), 
or as mean and 95% confidence intervals (CI) of the mean (mean [95% CI]) 
where stated. Distributions were compared using one-way ANOVA followed by 
Fisher’s least significant difference test or Games-Howell test for unequal 
variances where appropriate. Where specified, small sample size distributions 
were compared using nonparametric testing. Associations were explored with 
multivariate linear regression modeling or non-linear fit. Pearson’s R correlation 
coefficient was used to evaluate strength of association, and adjusted R2 
coefficient of determination to estimate contributions to variance. Variance 
inflation factor values of less than 10 were required to exclude collinearity 
where pertinent. A P value of less than 0.05 was considered statistically 
significant. Data analysis was performed with the statistical and graphing 
software packages SPSS version 16.0 (International Business Machines Corp., 
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Armonk, NY, USA) and SigmaPlot version 2000 (Systat Software Inc., San 
Jose, CA, USA). 
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PART I: BRONCHIAL BIOPSY BIOBANK DEPLOYMENT 
 
1. Implementation of multicenter logistics 
A collaborative center network has been implemented, where bronchial 
biopsies are collected and shipped to the Bronchial Biopsy Biobank site at the 
Research Institute of the Hospital de la Santa Creu i Sant Pau, Barcelona. The 
participating centers proceed following uniform SOPs in all aspects stated in the 
Methods section, employing the protocol, documents, materials and logistics 
resources issued in the kits provided to the collaborating investigators by the 
Bronchial Biopsy Biobank site.  
The Bronchial Biopsy Biobank participants up to date, including all 
supporters from preliminary stages and whether direct biopsy providers and/or 
in ancillary support roles, are in historical sequence and by institution: James G. 
Martin, Qutayba A. Hamid, Ron Olivenstein and Pierre Ernst, from the 
Meakins-Christie Laboratories and McGill University Health Center (MUHC), 
Department of Medicine, McGill University, Montreal, Canada; Catherine 
Lemiere, from the Hôpital Sacre Cœur, Université de Montréal, Montreal, 
Canada; Carmen Montero Martínez, Héctor Verea Hernando, Rebeca Fraga 
Iriso* and Óscar Amor Carro*, from the Complexo Hospitalario Universitario A 
Coruña and the Instituto de Investigación Biomédica de A Coruña (INIBIC), A 
Coruña, Spain; Francisco Javier González Barcala, from the Complexo 
Hospitalario Universitario de Santiago de Compostela, Santiago de 
                                                 
* RFI and OAC moved in January of 2011 to complete their doctoral training at the Research 
Institute and Respiratory Department of the Hospital de la Santa Creu i Sant Pau, 
Barcelona. 
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Compostela, Spain; Alfons Torrego Fernández, Oriol Sibila Vidal, Ana María 
Muñoz Fernández and Vicente Plaza Moral from the Hospital de la Santa Creu i 
Sant Pau, Barcelona, Spain; Antolín López Viña, from the Hospital 
Universitario Puerta de Hierro, Madrid, Spain; Santiago Bardagí Forns, from 
the Hospital de Mataró, Mataró, Barcelona, Spain; Patrick Berger, from the 
Centre Hospitalier Universitaire de Bordeaux, Institut National de la Santé et 
de la Recherche Médicale (INSERM) U1045, Université de Bordeaux 2, 
Bordeaux, France; Carlos Martínez Rivera, from the Hospital Universitari 
Germans Trias i Pujol, Badalona, Barcelona, Spain; and Teresa Bazús 
González, from the Hospital Universitario Central de Asturias, Oviedo, Spain.  
 
2. Implementation of specific procedures 
As stated in the Background chapter, the use of bronchoscopy and bronchial 
biopsy for research purposes is subjected to various methodological options and 
issues. Through the development of the Bronchial Biopsy Biobank up to present, 
certain procedural issues were critical, and were settled in early stages as 
follows: 
2.1 Normalization of bronchial biopsy forceps 
A frequent deficiency found in published work reporting data from bronchial 
biopsies in asthma research is the absence of any analysis of bronchial smooth 
muscle, yet airway smooth muscle remodeling is, as stated in the Background 
chapter, a crucial aspect of asthma physiopathology and a primary focus for the 
Experimental Pneumology Unit research line at the Bronchial Biopsy Biobank 
site. Although no comparative work has been published, the Olympus 35C 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 123 - 
forceps had previously been chosen as optimal for bronchial biopsy in order to 
sample airway smooth muscle assessable for research purposes including 
quantitative morphology, based on the accumulated experience at the Meakins-
Christie Laboratories and Montreal Chest Institute of McGill University. One of 
the significant challenges to develop a Bronchial Biopsy Biobank suitable for 
studies on airway smooth muscle was to implement the uniform use of this 
forceps (purchased with the Biobank grant funds and supplied in the kits) in all 
participating centers, because such forceps requires a "therapeutic" 
bronchoscope with a 2.8-mm minimum instrumentation channel. This fact 
prevented or delayed the participation of some collaborators. All participating 
centers collect the biopsies using the Olympus 35C forceps in a normalized 
fashion. 
2.2 Selection of tissue fixative 
An essential aspect of logistics to expedite subject recruitment, biopsy 
collection and shipping was to set up a procedure that, at the bronchoscopy site, 
would not significantly interfere with the bronchoscopist and his/her assistant 
team workflow, and would subsequently allow for maximum analytic 
exploitation of the biopsy material. To this regard, the choice of method for 
tissue fixation and preservation is crucial due to its implications in all operating 
steps, as detailed in the Background chapter. Formalin (stabilized 4% 
formaldehyde in PBS buffer) was chosen as a fixative for the following reasons: 
(i) it is highly cost-effective; (ii) it does not require any local laboratory support 
nor special procedures at the bronchoscopy facility (i.e. the bronchoscopist only 
has to release the biopsy from the forceps into a formalin preloaded cryotube; 
(iii) it works at room temperature, therefore avoiding any logistics complexity 
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related to on-site freezing and the setup of a dry ice supply for transportation; 
(iv) upon receipt at the Bronchial Biopsy Biobank site, only conventional tissue 
processing and microtome equipment is needed, with no special, costly 
infrastructure required; (v) it yields maximum histopathological quality for 
microscope examination and imaging; and (vi) it preserves and makes detectable 
both protein antigens and nucleic acid sequences, therefore allowing for 
immunohistochemical/immunofluorescence and in situ hybridization 
procedures.  
Due to the cross-linking nature of formalin as a fixative, and the limitation 
that this means for the detection of some epitopes that may not be recoverable 
through antigen unmasking techniques, the original plan for the development of 
the Bronchial Biopsy Biobank comprised a comparative study with a new 
alternative fixative, commercially available (FineFix®). FineFix®, a proprietary 
formulation, was expected to avoid the problems derived from cross-linking 
covalent bonds while preserving a high morphological quality compatible with 
conventional tissue processing equipment, yet it was unknown whether it would 
preserve nucleic acids for in situ hybridization procedures. In early stages of the 
Bronchial Biopsy Biobank development, the participating centers were provided 
with a double set of preloaded cryotubes (50 tubes with formalin and 50 tubes 
with FineFix® per kit) and with instructions to employ the tubes in alternating 
sequence as the biopsies were collected. This was aimed at a comparative study 
that would eventually allow us to close a decision for a single, optimal fixative. 
However, the Bronchial Biopsy Biobank site started to receive early alerts from 
the participating centers about FineFix® volatility and a probable alteration of 
its properties over short time periods. This occurred despite the use of tight-seal 
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cup tubes and extra sealing with paraffin film. For this reason, which was 
readily viewed as incompatible with the Bronchial Biopsy Biobank logistics, the 
use of FineFix® fixative was discontinued without any further analysis and the 
protocol was set to employ 4% formaldehyde (formalin) as a standard fixative. 
2.3 Controlled time of tissue fixation 
Due to the cross-linking nature of formalin, a controlled, limited fixation 
time is crucial for research purposes and need to be standardized among the 
participating centers. A 24-hour room-temperature fixation in formalin is 
appropriate for research purposes, and this requirement synchronizes with the 
overnight shipping of specimens by DHL, which allowed for the standardization 
of the time of fixation for all samples sent from the different participating 
centers. 
2.4 Feedback on specimen tissue sections and histopathology 
One of the aims of the Bronchial Biopsy Biobank is to provide feedback of 
potential clinical utility to the collaborating investigators, when requested. This 
involves two possibilities, both put into practice and used through the 
development of the Biobank: sending stained tissue sections back to the center 
of origin, or issuing a report by a Biobank assigned pathologist. 
 
3. Quality control outcomes on bronchial biopsies 
Bronchial biopsies, collected and processed as per the established 
methodology, reached overall the required quality standards for research 
purposes. The specimens submitted by the Spanish network of collaborating 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 126 - 
centers averaged 2.84 biopsies per subject and bronchoscopy session (3,15 in the 
case of severe asthmatics), which is above the minimum of two biopsies per 
subject and bronchoscopy recommended by the guidelines. Once mounted on 
microscope slides, the biopsy tissue sections averaged a microtome section 
surface area of 1,15 ± 0,10 mm2 with good structural preservation, excellent 
optical quality for histopathology and quantitative morphology, and successful 
sampling of assessable airway smooth muscle. Figure 8 provides a general 
illustration of bronchial biopsy performance for the histopathological 
assessment of airway inflammation and the major features of airway 
remodeling.  
 
 
Figure 8 (next page). Overview of airway inflammatory and remodeling features in 
bronchial biopsies (right), referenced to murine experimental asthma (left). (A) Airway 
inflammatory infiltrates (arrow, hematoxylin-eosin stain). (B) Immunostaining for CD3+ 
cell detection (black signal). The airway epithelium is in the lower-right position of the 
micrograph. Heavy T cell inflammatory infiltrates can be appreciated, mostly located in 
the lamina propria beneath the epithelium. (C) PAS staining showing hyperplasia and 
hypertrophy of mucus-producing goblet cells (purple color). (D) Enlarged mucosal 
glands (arrow) located under the bronchial smooth muscle (red immunostaining). (E) 
Masson's trichrome staining showing subepithelial fibrosis (blue color). (F) 
Subepithelial fibrosis (arrow, hematoxylin-eosin staining), shown as a thick, 
structureless and almost acellular deposit. (G) Thickened airway smooth muscle layer 
(green immunofluorescence). (H) Increased bronchial smooth muscle, directly visible 
with a hematoxylin-eosin staining (arrow). The smooth muscle occupies a large portion 
of the biopsy section area and approaches abnormally the bronchial epithelium 
(purple). Figure source: original, unpublished.  
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4. Bronchial Biopsy Biobank inventory 
Table 2 shows a cumulative inventory of the Bronchial Biopsy Biobank as of 
its most recent update before thesis data closure on August 15th, 2015. 
 
Table 2. Bronchial Biopsy Biobank cumulative inventory 
 No. of subjects No. of biopsies 
Severe asthma 92* 266 
Moderate asthma 34† 38 
Intermittent asthma 7‡ 7 
Control airway wall 15§ 31 
Sarcoidosis 2§ 6 
COPD 25§ 61 
 
Total specimens 175 409 
*: 81 subjects from the Spanish network and 11 subjects from McGill University 
(Canada). †: 4 subjects from the Spanish network, 13 from McGill University 
(Canada) and 17 from Université Bordeaux (France). ‡: 7 subjects from 
Université Bordeaux (France). §: all subjects from the Spanich network. Data as 
of August 15th, 2015. 
 
 
 
 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 129 - 
PART II: TRANSLATIONAL ANALYSIS OF A T-CELL/AIRWAY 
SMOOTH MUSCLE CELL “SYNAPSE” IN AIRWAY 
REMODELING 
 
1. Introduction 
The work presented in this chapter pertains to the core research line on 
airway smooth muscle remodeling, carried out by the Experimental Pneumology 
Unit that drives the Bronchial Biopsy Biobank. Here, bronchial biopsy tissue 
sections were processed and analyzed in search of evidence in human asthma of 
a disease mechanism previously demonstrated in an animal model of 
experimental asthma. This is the earliest work exploiting the Bronchial Biopsy 
Biobank at its initial stages where, through international collaboration, biopsy 
tissue sections provided by McGill University, Canada, were merged with the 
first bronchial biopsies contributed in Spain to produce the results presented 
here and published in Am J Respir Crit Care Med 2010; 182: 317-24.17 
The role of T cells in driving chronic airway inflammation, and the 
association of inflammation with airway remodeling,59 led us to hypothesize that 
T cells drive airway smooth muscle remodeling. In the aforementioned work 
employing an experimental asthma model, we demonstrated that T cells induce 
airway smooth muscle cell proliferation and an increase in airway smooth 
muscle mass.102 Confocal microscopy suggested direct contact between T cells 
and airway smooth muscle cells in vivo, and the growth of airway smooth 
muscle depended on direct contact between the T cells and the smooth muscle 
cells in culture. These data support the hypothesis that a direct interaction 
between T cells and myocytes is involved in the mechanism of airway smooth 
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muscle remodeling. In the work presented here, we studied the relevance of this 
hypothesis to human asthma by analyzing bronchial biopsies for evidence 
suggesting contact between T cells and airway smooth muscle cells or their 
potential precursors, and its relationship with target cell proliferation and airway 
smooth muscle mass. We employed α-SMA as a marker of both smooth muscle 
cells and less differentiated cell phenotypes that may potentially act as smooth 
muscle precursors, since α-SMA is expressed by smooth muscle cells,438 
myofibroblasts439 and poorly differentiated cells suggested to derive from 
circulating fibrocytes.12-16 Furthermore, we analyzed the expression and 
distribution of VCAM-1, a T cell ligand suggested by in vitro data to play a role 
in a direct interaction between T cells and airway smooth muscle cells.440 
 
2. Subjects 
For this study, biopsies containing sufficient airway smooth muscle for 
assessment were employed from 16 moderate and 14 severe asthmatics, and 7 
control subjects. Demographics and clinical data are displayed in Table 3. 
Indications for bronchoscopy in the control subjects are listed in Table 4. There 
was no significant difference among controls, moderate and severe asthmatics in 
age (P=0.185) or gender distribution (P=0.645). The ratio of atopic to non 
atopic cases was homogeneous among the moderate and severe asthmatics 
(P=0.226). The FEV1 (% of predicted) and FEV1/FVC ratio were significantly 
lower in the severe asthmatics, compared with the controls (P<0.001 and 
P=0.001 for FEV1 and FEV1/FVC respectively) and moderate asthmatics 
(P<0.001 for both FEV1 and FEV1/FVC), reflecting a fixed component of 
airflow limitation in the severe asthmatics, despite maximal medical therapy. In 
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one moderate asthmatic, the bronchoscopy was a follow-up examination after 
carcinoid tumor resection. In the control group, no histopathological evidence of 
tumor-on-scar malignancy was found in case 1. Cases 3 and 5 were confirmed 
as sarcoidosis without bronchial involvement. A limited area of bronchial 
telangiectasia was found in case 4.  
Table 3. Demographics and clinical data 
 
Age 
mean  SEM 
[range] 
Gender 
male:female 
Atopy 
Yes:No 
FEV1, % predicted 
mean  SEM 
FEV1/FVC ratio, % 
mean  SEM 
Controls 
52.7  2.5 
[44, 62] 
2:5 0:7 98.1  4.8 80.9  2.4 
Moderate 
asthmatics 
46.5  3.4 
[26, 74] 
7:9 10:6 95.4  3.6 78.3  1.4 
Severe 
asthmatics 
41.7  3.9 
[17, 61] 
7:7 12:2 69.9  4.7 64.0  3.6 
 
 
SEM: standard error of the mean. 
 
Table 4. Indications for bronchoscopy in the control subjects 
Case No. Indication for bronchoscopy  
1 Rule out malignancy in a prior tuberculous scar. 
2 Focal infiltrate and anterior mediastinal lymphadenopathy; suspected tuberculosis. 
3 Mediastinal lymphadenopathy; suspected sarcoidosis. 
4 Hemoptysis of unknown origin. 
5 Erythema nodosum and mediastinal lymphadenopathy; suspected sarcoidosis. 
6 Laser treatment of tracheal stenosis, post-thyroidectomy. 
7 Chronic cough; asthma and gastroesophageal reflux ruled out. 
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3. Subjects with asthma develop a compartment of non-
organized airway contractile elements (NOACE) and a gradient of 
α-SMA+ tissue mass  
Airway smooth muscle was identified on the basis of α-SMA expression on 
histologically defined airway smooth muscle bundles, and measured as airway 
smooth muscle mass (Fig. 9 A-C, H). The subjects with asthma demonstrated 
small α-SMA+ tissue components scattered in the lamina propria, in the form of 
isolated cells or clusters, not forming part of histologically defined 
microvascular structures and not associated with cells of endothelial appearance 
(Fig. 9 D-G). The level of α-SMA expression by these elements ranged from a 
thin perinuclear ring in spherical cells in a subepithelial location, to a dense 
cytoplasmic filling in fusiform, mature smooth muscle-like cells, aligned aside 
the outer edge of structured smooth muscle bundles as in a process of 
apposition. These regional and phenotypic variations suggested evolving stages 
of α-SMA+ cell differentiation, from a poorly differentiated stage to 
myofibroblasts and mature smooth muscle cells. We termed this phenotype 
spectrum as non-organized airway contractile elements (NOACE) and we 
measured it as a separate α-SMA+ compartment. NOACE was present in the 
control subjects in the form of rare, isolated cells, with an intermediate α-SMA 
content and a phenotypically homogeneous appearance. Asthmatic subjects 
developed the NOACE phenotype spectrum and an increased NOACE mass that 
ranged from 16.8-fold (moderate asthmatics) to 47.1-fold (severe asthmatics) 
over the controls, with a gradient (P=0.002) from controls to severe asthmatics 
(Fig. 9 H). The airway smooth muscle mass showed a gradient (P<0.001) with a 
3.6-fold increase in the moderate asthmatics over the controls, and 8.6-fold in 
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the severe asthmatics, and correlated negatively with the FEV1/FVC ratio 
(R=0.62, adjusted R2=0.35, P<0.001; Fig. 9 I). NOACE accounted for 0.67% 
[0.10%, 1.23%] (mean [95% CI]) of the total airway α-SMA+ tissue in the 
controls, and was increased to 4.42% [2.52%, 6.31%], P<0.01, in the asthmatics. 
Numerical data are shown in Table 5. 
 
Figure 9. Airway smooth muscle (ASM) and non-organized airway contractile elements 
(NOACE). (A-C) Overview of biopsy sections representing control (A), moderate (B) and 
severe (C) asthmatics. The -SMA signal is red and the numbers at the bottom refer to 
the ASM mass. Black arrows indicate ASM bundles closely underlying the airway 
epithelium in the asthmatics. The open arrow in (C) points to an area of largely 
increased submucosal glands. (D-G) NOACE. (D) illustrates a control subject. (E) shows 
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subepithelial NOACE in a moderate asthmatic, with varying cell shape and -SMA 
content. Some cells are small-sized spherical with a faint -SMA ring. (F) shows a 
range of smooth muscle-like differentiation stages in the deeper lamina propria, in the 
proximity of an ASM bundle. (G) illustrates one extreme case of NOACE density in a 
severe asthmatic. Ep: bronchial epithelium. (H) ASM and NOACE mass (mean and 95% 
confidence interval of the mean). *: P<0.05 versus control group. †: P<0.05 versus 
moderate asthmatics. (I) Relationship between spirometric airflow obstruction and 
ASM mass. Scale bars: 200 m in (A-C); 50 m in (G); 10 m in (C-E). 
 
 
Table 5. Airway smooth muscle and NOACE mass 
 mean [95% CI] P Mean  [95% CI] 
Controls 0.05 [0.02, 0.08] - - - - 
Moderate 
asthmatics 
0.18 [0.13, 0.25] <0.001* - 0.13 [0.06, 0.20]* - ASM  
Severe 
asthmatics 
0.43 [0.30, 0.57] <0.001
†
 0.005
‡
 0.38 [0.21, 0.55]
†
 0.25 [0.08, 0.42]
‡
 
Controls 0.38 [0.06, 0.70] - - - - 
Moderate 
asthmatics 
6.37 [3.79, 8.95] <0.001* - 5.99 [2.84, 9.15]* - 
NOACE  
(x10
-3
) 
Severe 
asthmatics 
17.87 [8.20, 27.54] 0.005
†
 0.007
‡
 17.49 [5.67, 29.31]
†
 11.50 [3.43, 19.56]
‡
 
 
 
Airway smooth muscle (ASM) and non-organized airway contractile element (NOACE) 
mass is dimensionless. Variability is expressed as 95% confidence intervals (CI) of 
the mean. P values are from post-ANOVA multiple comparisons. The 95% CIs of the 
mean increment () estimate the size of the effects. *moderate asthmatics versus 
controls; †severe asthmatics versus controls; ‡severe versus moderate asthmatics. 
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4. NOACE and airway smooth muscle comprise proliferating α-
SMA+ cells 
We investigated cell proliferative activity on the basis of PCNA co-stained 
with α-SMA. PCNA+ nuclei were found in both NOACE and airway smooth 
muscle, in cells with variable cytoplasmic α-SMA content (Fig. 10 A-F). This 
ranged from cells that were integrated in airway smooth muscle bundles but 
showed low α-SMA, suggesting a “secretory” smooth muscle cell phenotype, to 
cells of “contractile” phenotype showing full differentiation with complete 
cytoplasmic α-SMA filling. Therefore the presence of a PCNA+ nucleus in a 
particular cell was not related to the α-SMA content. In the airway smooth 
muscle bundles of control subjects, α-SMA+PCNA+ cells existed as low 
frequency events, suggesting a proliferation baseline that may be involved in 
physiological turnover. NOACE α-SMA+PCNA+ cells were rare in the control 
group, where no such event was detected in 4 of the 7 subjects. From controls to 
severe asthmatics, the frequency of α-SMA+PCNA+ cells showed a gradient 
(P<0.001), with 8.2–fold and 7.3–fold overall increases in the airway smooth 
muscle and NOACE respectively (Fig. 10 F and Table 6). Cell proliferation 
activity relative to α-SMA surface area was 10.6-fold greater in NOACE than in 
the airway smooth muscle (14.59 [6.12, 23.07] and 1.37 [0.96, 1.77] (mean 
[95% CI]) (cells/mm2)·10-4 respectively, P=0.003).  
We found evidence of smooth muscle cell proliferation in the intestine wall, 
in Crohn’s disease specimens used for optimization of techniques and quality 
control (Fig. 11). 
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Figure 10. -SMA+ cell proliferation. Proliferating cell nuclear antigen (PCNA) is shown 
as dark-purple nuclei, and -SMA is the red cytoplasmic signal. Black arrows indicate 
PCNA+ nuclei where appropriate. All micrography panels show PCNA negative cells 
with methyl-green counterstained nuclei for internal reference. (A-B) -SMA+PCNA+ 
cells in airway smooth muscle bundles, in control subjects. (A) shows PCNA+ cells with 
poor -SMA content, suggestive of a “secretory” smoooth muscle cell phenotype. (B) 
shows a PCNA+ nucleus surrounded by a dense -SMA cytoplasmic filling such as in  a 
“contractile” phenotype. (C-E) Phenotype spectrum of proliferating -SMA+ cells in 
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asthmatics. The isolated, small-sized spherical cells in (C), located in the lamina 
propria, bear a morphology suggestive of a poorly diferentiated status and represent 
one extreme of the proliferating cell phenotype gradient. (D) shows PCNA+ airway 
smooth muscle cells in a moderate asthmatic. In (E), proliferating cells with a mature 
smooth muscle cell aspect cluster aligned and appose the outer edge of a smooth 
muscle bundle, in a severe asthmatic. (F) Quantitative morphology for -SMA+PCNA+ 
cells per mm2 biopsy surface area. Data are mean and 95% confidence interval of the 
mean. *: P<0.05 versus controls. †: P<0.05 versus moderate asthmatics. Scale bars: 10 
m in (A-B, E); 5 m in (C-D). 
 
Table 6. -SMA+ cell proliferation 
 
Values express the frequency of proliferating cell nuclear antigen (PCNA)+ cells 
referenced to the biopsy surface area in the airway smooth mucle (ASM) and non-
organized airway contractile elements (NOACE). Variability is expressed as 95% 
confidence intervals (CI) of the mean. P values are from post-ANOVA multiple 
comparisons. The 95% CIs of the mean increment () estimate the size of the effects. 
*moderate asthmatics versus controls; †severe asthmatics versus controls; ‡severe 
versus moderate asthmatics. 
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Figure 11. -SMA+ cell proliferation in Crohn’s disease intestine. Proliferating cell 
nuclear antigen (PCNA), -SMA and CD3 are shown respectively as dark-purple 
nuclear, red cytoplasmic and brown cell membrane signals. (A) Low magnification 
overview of an intestine crypt. The epithelium (arrow) shows intense proliferative 
activity in its basal layer, and a dense T cell inflammatory infiltrate is seen in the 
connective lamina propria under the epithelium. (B) High magnification detail 
showing a myofibroblast-type, -SMA+PCNA+ cell in subepithelial location. (C) 
Proliferating cells in the smooth muscle layer of the intestine wall, a region devoid of 
inflammation. Scale bars: 25 m in (A); 5 m in (B-C). 
 
5. T cells infiltrate the airway smooth muscle in accordance with 
asthma severity and localize with proliferating α-SMA+ cells in 
the airway smooth muscle bundles and NOACE 
To examine the microlocalization of T cells related to the α-SMA+ tissue 
compartments and their proliferating pool, we performed triple immunostaining 
for α-SMA, PCNA and CD3 (Fig. 12 and Tables 7 and 8). A baseline T cell 
frequency was found in the controls, in intraepithelial and subepithelial location. 
In the asthmatics, most T cells were found as part of inflammatory infiltrates in 
the lamina propria. Other T cell pools were intraepithelial and infiltrating the 
airway smooth muscle bundles, respectively. The latter accounted for 17.5% 
[11.9%, 23.2%] (mean [95% CI] of the T cells in the asthmatics (P<0.001 versus 
controls). No T cells were found in the airway smooth muscle in 6 of the 7 
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controls (1.0% [0%, 3.6%]). The total T cell load in the bronchial wall was 3.1-
fold (P=0.001) in the severe versus moderate asthmatics, and was borderline 
(P=0.059) in the moderate asthmatics versus controls. In the airway smooth 
muscle, T cell infiltration increased significantly from controls to moderate and 
severe asthmatics.  
A subset of T cells localized with α-SMA+ cells, suggesting direct cell 
contact. Such T cell/ α-SMA+ cell juxtaposition events were rare in controls, and 
their frequency was increased in asthmatics, in accordance with the severity of 
asthma (5.1-fold in moderate asthmatics versus controls, and 1.8-fold in severe 
versus moderate asthmatics; P=0.004). The juxtaposition events were distributed 
in approximately equal frequencies in the airway smooth muscle (46.1% 
[34.6%, 57.6%]) and NOACE (53.9% [42.4%, 65.4%]).  
A portion of the juxtaposition events was observed on α-SMA+ cells that 
simultaneously expressed PCNA. This was seen in one of the 7 controls (in 
NOACE only; case 4 in Table 4, 0.11 [0, 0.39] events/mm2) and in 69.2% of the 
asthmatics, where it averaged 14.9% [8.5%, 21.3%] of the events (2.59 [1.04, 
4.13] events/mm2; P=0.003 versus controls). Most of these CD3+-on- α-
SMA+PCNA+ cell juxtaposition events occurred in the NOACE (73.0% [55.2%, 
90.7%], versus 27.0% [9.3%, 44.8%] in airway smooth muscle, P<0.001).  
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Figure 12. T cell infiltration and microlocalization. Bronchial biopsy sections were 
immunostained for simultaneous detection of CD3 (brown cell membrane signal), -
SMA (red cytoplasmic signal) and proliferating cell nuclear antigen (PCNA, dark-purple 
nuclear signal). (A) T cells in a control subject, in intraepithelial location (within the 
proliferating basal stratum) and some scattered in the lamina propria (lp). (B-C) Sites 
of T cell localization in asthmatics. (B) shows a dense T cell infiltrate in the lamina 
propria, between the bronchial epithelium and the airway smooth muscle. (C) shows a 
T cell within a transversally sectioned airway smooth muscle bundle and adjacent to 
the tip of a PCNA+ myocyte nucelus. (D-G) Juxtaposition events of T cells on -SMA+ 
cells in asthmatics. (D-E) show T cells juxtaposed to -SMA+PCNA+ non-organized 
airway contractile elements (NOACE) in the subepithelial region. In (D), one of several 
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T cells in a cluster is juxtaposed to an -SMA+PCNA+ myofibroblast-like cell. In (E), a T 
cell is juxtaposed to a PCNA+ stem cell-like (small, spheroid, low--SMA perinuclear 
content) cell, in a peri-microvascular location. (F-G) show juxtaposition events in 
airway smooth muscle, in the proximity of PCNA+ myocytes (F), or directly on a PCNA+, 
“secretory phenotype”-like myocyte (G). (H-I) Quantitative morphology of T cell 
infiltration (H) and T cell/-SMA+ cell juxtaposition events. Data are mean and 95% 
confidence intervals of the mean. *: P<0.05 versus controls. †: P<0.05 versus 
moderate asthmatics. Scale bars: 25 m in (A-B); 10 m in (C, E-G); 5 m in (D). 
 
 
 
Table 7. Biopsy and airway smooth muscle T cell infiltration 
 
Total T cells infiltrating the bronchial wall and T cells infiltrating the airway smooth 
muscle (ASM). Values are referenced to the biopsy surface area. Variability is 
expressed as 95% confidence intervals (CI) of the mean. P values are from post-
ANOVA multiple comparisons. The 95% CIs of the mean increment () estimate the 
size of the effects. *moderate asthmatics versus controls; †severe asthmatics versus 
controls; ‡severe versus moderate asthmatics. 
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Table 8. T cell on -SMA+ cell juxtaposition events 
 
T cell/-SMA+ cell juxtaposition events in controls, and moderate and severe 
asthmatics. Values are referenced to the biopsy surface area. Variability is expressed 
as 95% confidence intervals (CI) of the mean. P values are from post-ANOVA multiple 
comparisons. The 95% CIs of the mean increment () estimate the size of the effects. 
ASM: airway smooth muscle. NOACE: non-organized airway contractile elements. 
*moderate asthmatics versus controls; †severe asthmatics versus controls; ‡severe 
versus moderate asthmatics. 
 
 
6. VCAM-1 is upregulated in asthmatics and is expressed by 
endothelium, airway smooth muscle and NOACE 
To analyze the expression and distribution of VCAM-1 in asthma, we 
coimmunostained VCAM-1 and α-SMA. Endothelial cells were one site of 
VCAM-1 expression (Fig. 13 A-H, M; and Table 9). VCAM-1 was extensively 
expressed by the endothelium in the bronchial microvasculature of the 
asthmatics, particularly in postcapillary venules distributed in the lamina 
propria and adjacent to airway smooth muscle bundles, or running within 
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smooth muscle bundle packs. The length of VCAM-1+ endothelium referenced 
to the biopsy surface area was significantly greater in severe asthmatics 
compared with moderate asthmatics. Mononuclear inflammatory infiltrates were 
observed surrounding VCAM-1+ vessels. In the controls, endothelial VCAM-1 
expression was limited to infrequent, short vascular segments in the absence of 
inflammatory infiltrates. The expression of VCAM-1 by the endothelium, as per 
its immunohistochemical signal, behaved as a dichotomous yes/no response 
with comparable signal intensity in all VCAM-1+ vascular segments, regardless 
of the study group. The differences observed were in the profusion of VCAM-1+ 
microvasculature. This pattern was consistent with prior reports on the 
regulation of VCAM-1 expression, which is absent from resting endothelium but 
greatly up-regulated by inflammatory stimuli.441 
VCAM-1 was also expressed in the airway smooth muscle and NOACE of 
asthmatics, in the form of defined discoid patches suggesting receptor 
focalization and clustering for cell-to-cell interaction (Fig. 13 I-K, N; and Table 
10). We hereinafter refer to these discoid formations as VCAM-1 clusters. Some 
VCAM-1 clusters were associated with an adjacent, non α-SMA expressing cell. 
This was better appreciated in VCAM-1 clusters seen laterally at the edge of an 
α-SMA+ cell. In the airway smooth muscle, some VCAM-1 clusters were 
observed within rounded concavities defined by a ring of cytoskeletal 
rearrangement as per α-SMA distribution. The expression of VCAM-1 clusters 
in α-SMA+ structures was not observed in the control subjects, with the 
exception of one case (case #5 in Table 4, who showed 2.3 clusters/mm2 in 
airway smooth muscle and 3.4 clusters/mm2 in NOACE). In the asthmatics, 
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there was no significant difference in the frequency of VCAM-1 discoid clusters 
between the moderate and severe groups. 
Some VCAM-1 clusters suggesting VCAM-1 involvement in points of cell 
contact were observed in non α-SMA expressing cells in connective lamina 
propria tissue (Fig. 13 L; not subjected to quantitative analysis). 
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Figure 13 (previous page). VCAM-1 (dark-purple, cell surface signal) and -SMA (red 
cytoplasmic signal) co-immunostaining. (A-H) VCAM-1 expression in endothelium (A-D, 
controls; E-H, asthmatics). B, D and F show the endothelium outlined over grayscale 
replicas for reference. The panels show microvasculature of the bronchial circulation, 
comprising arterioles and venules. Some VCAM-1+ vessels run across connective clefts 
within airway smooth muscle bundle packs (G, arrow) or in their immediate proximity 
(H). Mononuclear inflammatory infiltrates can be seen in close association with VCAM-
1+ vessels in the lamina propria (E) and muscle (G). (H-inset) provides a maximum 
bright-field resolution view of a cross-sectioned post-capilary venule found within the 
airway smooth muscle, where VCAM-1 is expressed on the endothelial surface, in the 
form of dotted aggregates associated with intraluminal leukocytes. The arrow points 
to the nucleus of an endothelial cell. (I-J) VCAM-1 expression by airway smooth muscle 
as defined patches suggesting receptor clustering. (I) shows such VCAM-1 clusters 
(arrow), in association with a cell located in an upper focal plane (I, upper-right) or 
within concavities surrounded by ring-shaped -SMA reorganization (I, bottom). (J) 
shows VCAM-1 clusters viewed laterally at edges of cells and associated with non-
smooth muscle cells. (K) VCAM-1 expression by NOACE in a similar pattern. (L) VCAM-1 
interfaces in connective tissue of lamina propria. (M, N) Quantitation of endothelial 
VCAM-1 expression and VCAM-1 cluster counts, respectively. The triangles in (N) 
correspond to the data points of a sole control subject where VCAM-1 clusters were 
found. Data are mean and 95% confidence interval of the mean. *: P<0.05 versus 
controls. †: P<0.05 versus moderate asthmatics. Scale bars: 50 m in (A-G);  25 m in 
(H); 10 m in (H-inset) and (I-K); 5 m in (L). 
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Table 9. VCAM-1 expression by endothelium 
 
VCAM-1+ endothelium length referenced to the biopsy surface area. Variability is 
expressed as 95% confidence intervals (CI) of the mean. P values are from post-
ANOVA multiple comparisons. The 95% CIs of the mean increment () estimate the 
size of the effects. *moderate asthmatics versus controls; †severe asthmatics versus 
controls; ‡severe versus moderate asthmatics. 
 
 
 
Table 10. Frequency of VCAM-1 clusters 
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Table 10 legend (previous page). Numbers of VCAM-1 clusters in controls, 
moderate and severe asthmatics, referenced to the biopsy surface area. 
Variability is expressed as 95% confidence intervals (CI) of the mean. P values 
are from post-ANOVA multiple comparisons. The 95% CIs of the mean 
increment () estimate the size of the effects. ASM: airway smooth muscle. 
NOACE: non-organized airway contractile elements; *moderate asthmatics 
versus controls; †severe asthmatics versus controls; ‡severe versus moderate 
asthmatics. 
 
 
 
7. T cell microlocalization predicts α-SMA+ tissue mass and cell 
proliferation 
We used multivariate regression to model the variance of the airway smooth 
muscle mass as an output dependent variable. The numbers of T cells localized 
in the airway smooth muscle, the frequency of T cell juxtaposition events, the 
NOACE mass and the α-SMA+ cell proliferation accounted jointly for 56.8% of 
the airway smooth muscle mass variance (R=0.84, adjusted R2=0.57, P=0.001), 
in the absence of collinearity. The strongest contributors were: (i) the T cells 
infiltrating the airway smooth muscle (R=0.61, partial R [pR; the bivariate 
partial correlation that remains after eliminating the part of the correlation due to 
effects from the rest of the independent variables]=0.64; P<0.001), in the 
absence of correlation between the airway smooth muscle mass and the overall 
T cells in the biopsy (P=0.260); (ii) the frequency of T cell juxtaposition events 
on PCNA+ airway smooth muscle cells (R=0.56, pR=0.24, P=0.001); and (iii) 
the NOACE mass (R=0.45, pR= 0.22, P=0.014). In terms of airway smooth 
muscle cell proliferation, T cell load and the frequency of juxtaposition events 
accounted for 63.0% of the variance of PCNA+ airway smooth muscle cell 
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frequency (R=0.85, adjusted R2=0.63, P<0.001). The strongest predictors were 
T cell infiltration of the smooth muscle (R=0.71, pR=0.22, P<0.001) and T cell 
juxtaposition events on PCNA+ airway smooth muscle cells (R=0.49, pR=0.55, 
P=0.006). Therefore, multivariate regression keyed T cell infiltration of the 
airway smooth muscle as the main predictor of airway smooth muscle mass and 
proliferative activity in airway smooth muscle and NOACE (Fig. 14), yet the 
airway smooth muscle mass did not correlate with the total T cell numbers in the 
biopsy. The length of VCAM-1+ microvascular endothelium correlated with the 
numbers of total T cells and T cells infiltrating the airway smooth muscle. The 
NOACE mass was mainly predicted by the frequency of T cell juxtaposition 
events on NOACE (R=0.51, pR=0.41, P=0.004); NOACE cell proliferation was 
predicted by the T cells infiltrating the airway smooth muscle (R=0.75, 
pR=0.68, P<0.001) and juxtaposition events on NOACE (R=0.69, pR=0.61, 
P<0.001). Overall, smooth muscle T cell infiltration was the major predictor of 
airway smooth muscle mass and the frequency of α-SMA+PCNA+ cells in both 
airway smooth muscle and NOACE. 
 
Figure 14. Multivariate regression analysis. T cell infiltration of airway smooth muscle 
(ASM) as a predictor of (A) ASM mass and (B-C) cell proliferation in ASM and NOACE.  
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PART III: ROLE OF APOPTOSIS IN 
AIRWAY SMOOTH MUSCLE REMODELING 
 
1. Introduction 
The work presented in this chapter is a translational study where 
experimental asthma animal models were combined with a study on bronchial 
biopsies to elucidate the role of myocyte apoptosis in airway smooth muscle 
remodeling. Only the work done on the bronchial biopsies pertains to the present 
thesis and will be detailed, whereas a snapshot summary of the results from the 
animal models is provided in the present introductory section, to provide the 
necessary background for the biopsy data. The results are currently unpublished 
and a single manuscript combining the animal models with the clinical study on 
bronchial biopsies is in advanced preparation at the date of closing the present 
thesis. 
Whereas investigations on airway smooth muscle remodeling have largely 
focused on its growth mechanisms, there is an almost absolute lack of data on 
any role of apoptosis, an essential regulator of morphogenesis and tissue 
homeostasis. The prior experiments on adoptive transfer of antigen-specific 
CD4+ T cells in rat experimental asthma demonstrated T cell-driven airway 
smooth muscle remodeling and suggested a combined contribution of increased 
myocyte proliferation and inhibition of apoptosis.102 In horses with heaves, a 
naturally occurring, allergic airway obstructive disease, airway smooth muscle 
growth was associated with myocyte proliferation and, contrary to the short-
term rat model, myocyte apoptosis was increased.365 Those previous studies 
were consistent with the idea that the increase of airway smooth muscle mass in 
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asthma is at least partly due to hyperplasia, and also suggested that myocyte 
apoptosis may be involved in the remodeling process and be subjected to 
regulation through the natural history of the disease. In the work involved in this 
study, we aimed at providing proof-of-concept evidence of an involvement of 
myocyte apoptosis in airway smooth muscle remodeling.  
For this purpose, we first developed a murine asthma model based on 
allergic sensitization followed by repeated allergen bronchoprovocation with 
two cutoff points for data collection: (i) a short-term cutoff reflecting early 
disease and (ii) a late cutoff reflecting long-term disease. Airway 
hyperresponsiveness and airway smooth muscle remodeling (increased airway 
contractile tissue mass) were already present at the early cutoff point. Airway 
smooth muscle cell apoptosis was detected in the mouse lung tissue sections by 
TUNEL colocalization with α-SMA immunostaining. A double verification of 
apoptotic events in airway smooth muscle was carried out by co-
immunostaining of active caspase-3 with α-SMA, and quantitative morphology 
was performed for both signal combinations. At the early cutoff, the animals 
with experimental asthma showed the same baseline frequency of apoptotic 
events in airway smooth muscle cells as the control animals (sensitized mice 
submitted to PBS airway challenge). On the late cutoff, airway smooth muscle 
cell apoptosis was upregulated in the animals with experimental asthma. In all, 
the data show that a baseline frequency of apoptosis exists in airway smooth 
muscle, likely involved in the homeostatic maintenance of this structure. During 
the development of asthma, once airway hyperresponsiveness and smooth 
muscle remodeling have been established, an upregulation of airway smooth 
muscle cell apoptosis follows, which suggests a regulatory mechanism to 
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increase cell turnover and attenuate the excessive growth of airway smooth 
muscle. 
To provide a mechanistic demonstration of a role for apoptosis in airway 
smooth muscle homeostasis, and a regulatory involvement of upregulation of 
apoptosis through the development of airway smooth muscle remodeling, we 
developed an experimental asthma model under pharmacological inhibition of 
apoptosis. For this purpose, a broad spectrum caspase inhibitor drug (termed 
QVD-OPH for (3S)-5-(2,6-difluorophenoxy)-3-[[(2S)-3-methyl-1-oxo-2-[(2-
quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate) was 
administered to sensitized mice along with repeated airway allergen challenge, 
and an intermediate data collection cutoff was set midway between the early and 
late cutoffs of the previous model. This was a parallel, four-arm study where 
allergen-challenged animals, versus their counterpart PBS-challenged controls, 
received either QVD-OPH or its vehicle (dimethyl sulfoxide, DMSO). PBS-
challenged animals treated with QVD-OPH developed a spontaneous, 1.7-fold 
increase of airway smooth muscle versus their counterpart controls treated with 
DMSO, a finding attributable to a baseline role of apoptosis in maintaining 
airway smooth muscle homeostasis under physiological conditions. In the 
animals with experimental asthma, the in vivo inhibition of apoptosis led to: (i) 
chaotic pulmonary mechanics, reflected by an unusual response to methacholine 
challenge where the pulmonary resistance (RL) output was an unusual tracing 
combining features such as a lifted baseline RL, premature RL increments at low 
methacholine doses, a serrated RL profile resulting from sharp peaks and valleys 
in succession, and exaggerated, abrupt RL rises not consistent with the 
methacholine dosing; and (ii) inusitate, unstructured growth of airway 
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contractile tissue, i.e. an unusual pattern of airway smooth muscle remodeling as 
compared with the counterpart regular experimental asthma animals receiving 
DMSO, consisting of further thickening of the airway smooth muscle layer 
along with morphological features suggestive of disorganized growth of this 
structure. On lung tissue sections, colocalization of TUNEL, active caspase-3 
and c-PARP with α-SMA corroborated that a pharmacologically driven 
inhibition of airway smooth muscle cell apoptosis by QVD-OPH underlay such 
effects.  
In all, the data from the experimental asthma models provided evidence that 
airway smooth muscle cell apoptosis is involved in the homeostasis of this 
structure, and that an upregulation of myocyte apoptosis occurs in response to 
airway smooth muscle remodeling through the development of the disease. 
These findings called for further investigation employing bronchial biopsies, in 
search of support for such involvement of apoptosis in the pathophysiology of 
human asthma. 
 
2. Airway smooth muscle cell apoptosis is present in human 
asthma and c-PARP release correlates with asthma severity 
Our experimental data support that α-SMA+ cell apoptosis is involved in 
AwCT turnover and is further implicated in regulating the morphogenesis of 
airway smooth muscle under pathological conditions so as during the 
progression of experimental asthma. To search for evidence of such involvement 
of apoptosis in the pathophysiology of human asthma, we analyzed bronchial 
biopsy tissue sections from a sample population of 59 subjects with asthma, 
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comprising 7 subjects with intermittent asthma, 33 with moderate asthma and 19 
with severe asthma, plus 13 control subjects. TUNEL colocalization with α-
SMA immunostaining was done for all subject specimens, and quantitative 
morphology was performed to determine airway smooth muscle mass and the 
frequency of TUNEL+α-SMA+ cells (Fig. 15 A-F, J). Active caspase-3 
immunostaining was not technically feasible. c-PARP was co-immunostained 
with α-SMA in the control subjects and in a sample subset of 5 moderate and 8 
severe asthmatics (Fig. 15 G-I, K). Demographics and clinical data are provided 
in Table 11, and quantitative morphology data in Table 12. 
Airway smooth muscle mass showed a significant gradient from the control 
subjects through the subjects with severe asthma. A tendency to increased 
airway smooth muscle was already present in the subjects with intermittent 
asthma, with a borderline significant difference versus controls (P=0.087). 
Moderate asthmatics had significantly increased airway smooth muscle versus 
controls (P=0.003), and severe asthmatics showed a significant increase versus 
controls and moderate asthmatics (P<0.01 and P=0.023, respectively). An 
observed greater frequency of TUNEL+α-SMA+ cells in the asthmatics (by 6.15-
fold the baseline frequency in control subjects overall) did not yield a 
statistically significant output. Severe asthmatics did show a significant increase 
in the frequency of c-PARP+α-SMA+ cells (4.07-fold, P=0,008 versus controls 
and 3.78-fold, P=0.021 versus moderate asthmatics).  
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Figure 15. Apoptosis in human airway smooth muscle. Bronchial biopsy sections were 
processed for TUNEL (A-F), or immunostained for c-PARP detection (G-I), and the 
signals colocalized with α-SMA. Biopsy sections from control subjects, moderate and 
severe asthmatics are shown as indicated. The low-magnification micrographs in (A-C) 
illustrate the airway smooth muscle progression from controls through moderate and 
severe asthmathics. In (D-F), examples of TUNEL+ myocyte nuclei (filled arrowheads) 
and non-apoptotic myocytes as an intra-specimen negative reference (open 
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arrowhead) are shown. In (G-I), an increased frequency of α-SMA+c-PARP+ (dark 
nuclear signal) cells can be apreciated in the severe asthmatics. (J) Bronchial smooth 
muscle mass (ASM) and frequency of α-SMA+TUNEL+ cells. (K) Frequency of α-SMA+c-
PARP+ cells. *: P<0.05 versus control subjects. †: P<0.05 versus moderate asthmatics. 
Borderline significant differences are specified. Scale bars: 300 μm (A-C); 50 μm (G); 20 
μm (D-F, H-I). 
 
 
 
Table 11. Demographics and clinical data 
 
Age was homogeneously distributed among controls, and moderate and severe 
asthmatics. The subjects with intermittent asthma were significantly younger than the 
other groups (P = 0.001, P = 0.028 and P = 0.002 versus controls, moderate asthmatics 
and severe asthmatics, respectively). Gender was homogeneously distributed. Atopy 
was significantly more frequent in the severe asthmatics (P<0.001). FEV1 and the 
FEV1/FVC ratio were preserved in the intermittent and moderate asthmatics, and were 
significantly decreased in the severe asthmatics (P<0.001 versus all other groups for 
both parameters). 
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Table 12. Airway smooth muscle mass, and frequency of TUNEL+α-SMA+ and 
c-PARP+α-SMA+ cells in bronchial biopsies 
 
Values correspond to airway smooth muscle mass (α-SMA+ airway smooth muscle 
bundles), and the frequency of TUNEL+α-SMA+ and c-PARP+α-SMA+ cells referenced 
to the biopsy surface area. Data are presented as mean ± standard error of the mean. 
The 95% confidence intervals of the mean increment (Δ) estimate the size of the 
effects. P values are from post-ANOVA multiple comparisons. a: versus control 
subjects; b: versus intermittent asthma c: versus moderate asthmatics. 
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PART IV: Tregs AND MSCs IN BRONCHIAL BIOPSIES 
 
1. Introduction 
The core research line of the Experimental Pneumology Unit had formerly 
focused on the role of effector CD4+ T cells in airway smooth muscle 
remodeling. Those investigations stemmed from the demonstration of a T cell/α-
SMA cell "synapse" mechanism whereby effector CD4+ T cells drive airway 
smooth muscle remodeling in experimental asthma,102 and evidence for such 
disease mechanism in actual human asthma was later found through research on 
human biopsies, as presented in Part II of this Results section.17 However, 
simultaneous advances in the knowledge about CD4+ regulatory T cells (Tregs) 
and the immunomodulatory effects of mesenchymal stem cells (MSCs) drew the 
research line towards its current interest in Tregs and MSCs together, because 
they may share a dual therapeutic yet pathogenic potential for asthma, under the 
overall hypothesis that the mechanisms of immune regulation are coupled with 
the induction of repair responses. Immunoregulatory pathways reactive to 
chronic airway inflammation may sustain a dysregulated repair response that 
causes remodeling. As a result, any potential therapy based on biological, cell-
driven induction of immune regulation must be carefully evaluated through solid 
preclinical development. Tregs may be reactively increased in the asthmatic 
airways and their presence may contribute to airway remodeling through potent 
fibrogenic cytokines such as TGF-β. As for the MSCs, their promising 
effectiveness to treat graft-versus-host disease,397 an immune-mediated, life-
threatening disorder, led to a research "hot topic" into the potential use of MSCs 
to treat a variety of chronic inflammatory disorders.398 In the particular case of 
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asthma, this trend led to fast research that focused on the immunomodulatory 
properties of MSCs,442-446 yet completely overlooking the evidence suggesting a 
role for undifferentiated precursors in the growth of airway smooth muscle,12-17 
and therefore a possible fate of "therapeutic" MSCs as building blocks for 
airway remodeling. To clarify these issues, we have recently conducted 
investigations on Tregs and MSCs in experimental asthma. 
In the case of Tregs, the "obvious" hypotheses that arose and spread in the 
scientific community was that Tregs would be decreased in asthma, and 
therefore chronic airway inflammation would develop as a result of a failure of 
this regulatory arm. However, the published work that followed on this topic 
was scarce and inconsistent. We hypothesized that chronic airway inflammation 
does not arise from a primary failure of Tregs but, conversely, Tregs may be 
reactively increased in response to the sustained inflammation and may actively 
participate in inducing airway remodeling through their mediators related to 
tissue repair, such as TGF-β. We conducted an experimental asthma model 
(unpublished data) with three data collection cutoffs representing very early 
disease, an intermediate point of disease development, and long-term chronicity, 
respectively. Airway hyperresponsiveness peaked at the intermediate point and 
then plateaued with a subsequent trend to significant attenuation at the long-term 
disease cutoff, upon continued airway allergen challenge. Concomitantly, IL-10 
and TGF-β producing Tregs increased gradually and significantly from early 
disease through long-term disease. Tregs were identified in lung tissue sections 
as lymphoid cells bearing immunofluorescent FOXP3, IL-10 and TGF-β signal 
colocalization, and were found infiltrating the airway wall and bronchial-
associated lymphoid tissue. The progressive airway infiltration by Tregs through 
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disease development was paralleled by increasing goblet cell numbers and 
airway epithelial mucus mass, and subepithelial fibrosis. These results are 
consistent with the hypothesis that Tregs are not decreased but reactively 
increased in asthma, and may contribute to the development of airway 
remodeling features, particularly subepithelial fibrosis, through the action of 
their main secreted cytokine, TGF-β. Such outcome called for further 
translational research employing human bronchial biopsies, as advanced next in 
Section 2. 
As for investigations on the role of MSCs, a study was recently conducted at 
our Experimental Pneumology Unit where adipose tissue-derived MSCs from 
syngeneic donor mice were administered to mice with established experimental 
asthma.447 The MSCs were genetically engineered by retroviral transduction to 
permanently express GFP for in vivo follow-up, and data were collected at two 
time points after MSC administration: an early cutoff (72 hours post-MSC 
injection) to analyze early treatment effects; and a cutoff at two weeks after 
MSC injection and continued airway allergen challenge, to analyze late 
treatment effects upon sustained exposure to pathogenic stimuli as in human 
allergic asthma. The study was driven by the hypothesis that the injected MSCs 
would contribute to airway remodeling through their recruitment, differentiation 
and integration into the airway smooth muscle bundles. Consistently with 
previous reports, the MSCs abrogated airway inflammation at the early cutoff, 
yet this therapeutic outcome was followed by a rebound with full reinstatement 
of airway inflammation at the late cutoff. Conversely, airway 
hyperresponsiveness was unaffected at the early cutoff and was significantly 
attenuated at the late cutoff. The GFP labeled MSCs were found in the 
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inflammatory infiltrates and the lung parenchyma air spaces and could be 
retrieved in BAL, but a thorough scan of all lung tissue sections did not yield 
any evidence of MSC differentiation nor integration into airway wall tissues. 
Furthermore, the adipose-derived MSC treatment employed in these 
experiments induced a significant regression of the airway contractile tissue 
mass at the late cutoff, which was an unexpected outcome contrary to the 
original hypothesis. Therefore, different subpopulations of adult stem cells and 
progenitor cells may exist, still undefined, which may exert varying and even 
opposite functions, from a pathogenic participation in the mechanisms of airway 
remodeling, such as in the case of fibrocytes, to inducing a regression of the 
remodeled airway smooth muscle as seen for the MSCs employed here. 
The outcomes from the experimental asthma studies on Tregs and MSCs 
warrant clinical investigation on human bronchial biopsies with two main aims: 
(i) to confirm whether Tregs are present in increased numbers in the airway wall 
of asthmatics; and (ii) to discern whether MSCs are present in the airway wall of 
asthmatics in the form of adult stem cell populations other than fibrocytes, and 
to gain a deeper insight into their role. For both goals, research work is ongoing 
at the closing date of the present thesis and preliminary results are presented in 
the following sections, respectively. 
 
2. Tregs infiltrate the airway wall of subjects with severe asthma 
To translate the results from the experimental asthma model, and since no 
direct analysis of Treg markers had previously been performed in airway wall 
tissues, we performed FOXP3 immunostaining on bronchial biopsy tissue 
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sections. This was an exploratory analysis where bronchial biopsies were 
employed from 5 control subjects and 29 subjects with severe asthma, and plain 
FOXP3 immunostaining followed by hematoxylin counterstain was performed 
in the absence of colocalization with other signals (Fig. 16). For the purpose of 
this analysis, Tregs were identified as FOXP3+ lymphoid cells (FOXP3 was in 
fact exclusively expressed by mononuclear lymphoid cells). Such cells were 
mostly located in the lamina propria, and were almost exclusively found in the 
subjects with asthma (18.08 ± 4.49 cells/mm2), whereas the control subjects had 
virtually no FOXP3+ cells (0.91 ± 0.70 cells/mm2; P<0.001, severe asthmatics 
versus controls). Demographics and clinical data for the selected subjects are 
shown in Table 13, and the indications for bronchoscopy in the control subjects 
in Table 14. 
 
 
Table 13. Demographics and clinical data 
 
SEM: standard error of the mean. 
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Table 14. Indications for bronchoscopy in control subjects 
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Figure 16 (previous page). FOXP3+ cells in bronchial biopsies. Tissue sections from 
bronchial biopsies (A-D) were immunostained to detect FOXP3 (brown signal) and 
quantitative morphology was performed (E). Bronchial biopsies from control subjects 
were virtually devoid of FOXP3+ cells (A), whereas the biopsies from asthmatics 
showed significantly and largely increased number of lymphoid FOXP3+ cells infiltrating 
the subepithelial connective tissue (B-D). (D) shows a high-magnification detail. *: 
P<0.01 versus control group (CTRL). Scale bars: 100 μm in (A-B); 50 μm in (C); 2.5 μm 
in (D).  
 
 
 
3. Airway smooth muscle expresses MSC marker STRO-1 in 
asthma 
To test whether MSCs are present in the airway wall of subjects with asthma, 
we performed immunohistochemistry to detect STRO-1, a marker of bone 
marrow stromal  MSCs that is neither expressed by hematopoietic cells nor 
fibrocytes. Airway smooth muscle mass was measured by digital extraction 
from hematoxylin-eosin stained tissue sections from the same biopsies. For this 
pilot study, we employed biopsies 
from 8 severe asthmatics and 4 control 
subjects, and data analysis was done 
using Mann-Whitney's U test. The 
subjects with severe asthma had 
increased airway smooth muscle mass 
compared with the control subjects 
(0.68 ± 0.04 versus 0.24 ± 0.024 
respectively, P=0.007; Fig. 17). 
Individual, well-defined STRO-1+ cells 
Figure 17. Quantitative morphology of 
airway smooth muscle mass. *: P<0.05 
versus control (CTRL) subjects. 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 164 - 
were frequent events in the lamina propria of the asthmatic subjects (Fig. 18 A-
C), whereas there was virtually no existing STRO-1+ cells in the control 
subjects. In the airway smooth muscle, STRO-1 was expressed in the form of 
spotted antigen clusters (Fig. 18 A). Upon quantitative morphology (Fig. 18 D), 
the frequency of such clusters was by 9.5-fold  greater in the asthmatics 
compared with the control subjects (2.37 ± 0.76 versus 0.25 ± 0.14 STRO-1+ 
clusters/mm2 respectively, P=0.028). 
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Figure 18 (previous page). STRO-1 immunostaining in bronchial biopsies. Tissue 
sections were stained with anti-human STRO-1 antibody and developed with a DAB-
peroxidase kit. STRO-1+ cells were almost absent in the control subjects. In the 
asthmatic subjects (A-C), they were mainly located in the subepithelial region in the 
form of individual, recognizable cells, whereas the bronchial smooth muscle bundles 
presented STRO-1+ clustering spots suggesting residual expression by STRO-1+ cells 
previously migrated and integrated into the muscle. (A) shows a low-magnification 
micrograph for an overall appraise of STRO-1+ cell localization. A number of STRO-1+ 
cells can be appreciated in the lamina propria, as well as STRO-1+ spots in the 
bronchial smooth muscle (arrows). (B-C) show progressive magnification detail of the 
STRO-1+ cells. The numbers of STRO-1+ cells were significantly and largely increased in 
the subjects with asthma (D). *: P<0.05 versus control (CTRL) subjects. Scale bars: (A), 
100 μm; (B), 40 μm; (C), 100 μm.  
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DISCUSSION 
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Although the main anatomopathologic features of the asthmatic airway wall 
have been thoroughly described almost a century ago from postmortem 
specimens,349 the interest in airway remodeling gained momentum starting in the 
late 1990s upon cumulative evidence that such structural alterations of the 
airway wall, chiefly the growth of airway smooth muscle, underlie the clinical 
manifestations of asthma and its severity.2-4, 10, 59, 331, 336, 339, 343, 345, 350, 351, 408, 416, 
420, 421, 448-468 Such relevance of airway remodeling to asthma pathophysiology 
has not yet impacted the asthma management guidelines in its full strength, due 
to the lack of tools to regularly evaluate airway remodeling in the clinical setting 
and, most importantly, to treat it. Perhaps necessarily, asthma management 
guidelines carry a sustained lag between cutting-edge knowledge and its 
translation into clinical practice. In fact, the GINA guidelines were years back 
criticized for defining and insistently explaining asthma as a chronic airway 
inflammatory disorder, yet lacking any directions to clinically evaluate airway 
inflammation as an outcome to address asthma management, which was merely 
guided by symptoms and pulmonary function tests,324 and the problem persists 
as currently highlighted.469 Such type of gap has currently been translated to 
airway remodeling, which is almost exclusively sidelined to the research 
grounds. In fact, airway remodeling, despite being a close biological counterpart 
of airway inflammation and having as much physiopathological relevance, has 
not been included in the definition of asthma in the major current guidelines 
(GINA,470 NIH,471 GEMA,22 BTS469), except for the guidelines of the Canadian 
Thoracic Society since 2003.472 GINA guidelines have not included nor 
referenced the term "remodeling" until its most recent updates. In its 2015 
update,470 the GINA guidelines conceal airway remodeling to the scant 
description of an asthma "phenotype" termed "asthma with fixed airflow 
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limitation", regardless the evidence on the progression of airway smooth muscle 
remodeling according to asthma severity,1, 17, 413 and its involvement in the 
mechanism of airway hyperresponsiveness, variable airflow obstruction and 
disease severity.1-6, 17, 81, 345, 346, 413, 447 The remarkable fact that the GINA 
guidelines have largely been reluctant to mention airway remodeling, is not due 
to an inadvertent omission since some of its authors have had frontline scientific 
productivity in the field of airway remodeling. It rather reflects the fact that 
there is no established diagnostic tools nor therapies with a feasible translation 
to clinical practice at present. Nevertheless, the role of airway remodeling is not 
under any question. Recent and ongoing developments, especially in the field of 
humanized monoclonal antibody-based therapies, are expected to soon tackle 
airway inflammation offering improvements never seen before for a number of 
subjects with severe asthma or refractory, oral corticosteroid-dependent asthma. 
However, such expectations may be subject to drawbacks: (i) the only marketed 
biological asthma therapy at the closing date of the present thesis (omalizumab), 
and all other "umabs" under advanced clinical development, target molecular 
mediators of the classical Th2-driven allergic and/or eosinophilic asthma 
pathways, which will leave a significant proportion of severe asthmatics devoid 
of any innovative therapies; (ii) the primary outcome for virtually all ongoing 
Phase-II/III "umab" clinical trials is the reduction in the frequency of asthma 
exacerbations, perhaps due to a pharmacoeconomic focusing for compound 
development and future marketing strategies directed to healthcare managers, 
whereas outcomes related to lung function, symptoms and quality of life are 
always secondary and their output may be less clear overall;473-481 and (iii) there 
is evidence that airway remodeling, once established, persists dissociated from 
airway inflammation if inflammation is abrogated.346, 482, 483 All such 
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considerations on the closely upcoming "umabs" avalanche may bring us to the 
reflection that, when brought to actual clinical practice, a major proportion of 
subjects with severe and/or refractory asthma may be left out of the therapeutic 
scope of these biological therapies, as per the evidence provided by the 
exacerbation-oriented clinical trials on which the approval by the medicines 
agencies will predictably be based. This includes, at least: asthmatics arising 
from various "endotypes" whose clinical severity consists of a sustained status 
of poor lung function and limited quality of life, and not necessarily a sequence 
of well-defined, frequent "exacerbations"; and those asthmatics with clinical 
"phenotypes" such as neutrophilic, hypersecretory or pauci-inflammatory/highly 
remodeled, whose immunobiological pathways have been left out in the "umab" 
development race. Ongoing developments in the "umab" field shall bring 
tangible improvements for some carefully selected asthmatics, yet it is 
foreseeable that a general benefit for the overall population of severe/refractory 
asthmatics will have to await further scientific development and perhaps some 
redirection of global vision in the complex ecosystem of implicated 
stakeholders, involving among others capital investors, pharmacoeconomic and 
marketing strategists, health care providers, health system authorities, and 
medical specialties societies. For the reasons stated, meaningful research 
focused on asthma disease mechanisms and innovative therapies shall involve 
airway remodeling outcomes, and the only available procedure to clinically 
probe airway remodeling and its component features at histopathological and 
cell biology level is: bronchial biopsy. 
After the advent of bronchoscopic instrumentation techniques, bronchial 
biopsy has provided a significant deal of information about asthma pathology 
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and immunobiology, although investigations have generally being carried out on 
the basis of single-center collections or ad hoc arrangements for a particular 
trial. Yet the issues discussed above provide the grounds for the development of 
a stable, renewable system with multicenter SOPs so as to support present and 
future investigations on bronchial biopsies, whether immunobiological analyses 
on collected specimens from an observational standpoint, or as a preset platform 
to readily support the implementation of experimental designs aimed at specific 
clinical trials. Such is the rationale for the development of the Bronchial Biopsy 
Biobank presented in this thesis, which is a novelty in terms of being an 
implementation into a corporate structure, the Asthma Integrated Research 
Program (PII Asma) of SEPAR, and part of a national official biobank registry 
as a specialized repository with a well-defined commitment. Furthermore, the 
growth of the Bronchial Biopsy Biobank is by itself structuring and expanding a 
valuable multicenter cohort of asthmatic subjects, with in-depth clinical 
characterization to the point of bronchial biopsy availability. 
The startup and early rollout of the Bronchial Biopsy Biobank faced 
decision-making challenges concerning its design and SOPs. The main goal was 
to set up and optimize a process that would allow for: (i) the collection, 
preservation and shipping of bronchial biopsies within a multicenter context 
where busy bronchoscopist physicians and assistant personnel would not be able 
to perform on-site specimen processing operations; and (ii) to generate in such 
expedite fashion specimens yielding optimal versatility for scientific objectives 
not determined a priori. In other terms we envisioned that, in order to set up and 
maintain up and running a system that would feasibly yield a satisfactory flow 
of biopsy specimens, the on-site part of the procedures should not involve any 
BRONCHIAL BIOPSY BIOBANK  Nadia S. Brienza 
- 173 - 
other operations than patient selection, sign-up of the informed consent, release 
the biopsies into preloaded tubes with fixative during bronchoscopy, pack the 
tubes, and drop a call to DHL for pickup. To make this aim achievable, the 
method chosen for tissue fixation is of axial importance because it highly 
determines on-site requirements and the subsequent specimen processing and 
performance. Fixative properties required for the pursued goals were: (i) be non-
volatile and devoid of relevant inhalational toxicity at the volumes handled in 
the bronchoscopy room; (ii) be operational at room temperature; (iii) have an 
optimal fixation time compatible with overnight courier shipment; (iv) issue 
high-quality microscopic detail in tissue sections; (v) provide long-term, 
virtually limitless, antigen preservation; (vi) preserve nucleic acid sequences, 
including genomic DNA and mRNA, for in situ hybridization procedures; (vii) 
yield a limited level of background fluorescence in tissue sections, compatible 
with a good signal-to-noise ratio for immunofluorescent techniques using 
modern fluorochromes; and (viii) be suitable for reprocessing into preparations 
for ultramicrotome sectioning and electron microscopy. As quoted in the Results 
section, collaborating investigators were initially provided with a double set of 
preloaded tubes to alternate the use of two different fixatives, i.e. 4% 
formaldehyde (formalin) versus the recently marketed fixative FineFix®, due to 
the inconvenience that formalin is a cross-linking fixative that makes some 
epitopes unaccessible to primary antibodies for immunohistochemical or 
immunofluorescent detection. Following early warnings from site collaborators 
on FineFix® instability, this fixative was soon discontinued and formalin was 
chosen as the definite fixative for the Bronchial Biopsy Biobank standard 
procedures. Upon the accumulated experience so far, 24-hour formalin fixation 
followed by paraffin embedding has satisfactorily met all set requirements, and 
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antigen retrieval procedures have successfully overcome epitope detection 
hindering when needed, as has been the case for CD3, PCNA, VCAM-1, active 
caspase-3, c-PARP and FOXP3. Another technical matter encountered along 
with tissue fixation and processing was the normalization of biopsy harvesting 
during bronchoscopy, in terms of employing an optimal biopsy forceps, 
considering that appropriate sampling of airway smooth muscle is a critical issue 
for the Bronchial Biopsy Biobank goals. This aim has been successfully 
achieved by adhering to the Olympus 35C forceps, selected through prior 
experience at McGill University. This is a large, fenestrated cup forceps of 
uncommon use in regular clinical practice, and therefore is being purchased with 
the Biobank funding and issued to the collaborators as part of the working kits 
provided. A drawback of this forceps is that it requires a "therapeutic" 
bronchoscope due to its size, and this requirement limited the participation of 
some centers. One more aspect taken into consideration was to devise on-site 
paperwork so as to minimize the load on the collaborating investigators and ease 
case reporting. A key point in this regard is the assignment of prenumbered  
series for subject encoding to the participating centers. This provides a uniform, 
nonoverlapping subject encoding system across all participating centers, which 
facilitates central database keeping at the Bronchial Biopsy Biobank site, and 
whereby each site investigator has to only register the subject and label the 
specimen tubes using the number sequence issued with each working kit. 
Consent form procedure, subject registration and specimen numbering are the 
only essential administrative tasks at the point of biopsy collection and shipping. 
As for the rest of required paperwork, the CRFs for demographics, clinical data 
and biopsy registry have been designed aiming at maximum functionality and 
clarity. 
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Normative developments occurred while conceiving and implementing the 
Bronchial Biopsy Biobank into practice. Indeed, the inception of the Bronchial 
Biopsy Biobank and the early steps towards its design and implementation 
occurred ahead of the publication of the 14/2007 Law of July 3rd, 2007 on 
Biomedical Research.437 The 14/2007 Law establishes the requisites for the 
creation of biobanks and their operations. Key aspects of the Law are: the 
founding of a biobank must have Government authorization; the biobank must 
be registered in a National Registry of Biobanks held by the Instituto de Salud 
Carlos III; the biobank must have a director that oversees its activity, procedures 
and continued compliance with all legal requirements, and a permanent 
scientific committee that evaluates and authorizes the use of biobank specimens 
for the purposes of specific scientific projects; and the biobanks must be 
subjected to regular auditing by Government authorities. All such requirements 
drove the concept of biobanks towards administratively and juridically complex 
structures, with the requirement of sustained funding and assigned personnel, 
which could only be implemented and held at an institutional level, such as by 
accredited hospital research institutes or greater juridical entities such as the 
Centros de Investigación Biomédica en Red (CIBER) of the Instituto de Salud 
Carlos III. Such official biobanks are at present the entities entitled to hold the 
custody and management of investigator-driven specimen subsets, such as is the 
case of the priorly conceived Bronchial Biopsy Biobank. Due to the complexity, 
workload and funding needs involved in the setup of a registered biobank, the 
14/2007 Law has been progressively implemented over the years following its 
publication. Meanwhile, the Bronchial Biopsy Biobank adapted its SOPs and all 
pertinent documents including the informed consent form as per the 
requirements of the 14/2007 Law in preview of its incorporation into a 
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registered institutional biobank once operational. Following the launch of the 
official Hospital de la Santa Creu i Sant Pau Research Institute Biobank, a joint 
consensus involving the institutional biobank director, the Research Institute 
quality control manager, the director of the hospital Respiratory Department, the 
institutional Ethics Review Board, the Bronchial Biopsy Biobank project 
manager, and its principal investigator, operated and authorized the formal 
incorporation of the Bronchial Biopsy Biobank as part of the official, registered 
institutional biobank of the Hospital de la Santa Creu i Sant Pau Research 
Institute, as of november 12th, 2014. 
During its evolution up to date, the Bronchial Biopsy Biobank has 
successfully met its commitment to supply biopsy specimens and the associated 
demographics and clinical data for specific scientific objectives pertaining to a 
variety of research projects. Next, a structured discussion follows of the results 
achieved. 
 
Translational analysis of a T-cell/airway smooth muscle cell "synapse" in 
airway remodeling 
In a previous study employing an experimental asthma model,102 antigen-
specific CD4+ T cells were shown to induce airway smooth muscle hyperplasia 
through a mechanism dependent on direct T cell/α-SMA+ contact. In the 
subsequent work on bronchial biopsies presented in Part II of the Results section 
of this thesis, we demonstrate a substantial infiltration of the airway smooth 
muscle by T cells, which increases in relationship with asthma severity. Such T 
cell infiltration was concomitant with increased airway smooth muscle mass and 
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with the development of a subepithelial compartment of α-SMA+ cells that we 
first described in this work and we termed non-organized airway contractile 
elements (NOACE). On the basis of triple PCNA, CD4 and α-SMA 
colocalization, we demonstrated that T cells co-localized with α-SMA+ with a 
frequency gradient from controls to severe asthmatics, and that some of such 
juxtaposition events occurred on α-SMA+PCNA+ cells in the subjects with 
asthma. 
Previously, it had been demonstrated by others that mast cells were present 
in the airway smooth muscle of asthmatic subjects,371 and a subsequent analysis 
of airway ultrastructure by electron microscopy showed the presence of both 
lymphocytes and mast cells in the airway smooth muscle layer.85 T cells have 
the potential to drive airway smooth muscle remodeling by inducing 
proliferation, 102 and cell signaling studies showed that T cells may do so by 
altering the contractile phenotype of airway smooth muscle cells through the 
actions of cytokines such as IL-13 and TGF-β.484, 485 T cell microlocalization 
within the airway smooth muscle layer may be instrumental for T cell derived 
mediators to take action on the airway myocytes, since most cytokines act in a 
paracrine fashion. In subjects with asthma, the airway smooth muscle also 
secretes cytokines and chemokines that may have effects on T cell function.486 
furthermore, T cells have been shown to adhere to airway smooth muscle cells 
through CD44 and integrins involving the α4-integrin/VCAM-1 pathway,
440 a 
finding suggesting that the engagement of both cell types through these 
receptors may conduct signaling between them. In fact, experiments on co-
culture of T cells and purified airway myocytes demonstrated a direct cell 
contact-dependent crosstalk between both types of cells, whereby activated, 
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antigen specific CD4+ T cells induced myocyte proliferation and, reciprocally, 
myocyte contact inhibited post-activation induced apoptosis of the effector T 
cells.102 The results presented in this thesis on triple co-immunostaining of T 
cells, α-SMA and PCNA in bronchial biopsies are supportive to the hypothesis 
of a sort of immunological T cell/myocyte "synapse", i.e. a contact-dependent 
mechanism, involved in driving the hyperplastic growth of airway smooth 
muscle in asthma. The added data on VCAM-1 expression contribute a further 
insight into the mechanism by which T cells may interact with the airway 
smooth muscle and NOACE through direct cell-to-cell contact mediated by 
VCAM-1 interaction with its counter receptors, namely the α4β1 (CD49d/CD29, 
very late after activation antigen-4, VLA-4) and α4β7 (lymphocyte Peyer's patch 
adhesion molecule-1, LPAM-1) integrins, which participate in the homing of 
activated T cells to sites of inflammation.487 VCAM-1 expression is upregulated 
through activation by cytokines in the endothelium of asthmatics, and is 
involved in the extravasation of activated T cells at sites of inflammation.488 In 
the bronchial biopsies, the observation of VCAM-1+ vessels near the airway 
smooth muscle provides a histopathological basis for the possibility that some 
activated T cells are directly drawn into the airway smooth muscle. VCAM-1 
was as well expressed by the airway smooth muscle and NOACE in the form of 
discoid aggregates suggestive of receptor clustering in the cell surface. This 
finding further supports a VCAM-1 mediated mechanism of intercellular 
signaling between T cells and airway smooth muscle and/or NOACE cells. 
Downstream VCAM-1, there is a signaling pathway that leads to the activation 
of p38 mitogen-activated protein kinases involved in mesenchymal cell 
proliferation and differentiation.489 It was noticeable that some VCAM-1 
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clusters were located inside cell surface concavities defined by an α-SMA dense 
ring, likely reflecting cytoskeletal rearrangement. 
The mechanism of airway smooth muscle growth in asthma has remained 
elusive, and the in situ demonstration of myocyte proliferation was 
controversial. In the present study, we demonstrated PCNA expression by 
airway smooth muscle cells in the subjects with asthma, a finding attributable to 
proliferation of resident myocytes, since PCNA expression is coupled to 
chromosomal DNA replication.490 A baseline frequency of PCNA+ myocytes 
also existed in the control subjects, suggesting a physiological cell turnover. In 
some instances, PCNA+ nuclei were observed in swollen smooth muscle cells 
with sparse α-SMA content. This may reflect a dedifferentiation of airway 
smooth muscle cells to the so-called "proliferative" phenotype in order to 
traverse the cell cycle,491 or may also suggest that the PCNA+ cells observed in 
the smooth muscle derive from recently migrated and less differentiated 
progenitor cells. 
In this work, we also defined the NOACE term and concept17 from the 
observation of a fuzzy spectrum of α-SMA+ cell phenotypes found in the lamina 
propria. Such phenotypes ranged from small spherical, poorly α-SMA 
expressing cells with an appearance of MSCs or progenitor cells in early stages 
of differentiation, to fusiform cells with a dense α-SMA cytoplasmic content 
such as mature airway smooth muscle cells. The latter were in proximity to the 
outer edge of the airway smooth muscle bundles, but were surrounded by 
abundant extracellular matrix and not integrated as part of the compacted 
smooth muscle layer. Myofibroblasts, a cell phenotype defined on the basis of 
electron microscopy, are found in increased numbers in the subepithelial region 
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of the asthmatic airways,10 and populate this region in a fast and profuse fashion 
in response to allergic airway challenge.11 The NOACE is an inclusive concept 
that comprises the myofibroblasts plus the newly observed spectrum of α-SMA+ 
cells described here. It had been previously hypothesized that myofibroblasts 
derive from structural fibroblasts or from myocytes that migrate out of the 
airway smooth muscle bundles and dedifferentiate. In view of the evidence that 
airway smooth muscle remodeling occurs at least in part through the recruitment 
and differentiation of circulating precursor cells,12-16, 18 the observation of the 
NOACE phenotype gradient of α-SMA+ cells in the lamina propria comprising 
proliferating, α-SMA+PCNA+ cells, provides a morphological basis consistent 
with the idea that airway smooth muscle remodeling occurs at least in part 
through the apposition of cells that proliferate, mature and translocate in this 
compartment. Such process may also account for the shortened distance between 
the outer edge of the airway smooth muscle and the epithelium observed in 
asthmatics.413 Furthermore, the data presented in our work suggest that the T 
cell/α-SMA+ cell "synapse",17, 102 observed in both the airway smooth muscle 
bundles and NOACE, may be an early mechanism inducing precursor cell 
proliferation at the NOACE compartment and further contribute in this way to 
the growth of the airway smooth muscle in asthma. 
Although a mathematical inference, multivariate regression modeling further 
supported from our data a role in remodeling for the T cells that infiltrate the 
airway smooth muscle. It was in fact the numbers of the T cells within the 
airway smooth muscle, and not the total T cells in the overall inflammatory 
infiltrates, which provided the main contribution to the variance of the airway 
smooth muscle mass and the PCNA+ cell frequency. The other contributor to the 
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airway smooth muscle mass increment was the frequency of T cell juxtaposition 
events on PCNA+ smooth muscle cells. 
In summary, consistently with the prior experimental evidence of direct cell 
contact mediated T cell involvement in airway smooth muscle remodeling, we 
showed in the present study on bronchial biopsies that T cells infiltrate the 
airway smooth muscle and juxtapose proliferating α-SMA+ cells in the airways 
of subjects with asthma. VCAM-1 may participate in mediating such T cell/α-
SMA+ cell interaction. T cells may deliver morphogenic signals to α-SMA+ 
structural cells or their precursors through a direct, receptor-mediated "synapse" 
within the milieu of chronic inflammation and an associated dysregulation of 
repair responses. 
 
Role of apoptosis in airway smooth muscle remodeling 
The evidence on the involvement of airway smooth muscle remodeling in 
the mechanisms of airway hyperresponsiveness, airflow obstruction and asthma 
severity,2-4, 10, 59, 331, 336, 339, 343, 345, 350, 351, 408, 416, 420, 421, 448-468 led to extensive 
investigations on the mechanisms of airway smooth muscle growth. However, 
despite apoptosis being a basic mechanism of life crucially involved in organ 
morphogenesis and tissue homeostasis, virtually no attention was paid to a 
potential role of apoptosis in airway smooth muscle remodeling in asthma, nor 
its plausible involvement in the physiological homeostasis of this structure in 
vivo. Early work where airway smooth muscle cell apoptosis was explored, was 
the same rat experimental asthma study that led to the T-cell/α-SMA+ "synapse" 
theory.102 In this study, antigen-specific, effector CD4+ T cells were genetically 
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engineered by retroviral transduction to permanently express GFP for in vivo 
tracking, and were adoptively transferred to non-sensitized recipient rats that 
were subsequently airway challenged with antigen. The main outcome of the 
study was the demonstration of a T cell contact-dependent mechanism of airway 
remodeling. To gain a deeper insight into the mechanisms involved in the 
growth of airway smooth muscle, PCNA and TUNEL were co-localized with α-
SMA and quantitative morphology was performed in tissue sections. The T cell 
dependent increase in airway smooth muscle mass was found to occur through a 
combination of hyperplasia and inhibition of apoptosis of airway myocytes, 
which suggested that CD4+ T cells induce airway smooth muscle remodeling by 
regulating both myocyte proliferation and survival. Conversely, T cell/myocyte 
contact inhibited activation-induced apoptosis of the T cells, therefore providing 
evidence of a bidirectional signaling mechanism whereby T cells induce 
remodeling and the airway myocytes under T cell contact amplify sustained 
inflammation. 
Subsequent work analyzing the airways of horses with heaves, a naturally 
occurring equine, allergic airway obstructive disease, showed that airway 
myocyte apoptosis was increased rather than diminished.365 This mismatch 
between the rat experimental asthma model in the analysis of airways in horses 
with heaves was attributed to the fact that the experimental asthma in the rat was 
a short-term disease model, whereas the lung horse specimens represented long-
term chronicity. It made sense that, should an inhibition of myocyte apoptosis 
play a role in airway smooth muscle growth at early asthma stages, some 
regulatory events would have to take place beyond certain threshold of disease 
and remodeling development, because the growth of airway smooth muscle in 
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asthma is likely not unlimited. This rationale led us to conduct the series of 
experiments primarily focused on airway smooth muscle cell apoptosis, 
summarized in the introduction of Part III of the Results section. Those 
experiments, which combined experimental asthma modeling with three cutoffs 
of disease duration and pharmacological inhibition of apoptosis under 
experimental asthma, showed that airway myocyte apoptosis is in fact 
upregulated after early disease stages where airway hyperresponsiveness and 
smooth muscle remodeling get established. 
Following the series of results from the experimental asthma models, the 
next step was to seek for evidence of such operating involvement of airway 
smooth muscle cell apoptosis in actual human asthma. To undertake this aim, 
we analyzed bronchial biopsies representing a stepwise asthma scale from 
control subjects, through subjects with intermittent asthma and up to subjects 
with persistent moderate and severe asthma.  
Quantitative morphology on α-SMA immunostained tissue sections revealed 
a progression of airway smooth muscle mass in association with asthma 
severity, consistent with previously published reports.17 An interesting novelty 
in the case of this particular study was the inclusion of a subset of subjects with 
intermittent asthma managed in therapeutic step GINA/GEMA-1. Remarkably, 
airway smooth muscle remodeling was already present in these subjects, whose 
airway smooth muscle mass increment over controls was close to those subjects 
with persistent, moderate asthma. The statistical analysis of the intermittent 
asthma versus control difference yielded a borderline significant difference, 
attributable to a limitation of statistical power in the context of a 4-arm multiple 
comparison with alpha correction for statistical significance. 
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The evaluation of airway smooth muscle cell apoptosis by TUNEL 
colocalization with α-SMA showed the existence of a baseline frequency of 
myocyte apoptosis in the control subjects, which likely participates in regular 
cell turnover as part of the homeostasis of this structure. Whereas there is a 
general consensus that apoptosis participates in the homeostatic cell turnover of 
most tissues, virtually nothing was known about its presence in airway smooth 
muscle. Normal airway386 and vascular391 smooth muscle cells constitutively 
express Fas (CD95), a member of the tumor necrosis factor receptor superfamily 
whose engagement triggers programmed cell death. There is in vitro evidence 
that Fas cross-linking in smooth muscle cells leads to apoptosis,386, 391 which 
suggests that airway smooth muscle cells may be able to undergo apoptosis 
induced through the extrinsic signaling pathway upon Fas ligation in vivo. 
Cultured airway smooth muscle cells were also shown to express Fas ligand 
(FasL) and TNF-related apoptosis-inducing ligand (TRAIL), and undergo 
apoptosis upon exposure to IFN-γ, TNF-α, soluble FasL and TRAIL, as well as 
supernatants from Th1 and Th2 stimulated cells.385 In another study, cultured 
airway myocytes were shown to undergo a background level of apoptosis that 
was limited by survival signals delivered by extracellular matrix proteins such as 
fibronectin, collagen I and IV and laminin, through the fibronectin receptor α5β1 
integrin.492 All such studies suggest that apoptosis may be a general mechanism 
to control myocyte numbers for smooth muscle homeostasis, and its regulation 
may therefore be altered under pathological conditions.  
In the subjects with asthma, there was a tendency to an overall increased 
frequency of apoptotic myocytes over the control subjects. However, the 
TUNEL procedure was not sensitive enough so as to demonstrate such 
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increment of airway smooth muscle cell apoptosis through statistically 
significant differences upon quantitative morphology. One of the difficulties 
expected in the analysis of apoptosis in bronchial biopsies is that apoptotic cells 
are scattered events on microscopic examination, even in tissues that may be 
undergoing a significant amount of programmed cell death. As opposed to 
studies on experimental asthma models, where tissue slices comprising an entire 
lung section are available for analysis, bronchial biopsy represents a minute 
sampling of the airways. Such limitation can feasibly compromise the suitability 
of bronchial biopsy as a sensitive procedure for the detection of significant 
outcomes on events that naturally occur with very low frequencies. In view of 
the TUNEL data tendency, we attempted to attain further evidence on the role of 
apoptosis by co-localizing c-PARP, a byproduct of caspase activity, with α-
SMA. This co-immunostaining was performed as an exploratory study in a 
subset of specimens not including intermittent asthma, due to limited 
availability. In this case, the severe asthmatics showed an increment of c-PARP+ 
airway smooth muscle cells, statistically significant and large in terms of size of 
the difference, over the moderate asthmatics and the control subjects. This 
finding, along with the observed tendency in the frequency of apoptotic 
myocytes as per TUNEL detection, supports that airway smooth muscle cell 
apoptosis is increased in subjects with asthma, likely in association with asthma 
severity. Overall, the outcome of the analyses performed on bronchial biopsies 
is consistent with the data generated from the experimental asthma models. In 
summary, the joint experimental and clinical data suggest that an upregulation 
of airway smooth muscle cell apoptosis is involved in the mechanisms of airway 
smooth muscle remodeling, and may play a regulatory role in response to the 
growth of airway smooth muscle. 
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Tregs and MSCs in bronchial biopsies  
Following a period nowadays considered by immunologists as a "dark age" 
on a vague "suppressor T cell" concept,171, 172 the discovery of 
immunoregulatory CD4+CD25+ T cells in the 1990s173-175 started a fresh 
research gateway on immune regulation in different pathologies. The main 
conceptual turnaround was that CD4+ T cells were not anymore just effector T 
cells. Following the discovery of the transcription factor FOXP3 as a key 
molecular effector and marker of CD4+ regulatory T cells,176-178 the acronym 
"Tregs" spread into the general jargon of the scientific community to refer to 
such cells, although the scenario soon got complicated with the definition of a 
variety of immune cells with regulatory functions, not all of them necessarily 
expressing FOXP3, and the discovery of a quite versatile phenotypic plasticity 
among such cell populations. 
Asthma was a late comer to the Treg field, and scarce knowledge has been 
unearthed up to date on the role of Tregs in its pathophysiology. With no 
particular grounds, the first-impression hypothesis that Tregs would be 
decreased in asthma, spread as a prejudged explanation for a "logical" failure of 
the Treg driven immunoregulatory arm in asthma. Most of the few studies done 
were limited to peripheral blood analyses showing decreased Treg numbers,493-
495 or an impaired responsiveness to chemotactic stimuli,496, 497 and two studies 
done on BAL fluid showed decreased498 or increased499 Tregs, respectively. 
However, the immunoregulatory role of Tregs along with the fact that one of 
their mainly secreted cytokines is the highly fibrogenic TGF-β, suggests that 
Tregs may be a key hinge that couples the resolution of inflammation with the 
induction of repair responses. Contrary to common current of thought and in the 
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absence of any prior sound data (no study had directly sampled the airway wall), 
it made sense to us the possibility that, rather than a Treg failure underlying 
asthma, Tregs could be reactively increased in the asthmatic airways in response 
to sustained chronic inflammation and thus be involved in inducing the 
dysregulated repair response that airway remodeling consists of. This hypothesis 
led us to perform the series of animal model experiments summarized in the 
introduction of the Results section Part IV and find that, in experimental asthma, 
IL-10 and TGF-β secreting Tregs are increased in the airway wall and 
inflammatory infiltrates as the disease progresses, and that such Treg increase is 
associated with a plateauing of airway hyperresponsiveness and increased 
subepithelial fibrosis. To initiate research on the translation of the data on 
experimental asthma to the human disease, we performed the pilot study of 
bronchial biopsies presented here. In the absence so far of other co-localized 
markers, this pilot study showed that FOXP3+ lymphoid cells, i.e. most likely 
Treg cells, are strikingly increased in the airway wall of severe asthmatics and 
are almost absent in the control subjects. This outcome, although limited by the 
lack of a gradient of asthma severity in the biopsy specimens employed, is 
consistent with the experimental asthma data showing a gradual increase of 
infiltrating Tregs associated with disease progression. Further analyses on 
bronchial biopsies shall involve: (i) a more extensive phenotypic 
characterization of the FOXP3+ lymphoid cells by co-localizing other markers 
such as TGF-β; (ii) an extension of the asthmatic population studied; and (iii) a 
correlation with airway remodeling parameters, particularly subepithelial 
fibrosis. 
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Along with Tregs, the other type or family of cells that may play a crucial 
role in coupling the turnoff of inflammation with the induction of repair 
processes are MSCs, given their well demonstrated immunomodulatory 
potential395-397 and their ability to differentiate into a variety of mesenchymal 
structural cells such as fibroblasts, osteoblasts, chondrocytes, myofibroblasts 
and smooth muscle cells.394, 500 The fact that previous reports on MSC transfer 
as an anti-inflammatory therapy in experimental asthma were focused on the 
immunomodulatory properties of the MSCs and had ignored their potential for 
differentiation,442-446, 501, 502 and thus the possibility of getting the "therapeutic" 
MSCs recruited and incorporated into the growing airway smooth muscle, 
prompted us to run the published study447 also summarized in the introduction of 
the Results section Part IV. In that study, adipose-derived MSCs transferred into 
recipient mice with established experimental asthma did not get differentiated 
nor incorporated as airway wall to structural cells, contrary to our start 
hypotheses. Furthermore, the transferred MSCs showed an unexpected ability to 
induce a significant regression of airway smooth muscle remodeling. 
Nevertheless, the caution required before bringing any MSC-based therapy into 
clinical trials for asthma, and the possibility that a complex array of MSC 
phenotypes playing different functions may exist, led us to directly explore the 
presence of MSCs in the airway wall of asthmatics, employing bronchial 
biopsies. Likewise the Tregs, the MSC data presented in this thesis are from a 
limited pilot study503 where, in this case, STRO-1 was immunostained as a 
general marker of stromal MSCs.500 STRO-1+ cells were present in significant 
numbers in the lamina propria of the biopsy sections from subjects with severe 
asthma. Additionally, STRO-1 was also expressed by the airway smooth muscle 
of the severe asthmatics in a spotted pattern. A plausible interpretation for such 
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histopathological findings is that the STRO-1+ cells observed in the lamina 
propria had exited the microvasculature of the bronchial circulation located in 
this region, as leukocytes do to form inflammatory infiltrates, and at least part of 
such cells migrated to the airway smooth muscle bundles and differentiated into 
myocytes. Thus, the clustered STRO-1 antigen spots observed in the airway 
smooth muscle may reflect residual STRO-1 expression by former MSCs that 
migrated and got integrated into the airway smooth muscle bundles, and are 
undergoing final differentiation stages into myocytes. This is consistent with the 
fact that STRO-1 expression by MSCs is lost upon differentiation into mature 
cell phenotypes.500 The lamina propria, a loose connective tissue layer between 
the airway epithelium and the smooth muscle bundles, is the natural distribution 
path for the networks of bronchial microvasculature and nerve fibers. The 
almost 10-fold increase of STRO-1 clusters in the airway smooth muscle of 
subjects with severe asthma, and the fact that individually defined STRO-1+ 
cells in the lamina propria were frequent in asthma yet virtually absent in the 
control subjects, further supports that, in asthma, there is an increased 
trafficking of STRO-1+ cells exiting the bloodstream in the lamina propria and 
getting recruited to differentiate into airway smooth muscle cells. Therefore, the 
preliminary data from this pilot study503 suggest that different progenitor cell 
populations may be recruited during airway smooth muscle remodeling in 
asthma, and cells of stromal MSC origin may be involved. This finding from the 
analysis of bronchial biopsies does not match the outcome from the previous 
study on treatment with MSCs in murine experimental asthma,447 where there 
was no evidence of MSC integration nor differentiation into airway smooth 
muscle. There is no current explanation for such discordant results, nor obvious 
hypothesis at present. The understanding of MSC biology is still in early stages. 
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There is likely a variety of MSC subpopulations bearing different properties and 
behavior, and it is foreseeable that MSCs may have plasticity for phenotype 
switching among such subpopulations. The MSCs administered to the animals 
with experimental asthma were harvested from donor adipose tissue, whereas 
the STRO-1+ cells infiltrating the airway wall of the subjects with severe asthma 
were endogenous and, most likely, bone marrow-derived. Whether such 
difference in the origin of the MSCs may at least in part explain the mismatch 
between the MSC therapy in experimental asthma and the observations in 
bronchial biopsies, in terms of MSC potential for a pathogenic participation in 
airway remodeling, is unknown. Next research steps on bronchial biopsies 
following the pilot study presented here are: (i) to expand the study population, 
especially on subjects with asthma, as for the upcoming studies on Tregs; and 
(ii) to co-localize STRO-1 with α-SMA and collagen-I, in order to analyze 
whether some of the STRO-1+ cells observed in the lamina propria are into 
differentiation stages as myofibroblasts as part of the NOACE,17 and to verify 
whether such STRO-1+ cells are definitely a stem cell population different from 
fibrocytes.12-16, 18 In general, further research and solid preclinical development 
are warranted for any MSC-based asthma therapies, and the future may lead us 
to investigate on the production and therapeutic use of MSC-derived mediators 
rather than employing the MSCs themselves.  
 
Other projects 
The Bronchial Biopsy Biobank, as part of the SEPAR Asthma Integrated 
Research Program (PII Asma), has the goal of providing support to projects led 
by qualified investigators. In this front, three projects are currently ongoing 
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through different phases of development. The data generated by those 
investigations are not pertinent to the present thesis, and just a brief review of 
the projects follows. 
Therapeutic mechanism of bronchial thermoplasty. Principal investigator: 
Alfons Torrego Fernández, Hospital de la Santa Creu i Sant Pau, Barcelona. 
Bronchial thermoplasty is a new therapeutic option for some other subjects with 
uncontrolled severe asthma despite maximum available medical therapy. The 
theoretical basis and the goal of bronchial thermoplasty consist of a reduction of 
the airway smooth muscle layer by means of the bronchoscopic application of 
local radiofrequency, aiming at attenuating bronchial hyperresponsiveness and 
airflow obstruction. Animal models employed in the preclinical development of 
bronchial thermoplasty showed a reduction of bronchial smooth muscle 
associated with an improvement of airway hyperresponsiveness.79, 504 
Subsequent clinical trials on subjects with asthma showed improved quality of 
life and symptom scores and a reduction in the frequency of asthma 
exacerbations, yet no clear spirometric improvements where achieved.78, 81, 505, 
506 During the clinical development of bronchial thermoplasty, no data were 
obtained on its mechanism of action in humans. The procedure was approved by 
the USA Food and Drug Administration (FDA) and the European Medicines 
Agency (EMEA) and implemented as part of clinical practice through a number 
of centers in Europe and North America, in the absence of any direct 
demonstration that bronchial thermoplasty actually reduces the airway smooth 
muscle mass in the treated patients. In the project led by A. Torrego Fernández 
et al., with the support of the Bronchial Biopsy Biobank, bronchial biopsies are 
being collected and processed at different pre- and post-thermoplasty time 
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points with the aim of analyzing the effect of the treatment on the bronchial wall 
structure. 
Role of bacterial colonization in permanent airflow obstruction in asthma. 
Principal investigator: Carlos Martínez Rivera, Hospital Universitari Germans 
Trias i Pujol, Badalona (Barcelona). The primary goal of this project is to 
analyze whether asthmatic subjects that develop permanent airflow 
obstruction507-509 have airway colonization by potentially pathogenic bacterial 
species such as Haemophilus influenzae, Moraxella catharralis, Streptococcus 
pneumoniae or Pseudomonas aeruginosa, similarly to subjects with moderate-
to-severe COPD.510 Data on microbial colonization obtained from BAL will be 
referenced to airway inflammation and remodeling parameters generated from 
EBUS examination and quantitative morphology analyses on bronchial biopsies. 
Effect of bronchial bacterial colonization on the airway epithelium 
ultrastructure in severe COPD. Principal investigator: Oriol Sibila Vidal, 
Hospital de la Santa Creu i  Sant Pau, Barcelona, in collaboration with Philipp 
Jungebluth, Karolinska Institutet, Stockholm, Sweden. In this project, the 
Bronchial Biopsy Biobank logistics have provided support for the collection and 
processing of bronchial biopsies from subjects with severe COPD, and the 
formalin fixed, paraffin-embedded specimens have been reprocessed for 
electron microscopy analysis. The project aims at exploring, at ultrastructural 
level, the bronchial epithelium and its basement membrane in airway colonized 
versus pathogen-free, severe COPD subjects. 
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Closing remarks 
The Bronchial Biopsy Biobank has been successfully drawn from its 
inception as a novel initiative to its implementation into practice. Through its 
years of development, it has fostered multicentric collaboration, has yielded a 
sustained flow of quality biopsy specimens allowing to generate outcomes for 
specific scientific goals with sufficient statistical power, has evolved to meet the 
parallel normative developments, and has provided supportive logistics, 
methodological knowledge base, training, and specimen handling and analysis 
services to investigator-initiated projects other than those of the Experimental 
Pneumology Unit of the Hospital de la Santa Creu i Sant Pau Research 
Institute. 
The application of Bronchial Biopsy Biobank specimens to the scientific 
aims of specific research projects has allowed us to bridge outcomes from 
experimental asthma animal models and in vitro cell and molecular biology 
studies with the generation of supportive evidence consistent or not with such 
results, which is the ultimate goal of translational research. Such capabilities 
provided by the Biobank have spanned through the T cell/myocyte "synapse" 
theory of airway smooth muscle remodeling, the role of myocyte apoptosis in 
the maintenance of airway smooth muscle homeostasis and its consequent 
upregulation during remodeling, the likely reactive  increase of Tregs infiltrating 
the airway wall in severe asthma with its potential implications in the 
mechanisms of remodeling, and the intriguing results on the presence of STRO-
1+ cells in the lamina propria and remodeled airway smooth muscle of subjects 
with asthma, the latter fueling controversy on the therapeutic versus pathogenic 
potential of MSCs. 
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Two relevant limitations have so far been encountered during the 
development of the Bronchial Biopsy Biobank: (i) it is observational in its 
nature, i.e. specimen collection occurs as the biopsies are generated from 
bronchoscopies performed as part of clinical practice; and (ii) the former 
limitation conditions that the bronchial biopsies collected in Spain pertain, apart 
from control subjects, almost exclusively to severe asthmatics. As a result, a 
representative gradient of asthma severity is lacking in the Biobank and, for 
those results presented in this thesis where such gradient exists, the groups 
representing moderate and intermittent asthma were dependent on biopsy tissue 
sections provided from Canada or France. 
As for our current vision on future developments, several aspects are being 
considered. After a number of decades defining asthma as a chronic airway 
inflammatory condition, recent technological developments including FeNO 
determination, differential leukocyte counts in induced sputum, and the 
production of humanized monoclonal antibodies, are now allowing us to more 
closely characterize and follow up airway inflammation in clinical practice, and 
are providing a pipeline of novel therapies in current advanced development that 
specifically target key mediators of airway inflammation. After airway 
remodeling thoroughly irrupted into the field of asthma concepts in the 1990s, 
and since the evidence of its importance in asthma pathophysiology and severity 
has become compelling, it is now foreseeable that next move on therapeutic 
developments may aim at targeting airway remodeling. This means designing 
and bringing into practice clinical trials that evaluate airway remodeling 
outcomes, and such goal is indeed part of the present for some innovative trials 
on "umabs" targeting IL-13. Noninvasive, diagnostic imaging based procedures 
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to quantitatively assess airway remodeling have proven to be of quite limited 
utility. Developments on EBUS examination may reach greater imaging 
definition for airway wall assessment, yet this requires bronchoscopy. Airway 
remodeling results from structural alterations affecting different layers and 
tissues of the airway wall, and such alterations may combine differently to 
generate what future research will probably define as "airway remodeling 
phenotypes", perhaps related to particular asthma outcomes from the clinical 
standpoint. Innovative, high-technology therapies aiming at airway remodeling 
will necessarily target pertinent biological pathways in a very specific fashion. It 
is therefore predictable that, for the clinical development of any of such 
therapies, trials involving fine evaluation of airway remodeling outcomes at the 
histopathological and in situ molecular biology level on bronchial biopsies will 
have to be developed. The Bronchial Biopsy Biobank infrastructure, logistics 
and knowledge base shall provide readiness to aid the design and development 
of such clinical trials, whether at proof-of-concept initial development or upon 
large-scale, multicenter trials. Meanwhile, improvements being considered for 
close development are the implementation of electronic, online CRFs and the 
expansion to new collaborating centers. To mend the specimen gap representing 
low-severity asthma, a procedural variant where bronchoscopy and bronchial 
biopsy would be primarily performed for research purposes in asthmatic 
volunteers, as it is done in North America and some countries of the European 
Union, may be considered for future development under certain allowance that 
the 14/2007 Law on Biomedical Research offers. As a final consideration, it is 
remarkable that no formal guidelines nor official statements on the collection 
and use of bronchial biopsy for research aims have been issued since 1991, and 
those were limited to generally establishing the safety and pertinence of 
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bronchoscopy and overall bronchoscopic instrumentation, but lacked any further 
specificity on procedures. The development of the present Bronchial Biopsy 
Biobank as a specialized, multicentric, open, SOP normalized and sustainable 
structure fostered within a program of an official respiratory society is, to the 
best of our knowledge, an innovative worldwide first. An adapted extract of the 
present thesis, compiling the background, aims, methodology, procedural issues 
and developmental outcome of the Bronchial Biopsy Biobank shall be presented 
to the Executive Committee of the SEPAR Asthma Integrated Research 
Program (PII Asma) and the SEPAR Scientific Committee, for its consideration 
as a SEPAR Official Statement publication. 
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1. The design and implementation of a multicenter logistics network with 
uniform standard operating procedures for the collection, shipping and 
processing of bronchial biopsy specimens, obtained from bronchoscopy as 
indicated as per regular clinical practice, has allowed to establish a 
specialized Bronchial Biopsy Biobank capable of supplying quality airway 
wall tissue sections for a wide variety of investigations pertinent to scientific 
objectives of specific projects, within a research program of an official 
respiratory society (SEPAR). The Biopsy Bronchial Biobank has fostered 
multicentric collaboration, has met the necessary regulations as they were 
developed and implemented, and has provided supportive logistics, 
methodological knowledge base, training, and specimen handling and 
analysis services to a variety of investigator-initiated projects. Remarkably, 
the Bronchial Biopsy Biobank has allowed for the generation of clinical 
evidence supportive for the translation of outcomes from experimental 
asthma animal models. At present, the Bronchial Biopsy Biobank structure, 
logistics, knowledge base and standard operating procedures offer a basis for 
the design and implementation of specific clinical trials aiming at the 
development of innovative therapies targeting airway remodeling.  
2. Consistently with prior experimental evidence showing that antigen-specific, 
activated CD4+ T cells induce airway smooth muscle cell proliferation 
through direct intercellular contact, T cells infiltrate the airway smooth 
muscle of subjects with asthma in proportion to disease severity, and 
juxtapose proliferating (PCNA+α-SMA+) airway smooth muscle cells. 
VCAM-1 expression is upregulated in the airway smooth muscle of 
asthmatics, where it is found forming receptor clusters that suggest a cell 
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contact mechanism. Furthermore, we defined in this work the non-organized 
airway contractile elements (NOACE), a spectrum of cell phenotypes 
located in the lamina propria that suggests a dynamic α-SMA+ cell gradient, 
ranging from undifferentiated precursors to mature smooth muscle-like cells 
apposing the airway smooth muscle bundles, where proliferative activity and 
T cell contact were also observed. In human asthma, T cells may deliver 
morphogenic signals to α-SMA+ structural cells or their precursors through a 
direct, receptor-mediated "synapse", and this mechanism may promote 
airway smooth muscle remodeling starting at the level of precursor cells 
located in the NOACE.  
3. Consistently with experimental evidence showing that apoptosis is involved 
in the homeostasis of airway smooth muscle and is upregulated in response 
to the remodeling of this structure in asthma, and overall evaluation of 
TUNEL and c-PARP coimmunostaining with α-SMA in bronchial biopsies 
suggests that a baseline frequency of apoptosis exists in the airway smooth 
muscle as part of its homeostatic mechanisms and, in asthma, apoptosis is 
upregulated along with the increase in airway smooth muscle mass. 
Remarkably, airway smooth muscle mass was significantly increased in 
subjects with intermittent asthma. TUNEL+ cells showed a tendency to be 
overall increased in asthma, without reaching statistical significance. The c-
PARP byproduct of caspase activity, however, was significantly increased in 
the subjects with severe asthma.  
4. Consistently with experimental evidence showing that FOXP3+IL-10+TGF-
β+ regulatory T cells are progressively recruited into the airway 
inflammatory infiltrates along with disease progression, data from bronchial 
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biopsy tissue sections show that FOXP3+ lymphoid cells are importantly and 
significantly increased in the airway wall of subjects with severe asthma, 
and are particularly located in the lamina propria. The data suggest that 
regulatory T cells are reactively increased in asthma, in response to chronic 
airway inflammation.  
5. In disagreement with experimental evidence showing that syngeneic, 
transferred mesenchymal stem cells do not get recruited nor differentiate 
into structural cells of the airway wall tissues in an asthma model, the 
analysis of bronchial biopsy tissue sections showed that STRO-1+ cells, 
likely mesenchymal stem cells from the bone marrow stroma, infiltrate the 
lamina propria in the airway wall of subjects with severe asthma, in 
important and significant numbers. STRO-1+ epitope clusters were also 
observed in the airway smooth muscle bundles, suggesting residual 
expression by former bone marrow-derived, non-fibrocyte mesenchymal 
stem cells that migrated and differentiated into airway myocytes. The 
incongruence of this outcome in relation to the experimental asthma 
modeling data, suggests that different, not yet defined subpopulations of 
progenitor cells, including mesenchymal stem cells, may participate in 
airway smooth muscle remodeling in asthma. This result warrants further 
meticulous investigations on the phenotypes and roles of mesenchymal stem 
cells in asthma and may shed a caveat on the direct use of such cells for 
therapeutic purposes in subjects with asthma.  
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Appendix 1 
 
Bronchial Biopsy Biobank 
Ethics Review Board approval for incorporation into the 
registered institutional biobank of the  
Hospital de la Santa Creu i Sant Pau Research Institute 
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Appendix 2 
 
Informed Consent Form 
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Appendix 3 
 
Bronchial Biopsy Biobank Kit Documents 
 
▪ Kit contents log form (“Registro kit de colaboración”). 
▪ Summarized protocol ("Protocolo"). 
▪ "Documento 1": inclusion/exclusion criteria checkup, subject group 
assignment and indication for bronchoscopy. 
▪ "Documento 2": case report form (CRF). 
▪ "Documento 3": biopsy registry. 
▪ Anonymization registry document ("Registro de anonimización reversible").  
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